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Outline of Thesis
In Chapter I, a general introduction and rational concerning the 
subject chosen for this Thesis is presented. This includes the 
available evidence of the role of different diagnostic and therapeutic 
methods in the evaluation of disease activity and resolution of 
complications, and the evidence demonstrating the importance of 
infectious agents in the pathogenesis and disease activity in IBD.
In Chapter II, the aims of each of the six studies conducted for the 
present Thesis are presented.
In Chapter III, the publications that build the core for the present Thesis 
are presented.
In Chapter IV, an integrated discussion of all the articles is presented 
supporting the major conclusions of these Thesis.
In Chapter V, the conclusions are presented and areas for clinical research 
are pointed out.
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Abstract
Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory 
condition of the gastrointestinal tract, encompassing two diseases: 
Crohn´s disease (CD) and Ulcerative colitis (UC). The evidence that 
incidence and prevalence of IBD correlates with industrialization and 
westernalization of populations has driven much attention to possible
environmental triggers of disease. IBD is believed to manifest in a 
genetically predisposed individual who reacts inappropriately to the gut 
microbiome after exposure to an external trigger. In this context much 
attention has been driven recently by human virome. Some studies
have proved an interaction between eukaryotic viruses and IBD risk 
genes, suggesting a role for enteric virome in IBD pathogenesis. It has 
also been demonstrated that the viral population may be influenced by 
immunosuppressive therapy, with some specific viruses taking advan-
tage of the immunosuppressive status of the host. Despite the amount of 
evidence trying to implicate viral dysbiosis in the pathogenesis of IBD 
it has been difficult to confirm results across validation cohorts. The 
Human Herpesviridae (HHV) family is a DNA virus family encompassing
Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and Human Herpes 
simplex virus 6 (HSSV-6), that have in common being highly prevalent
in adulthood (>95%) and inducing lifelong latency in the host. During
periods of immunosuppression they may reactivate and have a 
role in exacerbating chronic inflammatory diseases. Data from the 
post-transplant setting demonstrate virus reactivation with clinical 
implications in this state of intense immunosuppression suggesting that 
this effect might also happens in IBD patients. Until the present time, it 
remains to be proved if the changes observed in number and richness 
of virus in IBD are biologically and clinical relevant in terms of disease 
phenotype, behavior and response to therapy. 
The access to the intestinal mucosa, healthy or involved in the disease 
process, is achieved with different modalities of endoscopy which allow 
the direct observation and histological appraisal of the inflammatory 
features within the gut. Besides its contribution to the clarification of 
disease pathogenesis, endoscopy has also an important role in disease 
monitoring and evaluation of response to therapy. 
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In the last decades, the way we approach and manage IBD has evolved 
enormously. The concepts of mucosal healing, transmural healing and 
bowel damage have changed the goals of therapy and subsequent 
follow-up. At the present time, the standard of care implies a close 
monitoring of the inflammatory burden of the disease in order to avoid 
disability. As clinical symptoms and serum biomarkers have proved to 
be inaccurate in predicting disease activity, and because endoscopy 
implies a certain degree of invasiveness, other noninvasive methods have 
been investigated. Fecal markers, cross-sectional imaging modalities
and video capsule endoscopy (VCE) have gained interest in disease 
monitoring. Despite all the encouraging data about their accuracy in 
disease evaluation, colonoscopy remains the gold standard against 
which all other methods are compared and validated. In addition to the 
direct evaluation of lesions severity and extension, endoscopy allows 
the performance of therapeutic techniques, like endoscopic balloon 
dilation (EBD). This technique not only contributes to symptom resolution 
and consequent bowel preservation but also allows to diagnose 
recurrence in the post-operative setting.
With this Thesis we sought to study how some endoscopic modalities, 
fecal markers and imagiology could contribute to the management of 
IBD patients in specific clinical settings.
First, we investigated the prevalence and role of some members of the 
Human Herpesviridae family in disease pathogenesis and course. We 
studied and performed endoscopy in a group of 95 IBD patients (UC 
and CD   patients) and 50 healthy subjects (HC). EBV and CMV were 
more prevalent in the IBD population, and in areas of mucosa with 
endoscopic activity. The prevalence of HHV6 was similar between 
patients and HC. CMV median viral load was higher in diseased mucosa of 
UC patients while EBV median viral load was higher in inflamed mucosa 
of CD patients. We did not find any influence of the immunosuppressive 
treatment regimens in viral serum prevalence. 
The second aim of this thesis was to assess the accuracy of fecal markers
in predicting disease recurrence after surgery, comparing two 
endoscopic scores- the Rutgeerts score and the Modified Rutgeerts 
score. In this study of 99 patients, FC and FL levels proved to be higher 
25
in patients with endoscopic recurrence compared to endoscopic remission. 
The Modified Rutgeerts score performed better than the Rutgeerts 
score with higher sensitivity, negative predictive value and accuracy in 
predicting recurrence. Cut-off values for both markers were established.
The third and fourth objectives were to evaluate the accuracy of 
fecal markers in predicting recurrence in patients with asymptomatic 
anastomotic strictures, selecting patients to EBD, and to evaluate the 
efficacy and safety of this technique. In our group of 178 patients who 
underwent colonoscopy, 48 were successfully dilated and recurrence 
was diagnosed only after dilation in 22 patients. Fecal markers were 
good predictors of endoscopic recurrence and can be used as guidance 
to EBD. EDB demonstrated to be an effective and safe alternative to 
surgery, with the possibility of being repeated as needed.
In order to monitor response to therapy we evaluated the performance of 
computed tomography enterography (CTE) and fecal markers compared 
to endoscopy at diagnosis and in the first year after beginning therapy. 
In a group of 29 consecutive patients with newly diagnosed CD we 
performed endoscopy, CTE and fecal calprotectin (FC) at M0 and M12. 
We found a good correlation between the 3 methods at both time 
points. In patients with endoscopic remission at one year, CTE findings 
of inflammatory activity significantly improved, CTE score decreased 
and FC values normalized. A combination of both noninvasive markers 
may be used to monitor response to therapy, with the advantage of 
evaluating transmural healing.
The last aim of this project was to evaluate the impact of VCE in CD 
management, since its role in treatment guidance is not completely 
defined. In a group of 83 patients with long-term disease in clinical 
remission, VCE identified unknown upper tract involvement in 49 
patients, and its findings translated in treatment changes in 40% 
of patients. These results highlight the importance of small bowel 
mucosal imaging in the management of CD.
In conclusion, despite the promising results obtained with noninvasive
methods in disease monitoring, being easy to repeat and gaining 
patient general acceptance, their definitive place in patients’ evaluation
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still needs to be defined. Direct mucosal observation, either by 
colonoscopy or VCE, still has a major role in IBD management. Cross 
sectional imaging modalities and fecal markers may and should be 
incorporated into patients’ algorithm management, selecting patients to 
endoscopy. Validated scores are needed in CTE, with special attention 
to mesenteric findings of inflammation, and in endoscopy, dissemination 
of the Modified Rutgeerts score should be implemented. EBD should be 
performed not only to induce symptoms resolution in stenotic patients
but also to gain access to otherwise inaccessible bowel segments, 
allowing therapeutic adjustments as needed.
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Resumo
A Doença Inflamatória Intestinal (DII) é uma doença crónica, inflamatória 
e recidivante do tubo digestivo, englobando a Doença de Crohn (DC) e 
a Colite Ulcerosa (CU). A associação entre o aumento da sua incidência
e prevalência e a industrialização e ocidentalização das populações tem 
despertado muito interesse para um potencial papel de agentes ambi-
entais na sua etiopatogénese. Assume-se que a DII se desenvolve num 
indivíduo geneticamente predisposto que reage de forma inadequada
ao seu microbioma após exposição a um estímulo externo. Neste 
contexto, nos últimos anos o viroma humano tem despertado muita 
atenção da comunidade científica. Alguns estudos demonstraram uma 
interação entre vírus eucarióticos e genes de susceptibilidade para a DII, 
sugerindo um papel para o viroma na patogénese da DII. O reconhe-
cimento de que a terapêutica imunossupressora influencia a população 
vírica entérica, coloca a hipótese de alguns vírus específicos poderem
aproveitar o estado imunossuprimido do hospedeiro para promoverem
o desenvolvimento de doença. Apesar de evidência cientifica 
implicando a disbiose viral na patogénese da DII, ainda não foi possível 
confirmar estes resultados em coortes de validação. Os vírus da família 
Herpesviridae humana são vírus de ADN englobando o CMV, EBV e 
HSSV- 6. Estes vírus têm em comum a elevada prevalência na idade 
adulta (> 95%) e persistirem num estado de latência ao longo da vida 
do hospedeiro. Durante períodos de imunossupressão a sua reativação 
pode ocorrer, com consequente exacerbação de doenças crónicas. Os 
dados existentes da transplantação demonstram que em estados de 
imunossupressão intensa se verifica a reativação vírica com implicações
clínicas, sugerindo que estes efeitos também possam ocorrer em 
doentes com DII. Até ao momento, continua por inequivocamente 
demonstrado, se as alterações de número e variabilidade de vírus na 
DII são biológica e clinicamente relevantes em termos de fenótipo, 
comportamento e resposta da doença ao tratamento.
As várias modalidades endoscópicas disponíveis garantem o acesso á
mucosa doente e saudável, e permitem a observação directa e 
histológica das manifestações inflamatórias no tubo digestivo. A endos-
copia para além de contribuir para o esclarecimento da patogénese da 
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doença tem também um papel na sua monitorização e na avaliação da 
resposta ao tratamento.
Os conceitos de cicatrização da mucosa, cicatrização transmural e dano 
intestinal (“bowel damage”), introduzidos recentemente na abordagem 
da DII, modificaram os objetivos terapêuticos. Na actualidade o seguimento
ideal destes doentes implica a monitorização regular da carga 
inflamatória de forma a evitar a irreversibilidade das lesões. Como os 
sintomas e os biomarcadores séricos demonstraram ser imprecisos na 
avaliação da atividade da doença, e pela invasividade que a endoscopia 
representa, foi explorada a utilização de outros métodos não-invasivos 
alternativos. Os marcadores fecais, os métodos de imagem radiológicos 
e a vídeo cápsula endoscópica (VCE) têm vindo a ganhar interesse na 
monitorização da doença. 
Apesar dos resultados encorajadores da acuidade destes métodos 
na avaliação da actividade da doença, a colonoscopia continua a ser 
a referência para comparação e validação dos restantes métodos. A 
endoscopia, além da determinação da gravidade e extensão das 
lesões, permite a realização de técnicas terapêuticas, como a dilatação 
endoscópica com balão (DEB). Esta técnica para além da resolução 
sintomática, permitindo a preservação do segmento intestinal, possibilita
o diagnóstico da recorrência da doença no pós-operatório.
Com esta Tese, procuramos estudar como alguns métodos endoscópicos,
os marcadores fecais e a imagiologia podem contribuir para o 
acompanhamento clínico dos doentes com DII em contextos clínicos 
específicos.
No primeiro estudo, investigamos a prevalência e o papel de alguns 
membros da família Herpesviridae na patogénese e na evolução da 
doença. Realizamos colonoscopia a 95 doentes com DII (DC e CU) e 50 
indivíduos saudáveis (HC). Os vírus EBV e CMV foram mais prevalentes 
na população com DII e em áreas de mucosa com atividade endoscópica.
A prevalência do HHV6 foi semelhante entre doentes e HC. A carga vírica
média do CMV foi mais elevada na mucosa ulcerada dos doentes com 
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CU, enquanto a carga vírica média do EBV foi maior na mucosa ulcerada 
dos doentes com DC. Não encontramos qualquer correlação entres os 
regimes terapêuticos imunossupressores e a prevalência vírica sérica.
O segundo objetivo desta tese foi avaliar a acuidade dos marcadores 
fecais como predictores de recorrência após a cirurgia e comparar dois 
scores endoscópicos - o score de Rutgeerts e o score de Rutgeerts 
modificado. Neste estudo com 99 doentes, os níveis de calprotectina 
fecal e lactoferrina fecal demonstraram ser mais elevados em doentes
com recorrência endoscópica em comparação com doentes em 
remissão endoscópica. O score de Rutgeerts modificado demonstrou
ser superior ao score de Rutgeerts na predição de recorrência, com 
maior sensibilidade, valor preditivo negativo e acuidade. Foram 
estabelecidos valores de cut-off para os dois marcadores fecais.
O terceiro e o quarto objetivos foram avaliar a acuidade dos marcadores 
fecais na predição de recorrência em doentes com estenose assintomática
da anastomose ileocólica selecionando os doentes para DEB, e avaliar 
a eficácia e segurança desta técnica. No nosso grupo de 178 doentes 
submetidos a colonoscopia, 48 foram dilatados com sucesso e foi feito o 
diagnóstico de recorrência apenas após a dilatação em 22 pacientes. Os 
marcadores fecais revelaram ser preditores de recorrência endoscópica
podendo ser utilizados como indicadores da necessidade de DEB. A 
DEB demonstrou ser uma alternativa eficaz e segura à cirurgia, com a 
possibilidade de poder ser repetida se necessário.
A fim de monitorizar a resposta à terapêutica, avaliamos o desempenho
da enterografia por tomografia axial computorizada (TAC) e dos 
marcadores fecais em comparação com a endoscopia, á data do 
diagnóstico e no primeiro ano após o início de tratamento. Num grupo 
de 29 doentes consecutivos com DC recém-diagnosticada, foi realizada
endoscopia, enterografia por TAC e doseamento de calprotectina fecal
ao mês 0 e ao mês 12. Os resultados demonstraram existir uma boa 
correlação entre os 3 métodos ao diagnóstico e ao primeiro ano de 
seguimento após o início do tratamento. Nos doentes em remissão 
endoscópica ao ano, os sinais de atividade inflamatória na enterografia 
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por TAC melhoraram significativamente, o score da enterografia por 
TAC diminuiu e os valores de calprotectina fecal normalizaram. A 
combinação dos dois marcadores não invasivos poderá ser utilizada 
para monitorizar a resposta á terapêutica, com a vantagem de avaliar 
a cicatrização transmural.
O último objetivo deste projeto foi avaliar o impacto da VCE no 
seguimento da DC, uma vez que o seu papel no estabelecimento da 
estratégia terapêutica não está totalmente definido. Em 83 doentes com 
doença de longa duração em remissão clínica, a VCE diagnosticou o 
envolvimento do trato digestivo superior em 49 doentes, condicionando 
alterações terapêuticas em 40% dos doentes. Estes resultados salientam
a importância da observação da mucosa do intestino delgado na 
abordagem da DC.
Em conclusão, apesar dos resultados promissores dos métodos não 
invasivos na abordagem da DII, com facilidade de repetição e maior 
aceitação pelos doentes, o seu posicionamento no algoritmo de 
avaliação precisa ser definido. A observação direta da mucosa, seja 
por colonoscopia ou VCE, ainda possui um papel fundamental na 
abordagem da DII. Os métodos de imagem radiológicos e os 
marcadores fecais poderão e deverão ser incorporados no algoritmo de 
seguimento, selecionando os doentes para endoscopia. É necessário 
o desenvolvimento e validação de scores na enterografia por TAC, 
incorporando os achados mesentéricos de inflamação. Na endoscopia, 
a disseminação do score de Rutgeerts modificado deve ser fomentada.
A DEB deve ser realizada não só para resolução sintomática em 
doentes com estenoses, mas também para permitir a avaliação de 
segmentos intestinais de outra forma inacessíveis, possibilitando 
modificações terapêuticas se necessário.
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(1) Crohn BB et al. The Mount Sinai 
Journal of Medicine. 2000.
Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory 
condition of the gastrointestinal tract, encompassing two different 
diseases: Crohn´s disease (CD) and Ulcerative colitis (UC). CD was 
described for the first time in 1932 at the American Medical Association
Meeting. In this session, a paper by Crohn, Ginzburg and Oppenheimer 
was presented, entitled “Regional Enteritis, a Pathological and Clinical
Entity”(1). A disease description was made, based on a study of 14 cases
up to 1932. The first report of UC goes back to the second half of 
nineteen century when Samuel Wilks reported a case of a young woman
who died of severe bloody diarrhea. Initially reported as sporadic 
diseases, since the middle of the 20th century, the incidence of both 
diseases has increased in the western world. Currently it is estimated 
that the prevalence of IBD in western countries is up to 0,5% of the 
general population. Defined as a chronic, incurable disease with a low 
mortality rate diagnosed predominantly at a young age, the pool of 
newly diagnosed patients every year exponentially increases the number
of prevalent cases.  
Since its first report, much as evolved in terms of diagnosis and treatment 
in IBD. 
The evidence that incidence and prevalence of IBD correlates with 
industrialization and westernalization of populations has driven much 
attention to the environmental triggers of disease. IBD is believed to 
manifest in a genetically predisposed individual who reacts inappro-
priately to the gut microbiome after exposure to an external trigger. A 
great deal of investment and research has focused on how immune 
dysfunction induces and maintains a chronic inflammatory state in IBD, 
resulting in an improved understanding of its immunopathogenesis. 
Despite that, a full comprehension of the cause and mechanisms of 
IBD is still lacking. The immune pathogenic mechanisms are only one 
of the arms of the equation, interacting with genetic, microbiome and 
environmental factors. 
At the present time, recognition of immunological mediators of the 
disease has led to the development of more directed therapies but data 
are still missing in terms of unravel the causal agent(s). It is widely 
accepted that no single component of this equation can alone trigger R
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the disease and a combined disruption of all the elements controlling 
intestinal homeostasis is necessary to disease initiation and mediation. 
The follow-up of IBD patients is challenging, since it implies an 
individualized strategy, which needs to be adjusted to the disease and 
the patient. In the last decades, the way we approach and manage 
this condition has evolved tremendously. The development of new 
and more powerful drugs, capable of reverting structural damage, the 
increasing use of more accurate biological markers of inflammation to 
early detect and predict disease activity and the availability of more 
accurate imaging technics, have changed the goal of the follow-up.
Actually, the standard of care implies a close monitoring of the 
inflammatory burden of the disease in order to avoid disability. This 
includes taking into account different parameters such as symptoms, 
biological markers, endoscopy and other imaging modalities, and 
adjust therapy according. 
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Metabolomics
The increasing progress in recent years in metabolomics as shifted 
again the attention to disease pathogenesis, mainly to the importance of 
the microbiome. There are some pathological features of CD suggestive
of an infectious etiology, such as aphthous ulcers of the mucosa, 
mural abscesses, suppurative fistulas, and macrophage and epithelioid 
cell granulomas. The possible implication of an infectious agent in CD 
was first postulated by Dalziel in 1913, before the classic description 
of CD, when he noted the similarities with Johne’s disease (a diarrheal 
disease in animals, caused by Mycobacterium avium paratuberculosis, 
with epithelial granulomas). However, no infectious agent has yet 
been unequivocally identified as inducer of CD. 
It has been well demonstrated that the composition of the luminal and 
mucosal bacteria differs in patients with IBD compared to the general 
population, with a decreased prevalence of anti-inflammatory bacteria. 
The increased incidence of IBD worldwide and especially in countries 
with previous low incidences, and the increased risk for developing IBD 
among people who migrate from low to high incidence zones appear 
to support the notion of environment-driven epigenetic modifications. 
It is known that geography and ethnicity, as well as diet, antibiotic 
consumption early in life, and certain lifestyle (like smoking and oral 
contraceptive use) influences microbiota composition. This may explain
the recent changes in the incidence of microbiota-related disorders, in 
which IBD is included. The identification of several gene loci associated
with the development of IBD has highlighted the existence of a 
gene-microbe-environment interaction in IBD pathogenesis. Key 
IBD risk genes include genes involved in the pathway of sensing and 
response to microbiota. Whether tissue damage results from an abnormal
immune response to a normal microbiota or from a normal immune 
response to an abnormal microbiota remains to be definitely and 
unequivocally answered. Possibly more important than the type and 
quantity of bacteria present in the gut and altered in IBD, is the functional
consequence of that alteration, interfering with pathways involved in 
inflammation regulation.
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Much less investigated has been the role of virome in IBD. In fact, 
virus comprise the most abundant biological entities within the gut, 
greatly outnumbering bacteria. It is known that the viral component
of the microbiome has the potential to influence host physiology
and homeostasis. Enteric virome consists of bacteriophages and 
eukaryotic viruses(2-7). Like the bacterial microbiome, the human 
gut virome is characterized by significative changes during the first 
2 years of life. In adult life bacteriophages decrease in richness and 
diversity, and their composition shifts significantly; these changes
are associated with increased richness of eukaryotic viruses, which is 
believed to depend strictly on environmental influences(8). 
Animal studies have proved an interaction between eukaryotic
viruses and IBD risk genes, indicating that members of the virome
may contribute to IBD(9-12). In a study of germ-free or antibiotic treated
mice infected with murine norovirus (MNV), Kernbauer et al(13) 
demonstrated that the beneficial function of commensal bacteria
in the gut may be replaced by virus. This study supports the 
hypothesis that similarly to bacteria, eukaryotic viruses have the 
capacity to support intestinal homeostasis and shape mucosal 
immunity. Most of the research on the potential role of virus in IBD 
has focused on bacteriohages due to their influence on bacterial 
populations. The interaction of persistent virus infection with commensal 
microbiome and immune system is believed to be responsible for a 
particular immunophenotype. Virus-susceptibility gene interaction 
could explain the clinical heterogeneity and the great variability of 
response to specific treatments options between different patients. 
The role of gut virome is IBD pathogenesis is just beginning to be 
understood, but there is evidence of being altered in patients with 
IBD with specific changes assessed between UC and CD. Normal et 
al demonstrated that patients with IBD have an increased number
and richness of phage virus, with specific populations identified 
in each disease type, associated with bacterial dysbiosis(14). It has 
also been demonstrated that viral population may be influenced by 
immunosuppressive therapy, with some specific viruses taking 
advantage of the immunosuppressive status of the host(15-18). 
Despite the amount of evidence trying to implicate bacterial and viral 
dysbiosis in the pathogenesis of IBD it has been difficult to confirm 
(2) Breitbart M et al. Journal of Bacterio-
logy. 2003;185(20):6220-3.
(3) Finkbeiner SR et al. Virology Journal. 
2008;5:117.
(4) Minot S et al. Proceedings of the 
National Academy of Sciences of the 
United States of America. 2013.
(5) Minot S et al. Proceedings of the 
National Academy of Sciences of the 
United States of America. 2012.
(6) Minot S et al. Genome Research. 
2011.
(7) Reyes A et al.  Nature. 2010.
(8) Lim ES et al. Nature Medicine. 2015.
(9) Basic M et al. Inflammatory Bowel 
Diseases. 2014.
(10) Cadwell K et al. Cell. 2010.
(11) Irving PM et al. Nature Clinical 
Practice Gastroenterology & Hepato-
logy. 2008.
(12) Sun L et al.  Current Opinion in 
Gastroenterology. 2011.
(13) Kernbauer E et al. Nature. 2014.
(14) Norman JM et al. Cell. 2015.
(15) Perez-Brocal V et al. Inflammatory 
Bowel Diseases. 2015.
(16) Madsen CD et al. HIV Clinical Trials. 
2002.
(17) Thom K et al. Journal of Medical 
Virology. 2007.
(18) McElvania TeKippe E et al. PloS 
One. 2012.
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results across validation cohorts. Other potential interest of virus in 
IBD would be their role as biomarkers of disease, as several works have 
demonstrated an increased richness and biodiversity of phage population 
compared to controls(14,19,20).
It has been shown that latent viral infections, like herpesvirus infec-
tions, possess a role in exacerbating chronic inflammatory diseases(21-24). 
The Human Herpesviridae family is a DNA virus family encompassing 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Human Herpes 
simplex virus (HSSV)-6. They have in common being highly prevalent in 
adulthood (>95%) and inducing lifelong latency in the host, with reac-
tivation during periods of immunosuppression. There is a large number 
of studies trying to implicate CMV and EBV in IBD pathogenesis and/
or disease course. Although CMV colitis in immunocompetent patients 
is extremely rare, its association with IBD has been reported for more 
than half a century(25). The exact prevalence of CMV in IBD population 
is not entirely known. Several studies have shown a higher prevalence 
of CMV in IBD patients, that have not been replicated by others. This 
may be explained by selection bias and the methods used to diagnose 
the infection. While latent or subclinical infection is diagnosed by the 
presence of a positive CMV IgG, the diagnosis of CMV colitis should not 
be based on the presence of CMV IgM, but rather on viremia detection 
and presence of the virus in the colon. 
There are 3 diagnostic methods to detect CMV in colonic mucosa: 
haematoxylin and eosin staining, immunohistochemistry and polymerase
chain reaction (PCR). PCR is the most sensitive and specific of the 3 
methods in diagnosing CMV disease, being able to determine viral load. 
Qualitative PCR can detect the presence of CMV DNA in colonic mucosa, 
but that does not discriminate between infection and disease. On the other
hand, the quantitative method seems more attractive, allowing for the 
quantification of viral DNA. That has proved to be useful on the context 
of EBV and CMV infection in the post-transplant population. Nevertheless,
in IBD no cut-off has until now been defined, although some papers 
state that a CMV viral load > 250 copies/mg of tissue in patients with 
active UC is predictive of nonresponse to steroids, infliximab and 
cyclosporine(26). 
(19) Wagner J et al. Inflammatory Bowel 
Diseases. 2013.
(20) Perez-Brocal V et al. Clinical and 
Translational Gastroenterology. 2013.
(21) Barton ES et al. Nature. 2007.
(22) White DW et al. Blood. 2010.
(23) Yager EJ et al. Viral Immunology. 
2009.
(24) Canny SP et al. Journal of Virology. 
2014.
(25) Powell RD et al. The American 
Journal of Medicine. 1961.
(26) Roblin X et al. The American Journal 
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It is also assumed that the difference in the immunological milieu 
between UC and CD is responsible for the lower rate of reactivation of 
CMV in CD compared to UC(27-29). 
Another issue that remains to be clarified is the role of CMV in disease 
severity. Some reports and studies suggest that colonic superimposed 
CMV infection is associated with an increased rate of complications, 
namely toxic megacolon and need for surgery(30-32). On the other hand, 
there are more recent papers suggesting that the viral load does not 
impact on clinical outcome(26, 33). 
Although the appealing nature of this association, it has been 
difficult to prove if CMV is really a causative factor in the pathogenesis 
of severe colitis or whether it simply represents a surrogate marker of 
a severe or steroid-refractory disease. 
At the present time there are several questions concerning CMV without
a definitive answer: whether it is more prevalent in IBD population
than in general population; if there is a significative difference in 
prevalence between CD and UC; whether viral load is higher in ulcerated
compared to normal mucosa; if the presence of CMV DNA in the colonic 
mucosa determines the severity of the disease and has therapeutical 
implications. 
Regarding EBV, the major concern is its association in immunocompromised
patients with several malignancies namely Hodgkin´s disease, T/NK-cell 
lymphoma, Burkitt’s lymphoma and gastric carcinoma. The implication 
of EBV on this malignancy risk translates from the transplant setting and 
its association with post-transplant lymphoproliferative disease (PTLD)(34).
In IBD, information regarding the role of EBV in disease course and 
prognosis is scant, due to the lack of a consensual and proved more 
specific method to define disease vs infection, and a greater focus 
on CMV infection. Increasing interest in EBV has derived from the 
published evidence of the increased risk of lymphoma in IBD, especially 
among young male patients under thiopurines. In immunosuppressed 
patients, this increased risk seems to be related to reactivation of a
latent or a primary EBV infection(35). There is the notion that EBV-positive
cells can be found in the colonic mucosa of more than half of IBD 
patients, predominantly in the inflamed areas(36-38). The reason for this 
high percentage is the increased number of infiltrating B-lymphocytes 
(27) Nakase H et al. Digestive Diseases 
and Sciences. 2010.
(28) Knosel T et al. Pathology, Research 
and Practice. 2009.
(29) Takahashi Y et al. Diseases of the 
Colon and Rectum. 2004.
(30) Domenech E et al. Inflammatory 
Bowel Diseases. 2008.
(31) Kojima T et al. Scandinavian Journal 
of Gastroenterology. 2006.
(32) Kambham N et al. The American 
Journal of Surgical Pathology. 2004.
(33) Leveque N et al. Journal of Medical 
Virology. 2010.
(34) Green M et al. Am J Transplant. 
2013. 
(35) Beaugerie L et al. Dig Dis. 2009.
(36) Wakefield AJ et al. Journal of Medical 
Virology. 1992.
(37) Ryan JL et al. Digestive Diseases 
and Sciences. 2012.
(38) Spieker T et al. The American Journal 
of Pathology. 2000.
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in the mucosa due to inflammation, and the increased EBV replication 
rate as a result of immunosuppression(39).
Several authors have studied the prevalence of EBV in IBD patients. In 
a work by Knosel T et al(28), EBV DNA detected by PCR was the second
most prevalent agent in patients with CD, and not detected in the 
control group. This higher prevalence in CD patients compared to 
healthy individuals in a German population, was also reported by 
Spieker et al(38) and Ruther et al(40). This evidence was not reproduced 
in a Belgian and French population(41) and the clinical relevance of 
EBV-positivity in colon cells remains unclear, either relatively to 
disease course and malignant complications. 
A recent prospective study by Ciccocioppo et al(42) evaluated the 
prevalence of CMV and EBV in both blood and colonic mucosa, by 
quantitative PCR and immunohistochemistry. The authors concluded
that quantitative real-time PCR was the best method to define 
disease. They found a higher prevalence of both CMV and EBV in 
refractory patients compared to non-refractory and the control group, 
a higher median mucosa viral load in refractory IBD, and a significantly
higher viral DNA load in disease vs non-disease mucosa. Mucosal 
viral load positively correlated to the degree of endoscopic activity, 
both for EBV and CMV. No difference was found between median 
viral DNA levels of non-diseased mucosa and those of non-refractory 
IBD patients and controls. 
A relevant finding was the determination of a cut-off value, above 
which viral related disease was considered, suggesting a closer 
follow-up and early recognition of patients at risk. Regarding the 
impact of therapy on viral prevalence, the authors found systemic steroid
use a significant risk factor for EBV and CMV colitis, and no correlation 
with de use of immunosupressants. By contrast, our group found a 
higher prevalence of EBV in patients under infliximab, irrespective of 
associated use of other immunosupressors(43). On the other hand we 
could not find any correlation between the number of copies in serum 
and therapeutic regimen or C-reactive protein (CRP) level. Despite this 
evidence, it remains to be established if and which IBD patients should 
be tested and followed in the long-term. In the post transplant context
serial monitoring of EBV viral load is advocated, and preventive 
treatment of the infection can reduce the morbidity and mortality of 
(39) Kumar S et al. The American Journal 
of Surgical Pathology. 2000.
(40) Ruther U et al. Hepato-Gastroen-
terology. 1998.
(41) Van Kruiningen HJ et al. APMIS: 
Acta Pathologica, Microbiologica, et 
Immunologica Scandinavica. 2007.
(42) Ciccocioppo R et al. World Journal 
of Gastroenterology. 2015.
(43) Magro F et al. Inflammatory Bowel 
Diseases. 2013.
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EBV-related lymphoproliferative disorders in PTLD(44). If this approach 
is to be implemented in IBD needs further evidence. 
Another HHV related to gastrointestinal symptoms in immunocompromised 
patients is Human Herpes Virus-6. The seroprevalence in adulthood is
estimated to exceed 95%. In IBD, data on HHV-6 is scarse. The 
importance of HHV-6 reactivation in immunocompromised patients is 
being recognized in the post-transplant population, being responsible 
for severe morbidity and sometimes graft lost. It has been identified as 
a possible trigger to other herpesvirus infections, especially CMV(45-48), 
being suggested that immunosuppressed patients harboring HHV-6 
should be more closed monitored. As HHV-6 DNA has been identified
in the mucosa of post-transplant patients with gastrointestinal 
symptoms, it was hypothesized that in IBD immunosuppressed 
patients it could be a trigger of relapse. Some studies have shown a high 
prevalence of HHV-6 DNA in the colon of both UC and CD patients(36, 
49). By contrast, archival tissue examination of CD patients using PCR 
technique found HHV-6 positivity in only 3.6% (2/56) of samples(28). 
A prospective study by Sipponem T et al(50) evaluated the prevalence 
of CMV and HHV-6 antigens in the mucosa in endoscopically active 
and inactive CD and UC patients and in a non-IBD control population. 
CMV and HHV-6 antigenemia were also evaluated in IBD patients. In 
this study, the authors found a higher positivity for HHV-6 in both UC 
(45%) and CD (44%) patients. This number was comparable with that 
seen in solid organ transplant recipients(51). Both virus were shown 
to be more prevalent in endoscopically active mucosa compared to 
endoscopically inactive segments, with a significant difference in 
HHV-6 antigen expression in more severe endoscopic disease (p=.042). 
One interesting finding was the simultaneous expression of both virus 
in patients under more than one immunosupressive medication and 
with endoscopically more severe disease (at least moderate disease). 
In IBD patients, clinical significance of this coexistence is unknown, 
but in transplant recipients the presence of HHV-6 in tissue has the 
potential to trigger other herpesvirus infections, especially CMV(45-48, 52). 
Another feature that remains to be elucidated is the role of anti-TNF 
alpha agents in patients testing positive for these viruses, with some 
conflicting results. In this series, the CMV expression in the mucosa 
was more intense in patients under biologicals or cyclosporine, but the 
same was not proved for HHV-6. 
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(50) Sipponen et al. Scandinavian Journal 
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Until the present time, it remains to be proved with no margin of doubt 
if the changes observed in number and richness of virus in IBD is 
biologically and clinical relevant in terms of disease phenotype, behavior 
and response to therapy. 
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Imaging Modalities
Endoscopy
One of major difficulties in IBD is establishing the correct diagnosis. 
Being a chronic, lifelong condition, needing in the majority of patients 
of prolonged and intensive immunosuppression, an unequivocal
diagnosis is mandatory. Despite typical, symptoms are not 
pathognomonic of either disease (CD or UC), and objective data are 
required to make the diagnosis. Ileocolonoscopy is the gold standard, 
allowing to rule out other conditions that may mimic IBD symptoms 
and to obtain tissue samples for histological assessment. It is accurate
in differentiating CD from UC and has a role in evaluating disease 
extent and severity, serving as a prognostic tool. 
Endoscopic scores developed to standardize reports of mucosal 
lesions in IBD, both in clinical trials and clinical practice. In CD, the first 
endoscopic score developed and validated was de Crohn´s disease 
endoscopic index of severity (CDEIS)(53). This score proved to be 
complex and cumbersome, with limited application in clinical practice. 
In 2004 a simplified version of CDEIS, the simple endoscopic score for 
Crohn´s disease (SES-CD)(54) was proposed and validated. This score 
ranges from 0 to 56, and mucosal healing is defined as a SES-CD<3. 
In UC, the most commonly used endoscopic scores are the Mayo 
Endoscopic subscore(55) and the Ulcerative Colitis Endoscopic Index 
of Severity (UCEIS)(56), a more recent and validated score. Endoscopic 
remission is defined as a Mayo Endoscopic subscore of 0 or 1 but for 
UCEIS no cut-off has yet been defined. UCEIS has proved to be useful 
in predicting medium and long term outcomes in UC patients. 
If initially mainly limited to establishing the diagnosis, nowadays the 
role of endoscopy has evolved tremendously, not only due to technical 
developments but also to a change in the treatment paradigm of IBD. 
The severity of endoscopic findings and the extent of the disease are 
known prognostic factors predicting response to therapy and need for 
(53) Mary JY et al. Gut. 1989.
(54) Daperno M et al. Gastrointestinal 
Endoscopy. 2004.
(55) Schroeder KW et al. The New 
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surgery. During disease flares, endoscopic evaluation of the mucosa 
allows to exclude other causes of exacerbation, namely infections. 
If traditionally the clinical effectiveness of therapy was evaluated by 
clinical indices, nowadays it is known that these indices have clear 
limitations and do not correlate with mucosal findings or clinical 
outcomes in the long time. In recent years, with the advent of new 
molecules capable of inducing mucosal healing (MH) (assessed by 
endoscopy), this became the new treatment goal both for CD and UC. 
In several clinical trials, the achievement of mucosal healing has been 
associated with improved outcomes, such as lower rate of relapse, 
steroid free remission, fewer hospitalizations and surgeries. There is 
also some evidence in UC that healed mucosa may be associated with 
a decrease rate of dysplasia and colon adenocarcinoma. Endoscopy
has become an important evaluation tool of response to therapy and 
before any treatment adjustment. The Selecting Therapeutics Targets
in Inflammatory Bowel Disease (STRIDE) program(57) developed 
recommendations for potential treatment targets to be used in clinical 
practice. Both in CD and UC, endoscopic remission was agreed as a target, 
and therapy adjusted if this goal was not achieved in the reevaluation 
endoscopy. 
The performance of endoscopy in IBD goes beyond being merely a 
diagnostic or prognostic tool because it allows therapeutic procedures. 
One major complication in CD is stricture formation, still the main 
reason for surgery (either strictureplasty or bowel resection). Small 
bowel strictures occur in approximately 25% of Crohn’s disease 
patients, and colonic strictures in about 10%.  Up to 50% of CD patients 
undergo surgical resection within the first 10 years of diagnosis(58). 
After surgery, symptomatic recurrence is as high as 38% at one year, 
with need to repeat surgery that can lead to short bowel syndrome. 
Endoscopic balloon dilation (EBD) has become an accepted alternative 
to surgery, with overall favorable results in terms of safety, efficacy, and 
patient satisfaction. Being a bowel conserving procedure with high 
technical (73%-100%) and clinical success rate (64%-70%), and a low 
rate of adverse events (2%-6.4%), its major drawback is the high rate 
of recurrence. Re-dilation may be required in up to 20% and 50% by 
1 and 5 years, respectively(59-61) with the same high success rate, 
supporting the evidence that repeated dilations do not reduce the 
procedural efficacy(62, 63).
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cology & Therapeutics. 2015.
(60) Morini S et al. Digestive and Liver 
Disease: Official Journal of the Italian 
Society of Gastroenterology and the 
Italian Association for the Study of 
the Liver. 2003.
(61) Thomas-Gibson S et al. European 
Journal of Gastroenterology & Hepa-
tology. 2003.
(62) Chen M et al. Inflammatory Bowel 
Diseases. 2014.
(63) Atreja A et al. Journal of Crohn’s & 
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A recent pooled analysis reported a technical success, clinical suc-
cess, long-term symptomatic and surgical recurrence rates of 89%, 
81%, 48% and 29%, respectively(64); these data are almost exclusively 
derived from retrospective cohort studies and may somewhat over-
estimate the actual benefit. In 2013, the European Crohn’s and Colitis 
Organization stated that EBD was safe and effective and allowed 
surgery to be avoided in CD patients with anastomotic strictures(65). 
The overall technical success rate in the meta-analysis performed 
by Hassan et al was 86% (71%-100%), while 41% of patients required 
repeated EBD allowing an overall long-term clinical efficacy (avoidance
of surgery) rate of 58% during a median follow up of 33 months(66). 
Navaneethan et al. reported in their systematic review that over a 
median follow-up period of 15-70 months, only 27% of patients 
required surgical interventions, and 44% of patients required only one 
dilation with long-term success(67). Notably, median time duration 
until the requirement of surgery was observed to be 4-33 months(67) 
underlining the role of EBD as a bridge to surgery if needed, in a 
significant proportion of patients. 
Risk factors associated with need for subsequent dilation or surgery
have been inconsistent. Disease duration, smoking, presence of 
inflammation, disease activity and therapy at the time of dilation 
have been suggested as predictive factors of a successful procedure. 
In the paper by Bettenworth et al(64) only a stricture length ≤5cm was 
associated with a re-dilation and surgery free outcome. It has also 
been extensively demonstrated that EBD is equally effective and safe 
in dealing with de novo strictures compared to anastomotic strictures.
After resection, due to ongoing inflammatory activity, disease 
recurrence is common, at or above the anastomosis. Endoscopy plays 
a key role in diagnosing and grading postoperative recurrence of CD. 
Endoscopic recurrence frequently occurs before symptoms develop, 
with a recurrence rate at 1 year of 83-93%. The Rutgeerts score is 
a grading score of endoscopic severity of disease recurrence at the 
ileocolonic anastomosis and neoterminal ileum. The grade of 
endoscopic recurrence has been shown to predict clinical recurrence. 
In its original paper, Rutgeerts demonstrated that 80% of patients with 
an endoscopic score of i0 or i1 at 1 year follow-up, remained stable at 
3 years, while 92% of patients with a Rutgeerts score of i3-i4, had a 
(64) Bettenworth D. Inflammatory Bowel 
diseases. 2017.
(65) Annese V et al. Journal of Crohn’s 
& Colitis. 2013.
(66) Hassan C et al. Alimentary Pharma-
cology & Therapeutics. 2007.
(67) Navaneethan U et al. Surgical En-
doscopy. 2016.
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progressive and severe evolution at 3 years(68). For the first time, in 
an era with no effective treatment for CD, it was postulated that 
“therapeutic efforts should be directed towards those patients with 
severe progressive lesions over a long segment of the neoterminal 
ileum at endoscopy within 1year after surgery”. It was also suggested
that postoperative management could aim at preventing early 
recurrent lesions and preventing the evolution of severe early lesions 
to symptomatic disease and its complications. 
Despite its great popularity and wide use, the Rutgeerts score has 
not yet been validated, lacks interobserver agreement and has been 
a source of debate concerning the i2 subscore, which groups lesions 
at the anastomosis and neoterminal ileum together. With this in 
mind, in 2014, Gecse KB et al published in the form of an abstract, 
a work designed to evaluate the intra and interobserver agreement 
using the Rutgeerts and the Modified Rutgeerts score(69). This 
Modified score subdivides the subgroup i2 in: i2a- lesions confined to the 
anastomosis, including anastomotic strictures, and i2b- more than 5 
aphthous ulcers or larger lesions, with normal mucosa in between, in 
the neoterminal ileum, with or without anastomotic lesions. Endoscopic
recurrence is considered only for a Modified Rutgeerts score ≥ i2b.
More than 20 years have gone since Rutgeerts´ publication and 
our understanding of the natural history of post-operative CD has 
improved. At present, there is major scientific evidence that supports 
early endoscopic evaluation of the neoterminal ileum in order to de-
tect recurrence and adjust therapy. The POCER trial(70) demonstrated 
the short-term benefit of postoperative endoscopic evaluation and step-
up treatment in case of endoscopic recurrence. This group of patients 
had a better prognosis at 18 months, with lower endoscopic recur-
rence, when compared to patients who received standard of care. A 
recent published technical review stated that endoscopic evaluation is 
recommended at 6 to 12 months postoperatively to evaluate for 
endoscopic recurrence with adjustment of medical therapy accordingly. 
Endoscopy of the Small Bowel
Being a pan-enteric disease, CD can affect any segment of the gastro-
intestinal tract. In almost 2/3 of patients the small bowel is involved 
and up to 30% of newly diagnosed CD patients have disease limited 
proximally to the reach of ileocolonoscopy(71). It is known that proximal 
(68) Rutgeerts P et al. Gastroenterolo-
gy. 1990.
(69) Gecse K et al. Gastroenterology.
(70) De Cruz P et al. Lancet. 2015.
(71) Annunziata ML et al. Digestive 
Diseases and Sciences. 2012.
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small bowel (jejunal) involvement carries a worse prognosis with more 
relapses, hospitalizations and surgery(72, 73), so correct diagnose of disease
extension and phenotype is mandatory. 
The endoscopic evaluation of the small bowel includes video capsule 
endoscopy (VCE) and device-assisted enteroscopy (DAE). VCE has 
been widely used since early 2000, is a non-invasive and well-tolerated
method, with a high diagnostic yield. Although in most cases the 
initial diagnosis of CD can be established only by ileocolonoscopy, the 
thorough evaluation of the entire digestive tract has implications in 
terms of prognosis and therapeutic decisions. 
According to ECCO (European Crohn´s and Colitis Organization) 
guidelines(74), VCE should be reserved for patients in whom the clinical 
suspicion for CD remains high despite negative evaluation by ileo-
colonoscopy and radiological examination. Despite this, VCE is often
used as a first line diagnostic tool after ileocolonoscopy in the 
suspicion of CD, as it is more accurate than sectional modalities in 
detecting lesions of the upper small bowel(75-77). Its major advantage is 
an elevated sensitivity to detect superficial mucosal lesions, especially 
in the jejunum where the larger mucosal surface, with redundant folds 
and lesser lumen distension, increases the rate of false positives and 
negatives with transversal imaging methods. 
In a recent meta-analysis(75) the diagnostic yield of VCE proved to be 
superior to ileocolonoscopy, small bowel follow-through and Computed
Tomography Enterography (CTE) (incremental yield ranged from 22% 
to 47%, respectively). Only the 10% incremental yield compared to 
Magnetic Resonance Enterography (MRE) did not reach statistical 
significance. A meta-analysis from Uri Kopylov et al(78), demonstrated 
a similar diagnostic yield for detection of SB inflammation by CE, MRE 
and small intestine contrast ultrasonography (SICUS), both in suspected
and established CD. However, CE consistently shows a superior 
accuracy for detection of proximal small bowel (SB) disease. This is 
of particular interest in the pediatric population, where proximal SB 
involvement as implications in management planning, and has a 
prognostic value being associated with a higher risk of surgery. A 
recent prospective study performed in CD patients in clinical remission
diagnosed previously unknown proximal involvement in 51% of 
patients(79). 
(72) Park SK et al. Journal of Clinical 
Gastroenterology. 2013.
(73) Flamant M et al. Inflammatory 
Bowel Diseases. 2013.
(74) Gomollon F et al. Journal of 
Crohn’s & cColitis. 2017.
(75) Dionisio PM et al. The American 
Journal of Gastroenterology. 2010.
(76) Jensen et al. Clinical Gastroen-
terology and Hepatology: the Official 
Clinical Practice Journal of the Amer-
ican Gastroenterological Association. 
2011.
(77) Pica R et al. Journal of Crohn’s and 
Colitis.
(78) Kopylov U et al. Digestive and Liver 
Disease: Official Journal of the Italian 
Society of Gastroenterology and the 
Italian Association for the Study of 
the Liver. 2017.
(79) Greener T et al. Journal of Crohn’s 
& colitis. 2016.
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Due to the need to standardize reports, two scoring systems were 
developed for CE. Both were prospectively validated and are able 
to quantify the inflammatory activity of CD, enabling the objective 
assessment of disease severity. The Lewis score(80), the more widely 
used, divides the small bowel into 3 equal parts - the tertiles - and has 
well established cut-offs to define remission, mild inflammation and 
moderate-severe inflammation. The Capsule endoscopy Crohn’s disease
activity index (CECDAI), or Niv score(81), divides the small bowel in 2 
segments, proximal and distal, and the segmental and total score is 
calculated based on a formula. There are no define cut-off values to 
grade disease activity other than a score less than 4, that defines 
endoscopic remission.
If its positioning in disease diagnosis is still a matter of debate, much 
less has been investigated concerning VCE findings in therapeutic 
guidance and therapeutic changes(82-84). Some studies addressed this 
issue, but with some limitations.  In recent years, there have been some 
evidence of treatment modifications in CD patients after VCE, both in 
adults and pediatric populations, with short and long-term disease.
If mucosal healing is the goal of treatment and does not correlate 
with symptoms, objective evaluation is needed. There are a limited 
number of published papers evaluating the role of VCE in mucosal 
healing assessment. In a meta-analysis published in 2017(85), mucosal
healing assessed by VCE was found to be associated with clinical
remission after a follow-up of 12 weeks to 24 months. Despite these 
promising results, currently there is no consensus definition of 
mucosal healing defined by VCE, and quantification of inflammatory 
activity by means of the validated Lewis score and CECDAI index is 
recommended. 
Other indication with therapeutic implications is the detection of 
acute lesions in patients in clinical remission. Our group published a 
paper addressing the role of VCE in the therapeutic management of 
CD. In patients in clinical and biochemical remission, 36% changed 
therapy after VCE(86). Immunosuppression and biological therapy was 
started in 28% and 5% respectively. In a prospective study evaluating 56 
CD patients in clinical remission, the presence of active inflammation 
detected by VCE was a predictor of clinical relapse.   
(80) Rosa B et al. Journal of Crohn’s & 
Colitis. 2012.
(81) Niv Y et al. Endoscopy. 2012.
(82) Long MD et al. Inflammatory Bowel 
Diseases. 2011.
(83) Lorenzo-Zuniga et al. Digestive 
Diseases and Sciences. 2010.
(84) Gralnek IM et al. Digestive Diseases 
and Sciences. 2012.
(85) Niv Y. European Journal of Gastro-
enterology & Hepatology. 2017.
(86) Santos-Antunes J et al. World Jour-
nal of Gastroenterology. 2015.
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An emerging indication for VCE is in postoperative evaluation, 
although the number of studies and patients included is very small. 
The 2 major advantages of VCE comparatively to ileocolonoscopy are 
the detection of lesions outside the scope of colonoscopy and patient´s 
preference(87-89). As VCE carries a theoretical increased risk of impaction 
in this setting, at the present time, its use should only be considered if 
colonoscopy is unsuccessful or contraindicated or to evaluate proximal
extension of the disease. There is only one pilot study(90) evaluating the 
performance of VCE in the diagnosis of postoperative recurrence of 
small bowel lesions in CD. In this study recurrence was defined as an 
increase of 100 points or more in Lewis Score at 6 months, compared
to the VCE performed one month after surgery. A pilot study(91) 
including 22 CD patients previously submitted to surgery, assessed the 
value of pan-intestinal capsule endoscopy (PICE) for the detection of 
recurrence. The authors concluded that PICE is feasible and provides 
significant findings in the postoperative surveillance of CD patients 
with impact on clinical management. 
The role of capsule endoscopy is still evolving in the management of CD 
patients, with its applicability expanding beyond just an initial diagnostic
method. As CD patients will require multiple imaging procedures 
during the course of their disease, ease of use and reduction of patient’s 
discomfort should always be considered as important. Patient preference 
may have a major impact on adherence with any monitoring strategy, and 
should be considered whenever possible.
Device assisted-enteroscopy (DAE) is an endoscopic method of 
examination of the small bowel with assisted progression in the 
lumen by a balloon or overtube. In the context of suspected Crohn´s 
disease, the diagnostic yield ranges between 22 % and 70%(92-94). Its 
major advantage is the possibility of histological assessment to 
confirm the diagnosis or to exclude other conditions which mimic the 
appearance of Crohn’s disease (92, 93, 95-98). In patients with a high clinical 
index of suspicion for active Crohn’s disease, DAE is more accurate 
than small-bowel barium contrast studies(99) and MRE(100, 101). It has the 
disadvantages of being an invasive and time-consuming procedure. 
(87) Bourreille A et al. Gut. 2006.
(88) Pons Beltran V et al. Gastrointesti-
nal Endoscopy. 2007.
(89) Kono T et al. World Journal of Gas-
trointestinal Endoscopy. 2014.
(90) Cesarini M et al. Inflammatory 
Bowel Diseases. 2008.
(91) Hausmann J et al. Scandinavian 
Journal of Gastroenterology. 2017.
(92) Gay G et al. Gastrointestinal En-
doscopy. 2007.
(93) Manes G et al. Surgical Endoscopy. 
2009.
(94) Heine GD et al. Endoscopy. 2006.
(95) Seiderer J et al. Scandinavian Jour-
nal of Gastroenterology. 2007.
(96) Sunada K et al. World Journal of 
Gastroenterology. 2005.
(97) May A et al. Gastrointestinal En-
doscopy. 2005;62(1):62-70.
(98) Prachayakul V et al. BMC Gastro-
enterology. 2013;13:103.
(99) Oshitani N et al. The American 
Journal of Gastroenterology. 2006; 
101(7):1484-9.
(100) de Ridder L et al. Gastrointestinal 
Endoscopy. 2012.
(101) Takenaka K et al. Gastroenterology.
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At the present date, according to recommendations of the European 
Society of Gastrointestinal Endoscopy (ESGE), the indication for DAE 
in the diagnosis of CD is limited to patients with noncontributory 
ileo-colonoscopy and with suspicion of Crohn’s disease on small-bowel 
cross-sectional imaging modalities or VCE. Its major indication is as a 
therapeutic modality in bleeding, strictures dilation or foreign bodies 
retrieval(93, 99, 102). Technical success rate in dilating strictures is reported 
to be between 60% and 80% and repeat endoscopic balloon dilation 
may be undertaken(103-105), but long-term outcomes are less well known. 
Complication rate, namely perforation, may be as high as 9%(103, 106-109).
An applicability that is being explored is its use in the assessment of 
mucosa healing, allowing evaluation of the activity of small bowel 
lesions as well as colorectal lesions by a single endoscopic procedure. A 
scoring system was developed, the modified Simple Endoscopic Score 
for Crohn’s disease (mSES-CD), which includes assessment of the 
endoscopic activity of small bowel lesions. This score evaluates 2 ileal 
segments, 80 cm proximal to the ileocecal valve, and the total score 
ranges from 0-67. This score showed predictive value in clinical outcome, 
with patients with higher scores having lower surgery-free survival(110).
Enterography
Imaging modalities are of foremost importance in the management of 
inflammatory bowel disease. Although endoscopy is still the reference 
method in diagnosing disease, disease recurrence in the post-operative 
setting, and mucosal healing, further investigation is recommended. 
Cross sectional imaging modalities, mainly magnetic resonance 
enterography (MRE) and computed tomography enterography (CTE), 
are complementary to endoscopy as they allow detection of transmural 
inflammation, penetrating and extraintestinal complications of CD, and 
evaluation of segments out of reach by conventional endoscopy. Both 
techniques are the current standards for assessing the small bowel, 
in terms of disease location, extension and activity, offering the op-
portunity to classify and stage disease. Radiological techniques have 
the advantage of identifying isolated transmural CD, not detected by 
endoscopic modalities.
(102) Lee BI et al. Gastrointestinal En-
doscopy. 2005.
(103) Despott EJ et al. Gastrointestinal 
Endoscopy. 2009.
(104) Swaminath A et al. Inflammatory 
Bowel Diseases. 2008.
(105) Di Nardo G et al. Gastrointestinal 
Endoscopy. 2010.
(106) Fukumoto A et al. Gastrointestinal 
Endoscopy. 2007.
(107) Pohl J et al. European Journal 
of Gastroenterology & Hepatology. 
2007.
(108) Hirai F et al. Digestive Endoscopy: 
Official Journal of the Japan Gastroen-
terological Endoscopy Society. 2014.
(109) Gill RS et al. Therapeutic Advances 
in Gastroenterology. 2014.
(110) Morise K et al. World Journal of 
Gastroenterology. 2015.
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CTE consists of a high spatial resolution imaging of the small bowel
with a multi-detector CT, after the ingestion of a neutral enteric 
contrast agent that allows luminal distension. The use of an enteric agent 
combined with an intravenous contrast agent permits to distinguish
the different layers of bowel wall and the perienteric fat and mesentery. 
Artifacts due to bowel and respiratory movements are effectively 
eliminated as data is acquired in a single breath-hold. Most of the 
studies conducted to evaluate the performance of CTE for active CD 
have revealed a sensitivity range from 80-90%(111-114). Disease activity is 
evaluated considering wall thickness, wall enhancement, mesenteric
fat proliferation and densification, the presence of comb sign and 
enlarged lymph nodes. Conflicting data exist concerning the relationship
between radiological signs of inflammation and disease activity. Some 
studies report a significant correlation between mural findings and 
biomarkers of disease activity(115) while others were not able to confirm 
these results(114, 116, 117). Few data exist about the relationship between 
signs of perienteric inflammation and clinical or biochemical indices 
of activity. Lee et al first described the association of prominent 
perienteric or pericolic vasculature and active CD(118). Colombel et 
al found a significant relationship between radiological findings of 
perienteric inflammation (increased fat density) and CRP(119). Minordi
et al evaluated both mural signs (parietal thickness, target sign or 
alternating rings of low and high density in the bowel wall) and 
extraenteric inflammation(120). There was a positive correlation 
between the target sign and fibro-fatty proliferation and the Crohn´s 
Disease Activity Index (CDAI) and between wall thickness, comb sign 
and perienteric stranding and CRP. These inhomogeneous findings 
have limited the development of a scoring system that objectively 
evaluates CTE activity, defines activity vs remission and compares its 
evolution over time. 
In clinical practice, the benefit of small bowel examination using an 
enterography technique has been explored. In a cohort of 357 patients 
with CD who underwent CTE, penetrating disease was identified in 20% 
of patients(121), representing a new finding in almost 2/3 of the patients. 
CTE also detected extraintestinal IBD in 18.8% of patients, being a new 
finding in 67.2%. In a prospective study involving 273 patients with 
(111) Bodily KD et al. Radiology. 2006.
(112) Booya F et al. Radiology. 2006.
(113) Hassan C et al. International Jour-
nal of Colorectal Disease. 2003.
(114) Solem CA et al. Gastrointestinal 
Endoscopy. 2008.
(115) Maccioni F et al. Abdominal Ima-
ging. 2000.
(116) Neurath MF et al. The American 
Journal of Gastroenterology. 2002.
(117) Schunk K et al. Investigative Ra-
diology. 2000.
(118) Lee SS et al. AJR American Jour-
nal of Roentgenology. 2002.
(119) Colombel JF et al. Gut. 2006.
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Medica. 2015.
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established or suspected CD, CTE findings altered management plans 
in 1 of every 2 cases independent of clinical, serologic, and histological 
findings(122). 
Its applicability goes beyond a diagnostic tool in assessing disease 
activity, extension and complications in a single time point. CTE may 
be and has been used in disease monitoring. In a preliminary study, 
Hara et al have reported the potential of CTE for longitudinal disease 
monitoring, noting its reliability to predict disease progression or 
regression(123). A retrospective study, published in 2011(124), showed that 
about 2/3 of patients treated with anti-TNF alpha had a significant 
radiological response as assessed by serial CTEs. Minordi et al also 
found a good correlation between clinical and radiological evaluation 
of 45 CD patients, before and after therapy(120). More recently, Deepak et 
al showed that achievement of complete or partial radiologic response 
at the first follow-up CTE/MRE after treatment decreased the risk 
for steroid usage by over 50% (hazard ratios: 0.37 [95% CI, 0.21–0.64]
and 0.45 [95% CI, 0.26–0.79], respectively(125). Complete response 
decreased the risk of subsequent hospitalization and surgery by over 
two-thirds (HR: 0.28 [95% CI, 0.15–0.50] and 0.34 [95% CI, 0.18–0.63], 
respectively). In addition, disease activity evaluated by CTE has proved 
to correlate with endoscopic activity(111, 119, 126), with the advantage of 
being a noninvasive method, better tolerated by patients and giving 
information about all the extension of the disease.
All these encouraging findings about the accuracy of CTE to evaluate 
disease response to therapy and its prognostic significance, gave rise 
to the suggestion that radiological response may be a more appropriate
therapeutic target. The persistence of transmural inflammation despite 
mucosal healing, not diagnosed by endoscopy, often leads to structural 
bowel damage (BD) and intestinal complications conducting to surgery 
and subsequent increased bowel damage. It is known that BD is asso-
ciated with a worse prognosis with a higher risk of hospitalization and 
surgery during follow-up. 
(122) Bruining DH et al. Inflammatory 
Bowel Diseases. 2012.
(123) Hara AK et al. AJR American Jour-
nal of Roentgenology. 2008.
(124) Bruining DH et al. Clinical Gas-
troenterology and Hepatology: the 
Official Clinical Practice Journal of 
the American Gastroenterological 
Association. 2011.
(125) Deepak P et al. The American 
Journal of Gastroenterology. 2016.
(126) Sakurai T et al. European Journal 
of Radiology. 2017.
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Even though MRE is attempting to replace CTE, due to concerns 
regarding radiation exposure, CTE is cheaper, more readily accessible, 
faster, with higher spatial resolution and better tolerated by patients. CTE 
may even be superior to MRE in terms of image quality and interobserver 
agreement(127). Nowadays there are several strategies available to reduce 
radiation dose exposure, with no compromise of diagnostic accuracy. 
(127) Qiu Y et al. Alimentary Pharma-
cology & Therapeutics. 2014.
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The Lémann Score 
(The Crohn’s Disease Digestive Damage Score)
One of the major limitations in changing the course of CD is the delay 
between onset of symptoms and diagnosis. This allows BD to progress 
and at the time of first disease assessment the magnitude of BD is 
consistent with several years of disease activity, being irreversible and 
conducting to intestinal resection.  
The clinical and endoscopic scores available to estimate disease severity
only assess inflammation at a specific time point and do not allow 
physicians to evaluate the cumulative structural bowel damage and 
thus do not capture the progressive, destructive course of the disease. 
There have also been identified several prognostic factors at diagnosis
associated with a worse outcome(128) (steroid-dependency, perianal 
disease, extensive small bowel disease, rectal involvement, extra-
intestinal manifestations, young age, ileal disease, penetrating behavior),
increased risk of surgery and hospitalization. Data from rheumatology
shows that the only effective way to slow disease progression, improve
the long-term benefits of therapy and alter the natural history of 
disease is intervening before tissue damage occurs. In CD, even during 
periods of clinical and biochemical remission subclinical inflammation
often persists and there is an evolution of disease phenotype to 
stricturing or penetrating disease(129, 130). Surgical resection of bowel, 
many times the treatment of these complications, should be recognized 
as the ultimate manifestation of bowel damage(57). Following surgery, 
this cycle often recurs, leading to progressive loss of intestinal function 
and disability. 
Treatment with immunomodulators or anti-TNF agents in the first 2 
years of disease diagnosis have proved to be associated with reduced 
risk of strictures, intestinal and perianal surgery and any complication, 
compared to its initiation after 2 years of diagnosis (131). This increased 
amount of evidence has been changing the way we approach CD. 
Despite not yet translated in clinical guidelines, it is of good clinical
(128) Zallot C et al. Digestive Diseases. 
2012.
(129) Louis E et al. Gut. 2001.
(130) Cosnes J et al. Inflammatory Bowel 
Diseases. 2002.
(131) Safroneeva E et al. Alimentary 
Pharmacology & Therapeutics. 2015. R
at
io
na
l a
nd
 In
tr
od
uc
tio
n
58
practice to stratify patients according to their risk of disease progression.
In those with a high risk, more “effective/aggressive” therapeutic 
strategies and strict follow-up monitoring should be provided in order to 
try to change disease course and prevent structural bowel damage.
The Lémann Index (LI), using a combination of endoscopic and imagiological
assessment of disease activity, is the first quantitative tool that 
measures the cumulative bowel damage by using resections and the 
extent and severity of lesions in the digestive tract of CD patients(132). 
The development of this score aimed at the possibility to measure 
cumulative bowel damage at a specific time point in patients´ evolution
and its progression over time; identify patients with CD at high (or low) 
risk of rapid damage progression; and assess the impact of treatment 
strategies on the progression of CD. In the near future, the LI calculation
may play an important role in CD management. A recent paper from 
G. Fiorino et al evaluated the prognostic value of the LI in early CD(133). 
In this study, the presence of BD at diagnosis, assessed by the LI, was 
associated with a higher risk of hospitalization and surgery during
follow-up (median 4.9 years). The authors also found that disease
activity, evaluated by MaRIA index, had little or no role in predicting
disease course. Taking all these evidences together, it is growing
the assumption that maybe we should explore this new therapeutic
endpoint: transmural healing (TH). At present there are few papers 
focusing on TH, with a limited number of patients(134-136). TH seems to 
be related to MH and disease duration, with higher response rates to 
anti-TNF alpha agents in early stages of the disease. 
On the basis of this findings, we can assume that an early effective 
intervention in the course of the disease, with disease modifying 
agents, translates into MH and TH. As both end points correlate 
with each other, cross-sectional modalities could be used to monitor 
disease, lowering the need for repeated colonoscopies.
(132) Pariente B et al. Gastroenterology. 
2015.
(133) Fiorino G et al. Journal of Crohn’s 
& Colitis. 2017.
(134) Ordas I et al. Gut. 2011.
(135) Rutgeerts P et al. Gastroenterolo-
gy. 2012.
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Fecal Biomarkers
Over the last 20 years, progress has been made in the identification,
quantification, and validation of a range of fecal biomarkers of 
inflammation. Conceptually, fecal markers would be more sensitive and 
specific in IBD due to some of their particularities. As the fecal stream 
is in direct contact with the inflamed mucosa, they are specific for 
intestinal inflammation and their concentration is assumed to reflect 
the extent and severity of the inflammation present and to promptly 
respond according to a decrease or increase in the inflammatory burden.
They have gained a major role in IBD management in the last years 
due to their noninvasive benefits which gives them the possibility to be 
repeated as needed. Their applicability includes the differential 
diagnosis between inflammatory and functional disease, selecting 
patients to further work-up; the prediction of relapse, aiding therapeutic 
decision-making, and informing patient prognosis.
Calprotectin (FC), a member of the S-100 family of proteins, is a 36-kDa
calcium-binding and zinc-binding protein complex constituting up 
to 60% of neutrophil cytosol protein that is released upon neutrophil 
activation(137). It has also been described as a damage-associated
molecular pattern (DAMPs) molecule. DAMPs molecules may be 
released by necrotic cells or secreted by activated inflammatory 
cells and are considered to function as a communication mechanism 
between innate and adaptive immunity to regulate immune 
function(138). FC excretion reflects increased neutrophil migration into 
the gut lumen through an inflamed mucosa, but despite being specific
for gut inflammation, it is not disease specific. FC has proved to 
provide a clear distinction between inflammatory disease, healthy 
controls, and functional bowel disorders(139-142). Apart IBD, it is increased 
in non-steroidal anti-inflammatory drug enteropathy, pancreatic 
insufficiency, alcoholic enteropathy, and colorectal cancer. 
Lactoferrin (FL), a 76-kDa iron-binding protein, similarly to FC is 
neutrophil derived, being the main component of secondary granules 
that degranulate during the inflammatory process(143). Several authors 
reported a high sensitivity and specificity of FL in differentiating IBD 
from IBS, with sensitivities ranging from 78% to 88%, and specificities
(137) Theede K et al. Inflammatory Bowel 
diseases. 2016.
(138) Garcia-Sanchez V et al. Journal of 
Crohn’s & Colitis. 2010.
(139) van Rheenen PF et al. BMJ. 2010.
(140) Licata A et al. Journal of Clinical 
Gastroenterology. 2012.
(141) Roseth AG et al. Scandinavian 
Journal of Gastroenterology. 1992.
(142) Tibble J et al. Gut. 2000.
(143) Abraham BP et al. Gastroenterolo-
gy Clinics of North America. 2012.
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between 85% and 100%. There is evidence that FL can be used in pediatric
population and that FL elevation occurs prior to clinical relapse(144, 145). 
Lactoferrin proved to correlate with clinical activity index both in CD 
and UC and with histological inflammation(146). Some authors found a 
significant correlation between FL and CDEIS, being able to predict 
mucosal healing and response to anti-TNF alfa therapy(147, 148). Patients 
with increased levels of FL were also at higher risk of postoperative 
recurrence compared to those with normal levels(149-151). Despite this 
encouraging results FL has not been yet validated as extensively as FC. 
There is also a large amount of evidence on the ability of FC in 
predicting endoscopic disease activity in IBD, both in CD and UC. In CD, 
CDEIS correlated better with FC than with CDAI(152). Different studies
have found different cut-off values of FC predictive of endoscopic 
remission and grading disease severity(152-154), limiting the comparison 
between studies and the establishment of a definitive and universal 
cut-off value. There is also some evidence suggesting a better correlation
between the FC levels and endoscopic activity when the disease has 
ileocolonic or colonic involvement than when it is only ileal(153). Other
studies have also found a good correlation between FC levels and 
the degree of disease activity detected by magnetic resonance 
enterography(155) and small bowel inflammation score in capsule 
endoscopy (Lewis score)(156).
In UC, endoscopic disease activity correlates better with FC than 
with blood biomarkers or the clinical activity index(157). Similarly to CD, 
different cut-off values of FC were able to discriminate among 
different grades of endoscopic severity(157). Notably, histologic features
of inflammation can be identified by FC measurements, with a 
significantly higher average level in patients presenting active histologic 
inflammation(158). The clinical and prognostic implication of this finding
is still a matter of debate, although several papers have found an 
increased risk of relapse in patients presenting histological activity 
despite endoscopic remission. 
In patients in clinical remission, serial monitoring of FC is able to 
detect subclinical mucosal inflammation and identify patients at risk of 
(144) Walker TR et al. Journal of Pediatric 
gastroenterology and nutrition. 2007.
(145) Vrabie R et al. Gastroenterology & 
Hepatology. 2014.
(146) Vieira A et al. BMC Research 
Notes. 2009.
(147) Sipponen T et al. Inflammatory 
Bowel Diseases. 2008.
(148) Jones J et al. Clinical Gastroen-
terology and Hepatology: the Official 
Clinical Practice Journal of the Amer-
ican Gastroenterological Association. 
2008.
(149) Scarpa M et al. Diseases of the Co-
lon and Rectum. 2007.
(150) Lamb CA et al. The British Journal 
of Surgery. 2009.
(151) Ruffolo C et al. Journal of Gastro-
intestinal Surgery: Official Journal of 
the Society for Surgery of the Alimen-
tary Tract. 2010.
(152) D’Haens G et al. Inflammatory 
Bowel Diseases. 2012.
(153) Lobaton T et al. Journal of Crohn’s 
& Colitis. 2013.
(154) Schoepfer AM et al. The American 
Journal of Gastroenterology. 2010.
(155) Cerrillo E et al. Inflammatory Bowel 
Diseases. 2015.
(156) Koulaouzidis A et al. Digestive 
Diseases and Sciences. 2016.
(157) Schoepfer AM et al. Inflammatory 
Bowel Diseases. 2013.
(158) Guardiola J et al. Clinical Gastro-
enterology and Hepatology: the Of-
ficial Clinical Practice Journal of the 
American Gastroenterological Asso-
ciation. 2014.
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relapse(159, 160). FC has also demonstrated to be a good tool in evaluating 
response to therapy with anti-TNF alpha(161, 162). 
Patients with low FC levels were associated with good response to 
therapy and long-term remission while patients with higher FC levels
relapse in the short-term. Once more, different cut-off values were 
found to associate with the probability of relapse and remission. The 
same way CRP was found to be predictive of response to treatment, FC 
changes after initiation of a new therapy in active disease correlated 
with treatment response(163). A decrease on FC concentration at week 
2 in UC patients undergoing infliximab induction therapy, correlates 
with endoscopic remission at week 10(164). 
(159) Costa F et al. Gut. 2005.
(160) D’Inca R et al. The American Jour-
nal of Gastroenterology. 2008.
(161) Ferreiro-Iglesias R et al. Journal 
of Clinical Gastroenterology. 2016; 
50(2):147-51.
(162) Ferreiro-Iglesias R et al. Scandi-
navian Journal of Gastroenterology. 
2016.
(163) Sands BE. Gastroenterology. 2015.
(164) De Vos M et al. Journal of Crohn’s 
& Colitis. 2012.
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Fecal Biomarkers 
in the Postoperative Setting
Surgery, albeit not a curative option for CD, is frequently needed in its 
management. Postoperative recurrence is common, with endoscopic 
lesions preceding the development of clinical symptoms. It is known 
that patients with more severe endoscopic lesions after surgery, will 
have a greater probability of future clinical recurrence(68, 165). This 
evidence has been the rational for an early detection of postoperative 
recurrence and subsequent intervention. The POCER trial has recently 
demonstrated that treatment should be personalized and based on the 
risk of recurrence(166). 
Today, ileocolonoscopy is the gold standard to monitor recurrence but it 
has some inconveniences and it is questionable its timely performance
in real-world clinical practice. It is desirable to develop a simpler, 
noninvasive, more acceptable and cheaper alternative to diagnose early 
postoperative recurrence. Based on the good diagnostic and monitoring 
performance of fecal markers in IBD, recent studies have focus on the 
utility of FC and FL in the postoperative setting(167-174). 
In a recent meta-analysis published in 2015, including 10 studies and 
613 postoperative CD patients, the pooled sensitivity and specificity for 
assessing endoscopic recurrence was 0.82 (95% CI, 0.73-0.89) and 0.61 
(95% CI, 0.51-0.71), respectively(175). The overall positive and negative 
likelihood ratios was 2.11 (95% CI, 1.68-2.66) and 0.29 (95% CI, 0.197-
0.44), respectively. As endoscopic recurrence is used to predict clinical 
recurrence, and a significant correlation between fecal markers and 
endoscopic score has been shown, it is assumed that fecal markers 
can have a role in predicting clinical recurrence after surgery in CD. In 
a series of recent studies, FC and FL levels were significantly higher
in patients with endoscopic recurrence than in those in remission, 
with a better correlation with endoscopic activity than serological 
biomarkers. A recent study by Yamamoto et al also found that 
consecutive monitoring of FC after the initial ileocolonoscopy in patients 
with no endoscopic recurrence is useful in their management(174). An 
(165) Yamamoto T et al. United Europe-
an Gastroenterology Journal. 2013.
(166) De Cruz P et al. Alimentary Phar-
macology & Therapeutics. 2015.
(167) Wright EK et al. Gastroenterology. 
2015.
(168) Boschetti G et al. The American 
Journal of Gastroenterology. 2015.
(169) Hukkinen M et al. Journal of Pedi-
atric Surgery. 2016.
(170) Lopes S et al. Inflammatory Bowel 
Diseases. 2016.
(171) Wright EK et al. Inflammatory 
Bowel Diseases. 2016.
(172) Herranz Bachiller MT et al. Scan-
dinavian Journal of Gastroenterology. 
2016.
(173) Garcia-Planella E et al. Inflamma-
tory Bowel Diseases. 2016.
(174) Yamamoto T et al. Therapeutic 
Advances in Gastroenterology. 2016.
(175) Qiu Y et al. Inflammatory Bowel 
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increase in FC levels indicates the need to repeat ileocolonoscopy,
while sustained low FC levels predicts a low risk of endoscopic 
recurrence, avoiding an unnecessary invasive endoscopic examination.
The drawback that limits the generalized use of these markers in 
clinical practice and in disease monitoring, is the large quantitative 
difference between the different assays, limiting its use interchangeably
and making impossible to compare studies and standardize cut-offs.
In the POCER study, a FC level greater than 100 mg/g indicated 
endoscopic recurrence, while in others, a cutoff value of 200 mg/g was 
used as predictor of recurrence(153, 176).
Much is still unsolved regarding fecal markers. It is assumed that fecal
biomarkers present a considerable day-to-day variability, are not 
specific for IBD and their levels vary with age, making difficult to 
establish a unique cut-off value. Their utility in proximal small bowel 
disease has yet to be fully elucidated. In contrast, there is an increasing
amount of evidence suggesting that FC can be used as a marker of 
disease recurrence after surgery and correlates with histological 
activity. The benefit of combining different fecal markers has not yet 
been irrefutably proven, with some authors suggesting that a composite
index may enhance test utility, while others have not shown additional
benefit in this combination(177-179). It is necessary to determine the 
appropriate time interval for monitoring disease activity in different 
clinical contexts, and to standardize the assays used in order to define 
the most suitable cutoff levels to define disease activity, response to 
therapy and mucosal healing.
In summary, fecal markers have emerged as surrogate markers of 
mucosal inflammation/healing, even though the predictive value of 
uniform thresholds at an individual level has not been clearly 
demonstrated. More important than an isolated measurement is to 
have serial determinations that allow physicians to evaluate response to 
therapy, anticipate flares and adjust interventions. 
(176) Orlando A et al. European Review for 
Medical and Pharmacological Sciences. 
2006.
(177) Schoepfer AM et al. Diseases of 
the Colon and Rectum. 2007.
(178) Schoepfer AM et al. Inflammatory 
Bowel Diseases. 2008.
(179) Judd TA et al. Journal of Gastroen-
terology and Hepatology. 2011.
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The specific aims of this Thesis were: 
1.  To evaluate the prevalence and viral load of Epstein–Barr virus, 
Cytomegalovirus, and Human Herpes virus 6 in blood and mucosa of 
adult patients with endoscopic active IBD. We intended to determine 
if the prevalence of these ubiquitous virus was higher in IBD patients 
compared to healthy controls, and to assess if virus prevalence was 
influenced by different therapeutic regimens. Associated objectives 
were to find a possible correlation between mucosal disease severity 
and viral load.
2.  To evaluate the accuracy and best cut-off value of FC and FL in 
diagnosing endoscopic recurrence in CD patients submitted to 
resection surgery, using the Modified Rutgeerts score compared to 
the Rutgeerts score. We also intended to compare fecal markers to 
a clinical disease activity index and serum biomarkers in predicting 
endoscopic recurrence.
3.  To assess the accuracy of FC and FL in predicting disease 
recurrence in asymptomatic CD patients presenting with 
anastomotic strictures, and selecting patients to endoscopic balloon 
dilation.
4.  To evaluate the incidence of anastomotic strictures after intestinal 
resection in Crohn’s disease, to demonstrate long-term efficacy and 
safety of endoscopic balloon dilation in CD strictures and its impact 
on the diagnosis of subclinical postoperative endoscopic recurrence. 
5.  To explore the correlation between endoscopic disease activity, 
fecal markers levels and CTE findings of inflammatory activity at 
diagnosis and one year after immunosuppressive therapy. We 
also aimed to determine the best cut-off value of FC to predict 
endoscopic remission and which CTE findings should be looked for 
when trying to define disease remission.
6.  To evaluate the impact of video capsule endoscopy findings in the 
management of asymptomatic CD patients. 
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Looking into Enteric Virome in Patients with IBD:
Defining Guilty or Innocence?
Susana Lopes, MD,* Patricia Andrade, MD,* Silvia Conde, MD,† Rodrigo Liberal, MD, PhD,*
Cláudia C. Dias, PhD,‡ Salomão Fernandes, MD,§ Jorge Pinheiro, MD,§ Joana S. Simões, MD,†
Fátima Carneiro, MD, PhD,§ Fernando Magro, MD, PhD,* and Guilherme Macedo, MD, PhD*
Background: Although there is some evidence suggesting that certain viruses may be involved in the onset of inflammatory bowel disease (IBD), data
regarding viral prevalence and viral load in blood and mucosa of patients with IBD are scarce. The main aim of this study is to evaluate the prevalence
and viral load of common Epstein–Barr virus (EBV), cytomegalovirus (CMV), and human herpes virus 6 in blood and mucosa of adult patients with
endoscopic active IBD.
Methods: From January to December 2014, ulcerative colitis and Crohn’s disease patients with active endoscopic disease were consecutively
enrolled. Subjects undergoing colonoscopy for colorectal cancer screening served as healthy controls (HCs). Paired blood and mucosal samples
from each patient and HC were collected for EBV, CMV, and human herpes virus 6 quantitative real time polymerase chain reaction assessment of
the viral load.
Results: One hundred forty-five subjects were included; 95 IBD patients with active endoscopic disease (43 ulcerative colitis and 52 Crohn’s disease)
and 50 healthy subjects. CMV and EBV DNA were detected more frequently in the mucosa of patients with IBD compared with HCs (CMV P ¼ 0.017;
EBV P , 0.001), irrespective of IBD type. The frequency of human herpes virus 6 DNA detection both in the blood and in the mucosa did not differ
between patients with IBD and HCs. EBV median viral load was similar in the inflamed and noninflamed mucosa was not affected by the use of
immunomodulators and/or anti–tumor necrosis factor alpha agents, and did not correlate with endoscopic disease activity.
Conclusions: EBV, and to a lesser extent CMV, were more prevalent in patients with IBD than in HCs. Mucosal viral load was not influenced by the
therapeutic regimen, did not differ between inflamed and noninflamed mucosa, and did not seem to be influenced by the endoscopic activity of the
disease, suggesting that EBV may be more involved in the onset of IBD than in its severity and clinical evolution.
(Inflamm Bowel Dis 2017;23:1278–1284)
Key Words: inflammatory bowel disease, pathogenesis, human herpes virus 6, cytomegalovirus, Epstein Barr virus
T he mechanisms underlying the pathogenesis of inflammatorybowel disease (IBD) are not fully understood.1 Although the
recent advent of genome-wide association studies have unambig-
uously implicated several genes/loci, these do not explain the risk
in full.2 Several environmental factors have also been linked to
the pathogenesis of IBD. Akin to cigarette smoking, antibiotics
use and dysbiosis of the bacterial microbiome, there is evidence
pointing to the role of certain viruses in IBD onset.1,3 Importantly,
in animal models, certain eukaryotic viruses have been shown to
interact with IBD risk genes.4
Very little data exist regarding viral prevalence and viral
load among patients with IBD. The most investigated viral
candidates have been the cytomegalovirus (CMV), the
Epstein–Barr virus (EBV), and the measles virus.5–7 Both CMV
and EBV, members of the Herpesviridae family, are acquired
early in life, usually asymptomatic, and remain latent lifelong in
healthy people.8 It is well known that under immunosuppression
these viruses may give rise to symptomatic infections.9 IBD has
been associated with a higher prevalence of EBV and CMV
infection, being disputed whether they are really involved in the
pathogenesis of the disease, associated with disease flares, com-
plications, and response to therapy or are innocent bystanders.5,6
On the other hand, the increasing use of immunosuppressive
therapies, associated with an increased risk of opportunistic in-
fections10 had led to a recrudescence of interest on their role on
IBD. Despite all the evidence linking EBV and CMV to IBD, the
definitive role of these viruses in IBD is still a topic of ongoing
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controversy. human herpes virus 6 (HHV6) has also been studied,
with some studies demonstrating the presence of HHV6 DNA in
the inflamed mucosa of Crohn’s disease (CD) and ulcerative
colitis (UC) patients,11 although no definitive evidence had been
established between these 2 entities.12
The detection of these agents in blood or mucosa of
patients with IBD remains a clinical challenge, being hard to
distinguish between a superimposed infection and a disease
relapse.8 Recent data had highlighted the need and interest of
quantifying mucosal viral load by real time polymerase chain
reaction to achieve the correct diagnosis and establish proper
management.13,14
This study aims to evaluate the prevalence and viral load of
EBV, CMV, and HHV6 in the blood and mucosa (both inflamed
and noninflamed) of adult patients with active endoscopic IBD;
and to assess the influence of different therapeutic regimens on
viral prevalence. To our knowledge, this is the first study to
address simultaneously the detection of EBV, CMV, and HHV6
in the peripheral blood and mucosa of patients with IBD.
METHODS
Subjects
Consecutive adult patients followed-up at Centro Hospital-
ar Sao Joao (Porto, Portugal) with endoscopically active IBD
were prospectively enrolled between January and December
2014. Patients were included if the following criteria were met:
(1) presence of a definitive diagnosis of UC or CD based on
accepted clinical, radiological, endoscopic, and histological
criteria15,16; (2) requiring therapy with 5-aminosalicilates (5-
ASA), steroids, azathioprine (AZA), methotrexate (MTX), inflix-
imab (IFX), adalimumab (ADA), or any combination of the
above; and (3) presence of endoscopic activity, defined by a Sim-
plified Endoscopic Activity Score for CD (SES-CD)$ 3 or Mayo
Endoscopic Score for UC $ 2.17,18 Patients younger than 18
years, who were pregnant, or did not have endoscopically active
disease at the time of the study were excluded. Sex-matched
subjects undergoing colonoscopy for colorectal cancer screening
who were not taking any of the above drugs served as healthy
controls (HCs).
Clinical and demographic data, including age, sex, IBD
location and behavior, endoscopic activity, and therapeutic
TABLE 1. Clinical and Demographic Characteristics
Controls n ¼ 50
Age, mean, yrs (SD) 49.8 6 15.9
Man, n (%) 25 (50.0)
CD n ¼ 52
Age, mean, yrs (SD) 37.1 6 14.4
Man, n (%) 30 (57.7)
Age at diagnosis, n (%)
A1 (#16 yrs) 7 (13.4)
A2 (17–4 yrs) 41 (78.9)
A3 (.40 yrs) 4 (7.7)
Disease location, n (%)
L1 (ileal) 14 (26.9)
L2 (colonic) 14 (26.9)
L3 (ileocolonic) 19 (36.5)
L1 + L4 (ileal + upper gastrointestinal tract) 3 (5.8)
L3 + L4 (ileocolonic + upper gastrointestinal tract) 2 (3.9)
Disease behavior, n (%)
B1 (nonstricturing, nonpenetrating) 24 (46.1)
B2 (stricturing) 13 (25.0)
B3 (penetrating) 15 (28.9)
Concomitant treatment, n (%)
5 ASA 18 (34.6)
Steroids 9 (17.3)
Immunomodulators (azathioprine/methotrexate) 30 (57.7)/2 (3.8)
Anti–TNF-a (adalimumab/infliximab) 11 (21.1)/9 (17.3)
Time under immunomodulators, mean, mo (SD) 59 6 54
Time under anti–TNF-a, mean, mo (SD) 25 6 17
Combination therapy 10 (19.2)
Endoscopic activity
SES-CD 3–9 38 (73.1)
SES-CD $9 14 (26.9)
UC n ¼ 43
Age, mean, yrs (SD) 41.5 6 13.5
Man, n (%) 23 (53.5)
Location, n (%)
Proctitis 3 (6.9)
Left-sided colitis 22 (51.2)
Pancolitis 18 (41.9)
Concomitant treatment, n (%)
5 ASA 39 (90.7)
Steroids 2 (4.7)
Immunomodulators (azathioprine/methotrexate) 17 (39.5)
Anti–TNF-a (adalimumab/infliximab) 10 (23.2)
Time under immunomodulators, mean, mo (SD) 43 6 36
Time under anti–TNF-a, mean, mo (SD) 36 6 23
Combination therapy 8 (18.6)
TABLE 1. (Continued )
UC n ¼ 43
Endoscopic activity, n (%)
Mayo score 2 33 (76.7)
Mayo score 3 10 (23.3)
5ASA, 5 aminosalicylates; SES-CD, simplified endoscopic score for CD.
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regimen, were collected. Paired peripheral blood and mucosal
samples from each patient and HC were obtained at the time of
colonoscopy for detection and quantification of EBV, CMV, and
HHV6. For patients, mucosal samples were collected from both
inflamed (erosions or ulcers) and endoscopically normal (at least
20 cm from the former) areas.
DNA Extraction
EBV nucleic acid extraction used a DNA blood Kit
(Qiagen, Inc., Valencia, CA) protocol with EZ1 BioRobot
(Qiagen Inc.) from a 200 mL of whole blood sample. For CMV
and HHV6, plasma was obtained and 400 mL was extracted by
EZ1 virus mini Kit protocol (Qiagen Inc.) using the same robot.
For mucosal samples, biopsies were minced and digested
with proteinase K (Qiagen Inc.) at 568C until completely homog-
enized and DNA was extracted with an automatic processing
(QIAcube; Qiagen Inc.) and a spin column protocol (QIAmp
DNA mini kit, Qiagen Inc.).
DNA Amplification
CMV, EBV, and HHV6 were amplified using genesig
specific kits (Primer Design, Southampton, United Kingdom) and
LightCycler 480 II (Roche diagnostics, Indianapolis, IN). To
verify the accuracy and sensitivity of virus detection protocols,
these kits were at first tested with external quality control panels
(Quality control for Molecular Diagnosis, 2013). A calibration
curve was obtained for each virus, running, in duplicate,
successively diluted positive control samples.
To normalize those several targets quantitative results,
tissue samples were submitted to a quantitative parallel PCR
reaction targeting a region of the human apoprotein B (ApoB).19
The DNA obtained from a sample with concentrated and quanti-
fied blood leukocytes extraction was diluted, and tested, in dupli-
cate, for ApoB. Because ApoB is encoded by a single gene, the
human cells in each tissue sample could be calculated and the
virus quantification expressed in copies/105 cells.
Statistical Analysis
Categorical variables are described as absolute frequencies
(n) and relative frequencies (%). Median and percentiles are used
for continuous variables. When testing a hypothesis about
continuous variables, nonparametric tests (Mann–Whitney or
Kruskal–Wallis) were used as appropriate, taking into account
normality assumptions and the number of groups compared.
When testing a hypothesis about categorical variables a chi-square
test and Fisher’s exact test were used, as appropriate. All the
reported P values are 2-sided, and P values of ,0.05 were con-
sidered statistically significant. Statistical analysis was performed
using the software SPSS v.20.0 data (SPSS Inc., Chicago, IL).
Ethical Considerations
This study was conducted according to the Declaration of
Helsinki. The study protocols were approved by the Ethics
Committee of Centro Hospitalar Sao, Porto, Portugal. Informed TA
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consent was obtained from each patient and HC in accordance
with the local institutional board regulations.
RESULTS
Patients Characteristics
A total of 95 IBD patients with active endoscopic disease
and 50 HCs were enrolled. Forty-three patients had UC (mean age
41.56 13.5, 53.5% male), whereas 52 patients had CD (mean age
37.1 6 14.4, 57.7% male). Mean age of HCs was 49.8 6 15.9
years old and 50% were male. At the time of the study, a total of
49 (51.6%) patients were under immunomodulators and 30
(31.6%) under anti–tumor necrosis factor alpha (TNF-a) agents.
Eleven patients (9 with CD and 2 with UC) were on steroids at the
time of the study. Among the 43 patients with UC, 3 had proctitis,
22 had left-side colitis, and 18 had pancolitis. Of the 42 patients
with CD, 14 had ileal, 14 had colonic, 19 had ileocolonic, and 5
had upper gastrointestinal tract involvement (combined with ileal
involvement in 2 and ileocolonic in 3). Demographic and clinical
data are summarized in Table 1.
EBV Is the Most Prevalent Viral Agent in
Patients with IBD
CMV and EBV DNA were detected more frequently in
the mucosa of patients with IBD (CMV DNA 12.1%; EBV
DNA 67.0%) compared with HCs (CMV 0%, P ¼ 0.017; EBV
18.0%, P , 0.001). The prevalence of CMV and EBV DNA
was similar in patients with CD and UC, and in both groups
higher than in HCs (Table 2). Although CMV DNA was de-
tected in the blood of only 1 patients with IBD and in no HC
(P ¼ NS), EBV DNA was detected in the circulation of 20% of
both patients and HCs.
Regarding HHV6 DNA, 43% of patients with IBD tested
positive in the mucosa (35% CD and 51% UC) and 2% in blood,
whereas in HCs, 2% had detectable HHV6 in blood and 28% in
the mucosa (P ¼ NS for all comparisons).
When considering the prevalence of the different viruses
regarding the presence of ulceration/inflammation of the mucosa,
EBV and CMV DNA were more prevalent in inflamed mucosa
compared with noninflamed areas, although this difference was
only statistically different for EBV both in CD (P ¼ 0.025) and
UC (P ¼ 0.019) (Table 3 & see Table 1, Supplemental Digital
Content 1, http://links.lww.com/IBD/B537).
Immunosuppression Does Not Impact on
CMV or EBV DNA Prevalence
Because immunosuppression could impact viral prevalence,
we analyzed viral prevalence according to current treatment
regimens in patients with IBD. The prevalence of CMV, EBV,
and HHV6 DNA in both the blood and in the mucosa was similar
in patients under therapy with 5-ASA compounds only compared
with patients under immunomodulators (either AZA or MTX)
and/or anti–TNF-a agents (see Table 2, Supplemental Digital
Content 2, http://links.lww.com/IBD/B538).
EBV median viral load is similar in the inflamed and
noninflamed mucosa and does not correlate with endoscopic
disease activity.
An analysis comparing viral loads was also performed.
Viral load of EBV was higher in inflamed mucosa of patients with
CD compared with inflamed mucosa of patients with UC (P ¼
0.010). There were no significant differences in viral load of CMV
and HHV6 in inflamed mucosa of patients with CD compared
with inflamed mucosa of patients with UC (P ¼ NS for all com-
parisons). There were also no significant differences in viral load
of EBV and HHV6 in normal mucosa of patients with CD com-
pared with patients with UC (Table 4). No significant differences
were found regarding viral load of CMV, EBV, and HHV6 in
ulcerated versus nonulcerated mucosa of patients with CD and
UC (Table 5).
TABLE 3. Comparison of Viral Agents Prevalence Between Inflamed and Noninflamed Mucosa in Patients with
IBD and Controls
CMV, n (%) P EBV, n (%) P HHV6, n (%) P
IBD versus controls
Noninflamed mucosa 2 (2.3) versus 0 (0.0) 0.283 38 (43.2) versus 9 (18.0) 0.003 30 (34.1) versus 14 (28.0) 0.461
Inflamed mucosa — — — — — —
CD versus controls
Noninflamed mucosa 1 (2.2) versus 0 (0.0) .0.999 15 (33.3) versus 9 (18.0) 0.306 13 (28.9) versus 14 (28.0) .0.999
Inflamed mucosa — — — — — —
UC versus controls
Noninflamed mucosa 1 (2.3) versus 0 (0.0) .0.999 23 (53.5) versus 9 (18.0) ,0.001 17 (39.5) versus 14 (28.0) 0.825
Inflamed mucosa — — — — — —
CD versus UC
Noninflamed mucosa 1 (2.2) versus 1 (2.3) .0.999 15 (33.3) versus 23 (53.5) 0.255 13 (28.9) versus 17 (39.5) .0.999
Inflamed mucosa 5 (10.6) versus 6 (14.0) 0.631 26 (55.3) versus 29 (67.4) 0.849 13 (28.9) versus 17 (39.5) .0.999
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When we compared the median values with ranges of DNA
copies of all viruses, as obtained by pooling together the data in
the IBD group, from both inflamed and noninflamed mucosa, we
did not find significantly different values between CD and UC.
With respect to EBV and HHV6, when comparing IBD as a group
or each disease separately with the control group, no differences
were found (Table 6).
Last, to assess whether viral infections were associated with
endoscopic activity, median viral loads were compared according
to the SES-CD or the Mayo Endoscopic Score for UC (see
Table 3, Supplemental Digital Content 3, http://links.lww.com/
IBD/B539). The median EBV and HHV6 load was similar in
patients with CD with a SES-CD 3 to 9 and those with a score
$9. For patients with UC, those with a Mayo score 2 had a EBV,
CMV, and HHV6 load that did not differ significantly from pa-
tients with a Mayo score 3.
DISCUSSION
In this study, we show that EBV, and to a lesser extent
CMV, are prevalent agents in the mucosa of patients with IBD.
Their prevalence does not seem to be influenced by the different
immunosuppressive regimens. In addition, mucosal viral load
does not differ between inflamed and noninflamed mucosa and
does not correlate with endoscopic severity of both CD or UC,
suggesting that viral agents, more strongly EBV, may play a role
in the onset rather than in the severity of IBD.
Despite growing interest in the role of bacterial microbiome
dysbiosis in intestinal inflammation,1 less attention has been
drawn to the role of the enteric virome in the pathogenesis of
IBD. A recent study showed an alteration in the enteric virome
of both CD and patients with UC that seemed to be the contrib-
utory factor to intestinal inflammation and bacterial dysbiosis.20 It
is well known that Herpesviridae family is characterized by
chronic infection or viral latency after a primary infection, after
which the virus may be reactivated. Despite clinical disease being
rare in the immunocompetent patient, there are some doubts about
the pathogenic effect of these agents under immunosuppressed
states: whether they are responsible for the disease and their com-
plications or they are only simple bystanders remains to be
defined.5
Previous studies have attempted to determine the preva-
lence of different viruses in patients with IBD. Most of them are,
however, marred by their retrospective nature, by the inclusion of
surgery specimens, and for assessing only one virus at each
time.6,21–24 In this study, the detection of EBV, CMV, and HHV6
in the peripheral blood and mucosa of patients with IBD was
addressed simultaneously for the first time. Herein, we show that
the prevalence of EBV and CMV DNA in peripheral blood does
not differ between HCs and patients with IBD, but a higher prev-
alence of EBV, and to a lesser extent of CMV, was found in the
mucosa of patients with IBD compared with HCs. In accordance
with the results reported by others, we also found EBV as the
most prevalent agent, with 2/3 of patients with IBD showingTA
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positivity for EBV.14 Also, noteworthy is the finding of a higher
prevalence of viral DNA in intestinal mucosa compared with the
peripheral blood. This may suggest a potential role for EBV and
CMV in the immune disturbance present on intestinal mucosa;
alternatively, in case of CMV, it may only reflect its known
tropism for inflammatory cells.25
Despite previous studies focused on the role of CMV in
UC,21,23 in this study, we only found a higher prevalence in
diseased mucosa for EBV, both in CD and UC. However, when
analyzing the EBV viral load within the IBD group of patients, the
median values were not found to be significantly higher in dis-
eased versus nondiseased mucosa. The observation that EBV is
equally found in inflamed and noninflamed mucosa, suggests its
role as a trigger of IBD rather than causing a superimposed infec-
tion. Because of the inexistence of CMV DNA in normal mucosa,
and the very low viral load in inflamed mucosa, no conclusion
could be drawn regarding CMV infection.
The possible role of viruses as trigger(s) of IBD is further
supported by the absence of correlation between the mucosal viral
load and the degree of endoscopic activity. Even in normal mucosa,
there were no significant differences in the median viral DNA
levels in patients with IBD compared with the control group.
On the other hand, HHV6 seemed to have no role in the
pathogenesis of IBD, as prevalence and viral load was similar
between the IBD population and the control group, suggesting
that not all viruses are associated with IBD pathogenesis.
In contrast to published evidence of a significantly
increased risk of EBV and CMV reactivation under immunomod-
ulator therapy,6,26 we did not find any positive relation between
both anti–TNF a and/or AZA/MTX use and viral prevalence. In
a previous study by our group,6 where we aimed to evaluate EBV
prevalence in the blood of patients with IBD at remission and
compare that with the general population, we found that reactiva-
tion of EBV is more frequent among patients with IBD and that
therapeutic regimen did influence the prevalence of EBV.
Although the methodology used to detect EBV DNA in both
studies were the same, in the current study, we have included
patients with endoscopically active disease only, and therefore,
we were not able to reproduce such finding. In addition, although
in the 2013 study the mean age of the control group was 35 years,
in the current it was 49.8 years6; the age difference between the 2
studies was because of ethical constraints in obtaining intestinal
mucosa from healthy subjects younger than 50 years. In line with
the current study, there are studies suggesting that only steroids
and anti–TNF-a agents are associated with EBV colitis, but not
the use of immunosuppressants or the duration of therapy.14
In summary, we provide evidence that EBV, and to a lesser
extent CMV, are prevalent in patients with IBD, and that their
prevalence is not affected by different therapeutic regimens. In
addition, mucosal viral load does not differ between inflamed and
noninflamed mucosa, and does not seem to be influenced by the
endoscopic activity of the disease. Taken together, these data
TABLE 5. Comparison of Median Viral Loads in Inflamed Versus Noninflamed Mucosa in Patients with CD and UC
CD UC
Inflamed Mucosa Noninflamed Mucosa P Inflamed Mucosa Noninflamed Mucosa P
EBV
Median, copies/105 cells, (IQR) 3.60 (1.00–240.20) 1.00 (1.00–37.00) 0.333 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.612
HHV 6
Median, copies/105 cells, (IQR) 1.00 (1.00–1.00) 7.50 (1.00–32.60) 0.173 1.00 (1.00–1.00) 1.00 (1.00–1.00) .0.999
CMV
Median, copies/105 cells, (IQR) 1.00 (0.8–8.10)— — — 3.77 (1.00–75.5)— — —
E.Coli, Eschiria Coli; IQR, interquartile range.
TABLE 6. Comparison of Viruses Median Viral Load in Mucosa of Patients with IBD (Inflamed + Noninflamed
Mucosa) and Controls
IBD Versus Controls, n (%) P CD Versus Controls, n (%) P UC Versus Controls, n (%) P CD Versus UC, n (%) P
CMV — — — — — — 1.0 (0.8–8.1)
versus 3.77 (1.0–1229.9)
0.304
EBV 1.0 (1.0–62.3)
versus 1.0 (1.0–3.8)
0.641 3.6 (1.0–153.5)
versus 1.0 (1.0–3.8)
0.251 1.00 (1.0–36.4)
versus 1.0 (1.0–3.8)
0.816 3.6 (1.0–153.5)
versus 1.00 (1.0–36.4)
0.067
HHV6 1.0 (1.0–21.9)
versus 1.0 (1.0–5.2)
0.488 3.8 (1.0–36.8)
versus 1.0 (1.0–5.2)
0.132 1.0 (1.0–1.0)
versus 1.0 (1.0–5.2)
0.831 3.80 (1.0–36.8)
versus 1.0 (1.0–1.0)
0.099
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support a putative role of certain viral agents, most notably EBV,
in IBD pathogenesis and suggest that their frequent detection is
not associated with either disease severity or superimposed
infection. A note of caution, however, should be made when
trying to extrapolate the findings obtained from our patients’
cohort that included patients with endoscopically active disease,
a relatively high proportion of subjects under immunomodulators
and/or anti–TNF-a agents, to IBD population in general. Larger
studies are needed to address other potential caveats (i.e., age at
disease onset) and make these investigations more readily
applicable.
REFERENCES
1. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the
art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
2. McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel
diseases. Gastroenterology. 2015;149:1163–1176.e1162.
3. Wright EK, Kamm MA, Teo SM, et al. Recent advances in characterizing
the gastrointestinal microbiome in Crohn’s disease: a systematic review.
Inflamm Bowel Dis. 2015;21:1219–1228.
4. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene
interaction determines Crohn’s disease gene Atg16L1 phenotypes in intes-
tine. Cell. 2010;141:1135–1145.
5. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease:
pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–1627.
6. Magro F, Santos-Antunes J, Albuquerque A, et al. Epstein-Barr virus in
inflammatory bowel disease-correlation with different therapeutic regi-
mens. Inflamm Bowel Dis. 2013;19:1710–1716.
7. Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-
control study of measles, mumps, and rubella and inflammatory bowel
disease. Inflamm Bowel Dis. 2007;13:759–762.
8. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based con-
sensus on the prevention, diagnosis and management of opportunistic in-
fections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468.
9. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necro-
sis factor-alpha therapy in inflammatory bowel disease: meta-analysis of
randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
10. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportu-
nistic infections in patients with inflammatory bowel disease. Gastroen-
terology. 2008;134:929–936.
11. Sipponen T, Turunen U, Lautenschlager I, et al. Human herpesvirus 6 and
cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease.
Scand J Gastroenterol. 2011;46:1324–1333.
12. Wagner J, Sim WH, Lee KJ, et al. Current knowledge and systematic
review of viruses associated with Crohn’s disease. Rev Med Virol. 2013;
23:145–171.
13. Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-time
PCR assay for early detection of cytomegalovirus infection in patients
with ulcerative colitis refractory to immunosuppressive therapies. Inflamm
Bowel Dis. 2007;13:1516–1521.
14. Ciccocioppo R, Racca F, Paolucci S, et al. Human cytomegalovirus and
Epstein-Barr virus infection in inflammatory bowel disease: need for
mucosal viral load measurement. World J Gastroenterol. 2015;21:
1915–1926.
15. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based
consensus on the diagnosis and management of ulcerative colitis part 1:
definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.
16. Van Assche G, Dignass A, Panes J, et al. The second European evidence-
based Consensus on the diagnosis and management of Crohn’s disease:
definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.
17. Daperno M, D’Haens G, Van Assche G, et al. Development and valida-
tion of a new, simplified endoscopic activity score for Crohn’s disease: the
SES-CD. Gastrointest Endosc. 2004;60:505–512.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic
acid therapy for mildly to moderately active ulcerative colitis. A random-
ized study. N Engl J Med. 1987;317:1625–1629.
19. Sanchez JL, Storch GA. Multiplex, quantitative, real-time PCR assay for
cytomegalovirus and human DNA. J Clin Microbiol. 2002;40:2381–2386.
20. Norman JM, Handley SA, Baldridge MT, et al. Disease-specific altera-
tions in the enteric virome in inflammatory bowel disease. Cell. 2015;160:
447–460.
21. Vega R, Bertran X, Menacho M, et al. Cytomegalovirus infection in
patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:
1053–1056.
22. Yanai H, Shimizu N, Nagasaki S, et al. Epstein-Barr virus infection of the
colon with inflammatory bowel disease. Am J Gastroenterol. 1999;94:
1582–1586.
23. Dimitroulia E, Spanakis N, Konstantinidou AE, et al. Frequent detection
of cytomegalovirus in the intestine of patients with inflammatory bowel
disease. Inflamm Bowel Dis. 2006;12:879–884.
24. Lavagna A, Bergallo M, Daperno M, et al. The hazardous burden of
Herpesviridae in inflammatory bowel disease: the case of refractory severe
ulcerative colitis. Dig Liver Dis. 2006;38:887–893.
25. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, et al. Epstein-Barr
virus replication linked to B cell proliferation in inflamed areas of colonic
mucosa of patients with inflammatory bowel disease. J Clin Virol. 2011;
50:31–36.
26. Nebbia G, Mattes FM, Sabin CA, et al. Differential effects of prednisolone
and azathioprine on the development of human cytomegalovirus replica-
tion post liver transplantation. Transplantation. 2007;84:605–610.
Lopes et al Inflamm Bowel Dis  Volume 23, Number 8, August 2017
1284 | www.ibdjournal.org
Copyright © 2017 Crohn’s & Colitis Foundation. Unauthorized reproduction of this article is prohibited.
Downloaded from https://academic.oup.com/ibdjournal/article-abstract/23/8/1278/4560706
by King's College London user
on 26 March 2018
R
es
ul
ts
 - 
Pu
bl
ic
at
io
ns
78
79
ORIGINAL ARTICLE
Correlation Between Calprotectin and Modified Rutgeerts Score
Susana Lopes, MD,* Patricia Andrade, MD,* Joana Afonso, MD,† Eduardo Rodrigues-Pinto, MD,*
Cláudia C. Dias, MD,‡ Guilherme Macedo, MD, PhD,* and Fernando Magro, MD, PhD*,†
Background: Endoscopic recurrence after surgery for Crohn’s disease (CD) is high, and it has important prognostic value. Crohn’s disease will recur in
the majority of patients after surgery. Fecal calprotectin (FC) and lactoferrin (FL) have attracted interest in the postoperative setting for predicting relapse.
We have evaluated the accuracy of FC and FL in diagnosing endoscopic recurrence (ER) using the modified Rutgeerts score (MRS) compared with the
Rutgeerts score (RS).
Methods: A series of consecutive patients who underwent ileocolonic resection for Crohn’s disease were evaluated. Biomarkers, clinical indexes, and
fecal markers were recorded on the day of ileocolonoscopy. ER was defined as a MRS $ i2b or a RS $ i2.
Results: Ninety-nine patients were included in this prospective cohort. The median time between surgery and colonoscopy was 87.5 months (IQR,
31–137). FC and FL levels were higher in patients with ER than in those in remission (Median FC, 196.5 mg/g [IQR, 96–634 mg/g] versus 42.1 mg/g
[IQR 19–91.60 mg/g; P , 0.001]; Median FL, 23.27 mg/g [IQR 8.9–47.8 mg/g] versus 2 mg/g [IQR 0.9–7.26 mg/g; P , 0.001]). Using the MRS, 34%
of patients presented with ER compared with 76% if the RS was used. The RS performed worse than the MRS with a decrease in sensitivity (74%
versus 48% for FC and 85% versus 55% for FL) and in NPV (91% versus 33% for FC, and 90% versus 37% for FL). Furthermore, the accuracy of the
MRS was higher than that of the RS (75% versus 55%).
Conclusions: Both FC and FL proved to correlate well with endoscopic findings in the evaluation of Crohn’s disease after surgery. Both markers
predicted recurrence with greater accuracy when the MRS was used. Fecal markers can be used to monitor disease recurrence after intestinal resection,
with patients being selected to undergo further endoscopic evaluation.
(Inflamm Bowel Dis 2016;22:2173–2181)
Key Words: Crohn’s disease, endoscopy, biomarkers
O ne of the major drawbacks of surgical treatment ofCrohn’s disease (CD) is the high recurrence rate after bowel
resection. It is assumed that almost 60% of patients will have
endoscopic recurrence within 5 years of surgery, and of those,
a third will have clinical recurrence.1 Disease recurrence may be
misdiagnosed if based solely on symptoms and serum markers
(C-reactive protein [CRP]) of inflammation. Despite being sen-
sitive in CD, they are rather nonspecific and frequently fail to
detect endoscopic recurrence.2–4 Furthermore, 20% to 25% of CD
patients experiencing flares do not exhibit increased CRP due to
genetic single-nucleotide polymorphisms in the CRP gene, which
affect CRP production.5,6 The clinical indexes used in CD,
namely the Crohn’s Disease Activity Index (CDAI) and the Har-
vey Bradshaw Index (HBI), have poor correlation with endo-
scopic findings in this setting.7 Ileocolonoscopy has been
considered the gold standard in diagnosing recurrence, which is
defined as de novo appearance of mucosal lesions in the neo-
terminal ileum, proximal to ileocolonic anastomosis.8 The Rut-
geerts score8 has been used to classify the endoscopic findings
after surgery. In 2014, Gecse KB et al9 published, in the form of
an abstract, a work designed to evaluate the intrarater and inter-
rater agreement using the Rutgeerts score and the modified Rut-
geerts score. This modified score performed well with high
interclass correlation coefficients, and the authors proposed its
validation for clinical use. Nevertheless, due to its invasiveness
and the need for bowel preparation, colonoscopy is not very well
accepted by patients and not easily repeated. The need for an
accurate noninvasive marker that could be sequentially carried
out and correlated with endoscopic recurrence and its severity
has led to a growing interest in fecal biomarkers.10–13
Calprotectin (FC) is a 36-kDa calcium-binding and zinc-
binding protein complex constituting up to 60% of neutrophil
cytosol protein that is released upon neutrophil activation.14 FC
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excretion reflects increased neutrophil migration into the gut
lumen through an inflamed mucosa, but despite being specific
for gut inflammation, it is not disease specific. Lactoferrin (FL),
a 76-kDa iron-binding protein, similarly to FC is neutrophil
derived, being the main component of secondary granules that
degranulate during the inflammatory process.14 Both these pro-
teins are remarkably stable and resistant to degradation, easily
detected, and measured in feces by commercially available ELI-
SA kits. Both markers have proved to reflect endoscopic disease
activity in CD, predicting endoscopic inflammation and being
a surrogate marker of mucosal healing.10,11 Until recently, the
studies addressing the role of fecal markers in the CD postoper-
ative setting have been limited, with a small number of patients,
with no correlation with endoscopic findings and with some con-
flicting results.1,15–20 In 2015, Wright EK et al21 published the
first prospective, multicentric, randomized, controlled trial in the
postoperative setting of CD, evaluating the accuracy of FC in
reflecting the presence and severity of disease recurrence. In this
work, FC measurement was sensitive enough to monitor for CD
recurrence after resection, and it also had a high negative pre-
dictive value, that is, patients with normal FC did not have endo-
scopic evidence of recurrence.
In our study, we evaluated the accuracy of FC and FL in
diagnosing endoscopic recurrence according to the modified
Rutgeerts score and compared its performance with the Rutgeerts
score and serum biomarkers of inflammation.
MATERIAL AND METHODS
Objectives
The primary objective of this work was to compare the
accuracy of FC and FL in diagnosing endoscopic recurrence
according to the modified Rutgeerts and Rutgeerts score and to
define which endoscopic score is more accurate in predicting
recurrence. Secondary end points were: to correlate the clinical
disease activity index (HBI) with the endoscopic index (modified
Rutgeerts score) and FC and FL levels; to compare fecal markers
with markers of inflammatory activity (CRP) in predicting
postoperative recurrence; to investigate how FC and FL correlate
with each other in the postoperative setting; to assess which fecal
marker is the best predictor of endoscopic recurrence; and to
determine the best cutoff value for FC and FL in the prediction of
relapse, in the postoperative setting.
Population
Ninety-nine adult (.18 yr) consecutive patients followed
at our inflammatory bowel disease (IBD) outpatient clinic with
a diagnosis of CD, who had undergone curative ileocolonic
resection for disease complication from 1994 to 2013, were pro-
spectively enrolled in this study. Patients were excluded if the
neoterminal ileum had not been endoscopically evaluated if they
had colonic active disease or if they had taken nonsteroidal anti-
inflammatory drugs in the month before the colonoscopy.
All patients gave informed written consent to participate in
the study, which was approved by the ethics committee of our
institution. Demographic data were collected prospectively from
a database (http://www.gediibasedados.med.up.pt) created for
patients with IBD. The analyzed information was: sex, date of
birth, age at symptom or disease onset, disease location and
behavior, smoking status, date of abdominal surgery, follow-up
after ileocolonic resection, time since surgery and colonoscopy,
and current and previous pharmacological therapy.
Methods
Clinical disease activity was assessed on the day of
endoscopic examination according to the clinical criteria of the
HBI. This index was chosen because it has proved to have a good
correlation with the CDAI and it is a simplified, less cumbersome
alternative to the CDAI, as it does not require a prospective 7-day
data collection, and is more suitable for use in clinical practice.7
The variables inquired were referred to the day before bowel
preparation. Clinically inactive disease was defined as an HBI
of less than 5. Blood tests included hemoglobin (Reference range
[RF]: 12.0 to 16.0 g/dL), leukocytes (RF: 4–11 · 109/L), platelets
(RF: 150–400 · 109/L), albumin (RF: 38–51 g/L), and CRP
(upper limit of normal ,3 mg/L). Blood samples were obtained
on the day of endoscopic examination if no previous results were
available from the last month. Blood results with #4 weeks were
accepted if there had been no changes in symptoms, and if no
changes in therapy had occurred during that time period. All
patients were referred for colonoscopic evaluation under propofol
sedation at the Gastroenterology Department of the Centro Hos-
pitalar São João, Porto, between November 2012 and October
2014. For bowel cleansing, we used a polyethylene glycol bowel
preparation solution (Klean Prep; Helsinn Birex Pharmaceuticals,
Dublin, Ireland). All the procedures were performed by a single
senior endoscopist (SL) with systematic intubation of the neo-
terminal ileum (if an anastomotic stenosis was present it was
immediately dilated in order to gain access to the ileum). Post-
operative disease activity of the neoterminal ileum was evaluated
according to the Rutgeerts8 and modified Rutgeerts score.9 Endo-
scopic remission was defined as a modified Rutgeerts score of i0,
i1, or i2a (i0—no lesions in the neoterminal ileum; i1—fewer than
5 aphthous lesions in the neoterminal ileum; i2a—lesions con-
fined to the ileocolonic anastomosis, including anastomotic ste-
nosis), and postoperative recurrence was defined as a modified
Rutgeerts score $i2b (i2b—more than 5 aphthous ulcers or larger
lesions, with normal mucosa in between, in the neoterminal ileum,
with or without anastomotic lesions; i3—diffuse aphthous ileitis
with diffusely inflamed mucosa; i4—large ulcers with diffuse
mucosal inflammation or nodules or stenosis in the neoterminal
ileum).
Stool samples were collected the day before beginning
bowel preparation (preferably from the first stool in the morning)
and then kept in the fridge until being brought to the hospital. For
lactoferrin evaluation, stools were stored at 2808C upon arrival
at the laboratory. For calprotectin, within a maximum of 7 days
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after collection, stools were extracted in accordance with the
manufacturer’s instructions, using a “Faecal sample preparation
kit” (Roche Diagnostics, Mannheim, Germany). Sample extracts
were stored at 2808C until the assays were performed at the
Department of Pharmacology and Therapeutics, Faculty of Med-
icine of the University of Porto, by a single operator (JA). Sam-
ples were thawed and analyzed using a commercially available
quantitative enzyme-linked immunoassay test (IBD-Scan; Tech-
Lab, Blacksburg, VA) for lactoferrin and fluoroenzyme immuno-
assay (EliA Calprotectin; Thermo Fisher Scientific, Freiburg,
Germany) for calprotectin. The techniques for measurements of
both fecal markers and the cutoff values followed the manufac-
turer’s guidelines (7.25 mg/g for lactoferrin and 50 mg/g for
calprotectin).
Statistical Analysis
Categorical variables were described as absolute frequen-
cies (n) and relative frequencies (%). Median and percentiles were
used for continuous variables.
When testing a hypothesis about continuous variables,
nonparametric tests (Mann–Whitney or Kruskal–Wallis) were used
as appropriate, taking into account normality assumptions and the
number of groups compared. When testing a hypothesis about
categorical variables, a chi-square test and Fisher’s exact test were
used, as appropriate. Spearman’s rank-order correlation test (rs) was
used to assess any correlation between calprotectin and lactoferrin,
and between both variables and continuous parameters. Receiver
operator characteristics (ROC) for lactoferrin and calprotectin (sen-
sitivity and specificity) were assessed by curve analysis as
described. All the reported P-values were 2-sided, and P-values
of ,0.05 were considered statistically significant.
For estimating a proportion of 0.7 with an effect size of
0.20, the sample power is higher than 85%, for a confidence level
of 95%. All data were arranged, processed, and analyzed with
SPSS v.20.0 data (Statistical Package for Social Sciences).
RESULTS
Endoscopic Recurrence
From November 2012 to October 2014, a total of 99
consecutive patients were included in this study. The mean age at
the time of colonoscopy was 45 6 14 years, the median disease
duration between diagnosis and resection was 38 months (IQR,
6.5–119), and the median time between surgery and colonoscopy
was 87.5 months (IQR, 31–137). Demographic and clinical char-
acteristics of the study population are shown in Table 1. Of the
99 patients included, only 9% had clinically active disease
defined as an HBI $ 5.
Endoscopic scores were i0 + i1 in 24 patients, i2 in 51
patients (i2a in 41 and i2b in 10 patients), and 24 patients pre-
sented endoscopic scores of i3 and i4. Considering recurrent
endoscopic disease to be evaluated as a modified Rutgeerts score
$ i2b, 34% of patients presented with recurrent disease (Table 2).
If we had used the Rutgeerts score, 76% of patients would have
presented with recurrent disease (Rutgeerts score $ i2). No
patient presented with colonic active disease.
There was no significant association between the HBI and
either of the endoscopic scores (P¼ 0.575 for MRS and P¼ 0.417
for RS). There was also no association between endoscopic
recurrence (assessed by both scores) and elapsed time from surgery
to examination (P ¼ 0.442 for MRS and P ¼ 0.622 for RS); age at
TABLE 1. Demographic and Clinical Characteristics of
the CD Patients at the Time of Colonoscopy (n ¼ 99)
n
Sex, n (%)
Male 47 (47)
Female 52 (53)
Age at endoscopic evaluation (mean [SD], yr) 45 6 14
Time between surgery-endoscopic evaluation
(median [IQR], mo)
87.5 (31–137)
Montreal classification n (%)
Age at diagnosis
A1 10 (10)
A2 75 (76)
A3 14 (14)
Disease location
L1 57 (58)
L2 6 (6)
L3 32 (32)
L1 + L4 3 (3)
L3 + L4 1 (1)
Disease behavior
B1 5 (5)
B2 50 (51)
B3 44 (44)
Perianal disease
Yes 22 (22)
Smoking
Yes 22 (22)
Obstructive symptoms at colonoscopy
Yes 14 (14)
Therapy at time of colonoscopy
Mesalamine 35 (35)
Immunomodulators 63 (64)
Corticosteroids 7 (7)
Anti-TNFa 30 (30)
Harvey Bradshaw Index
Remission (HBI , 5) 90 (91)
Mild disease (HBI 5–7) 8 (8)
Severe disease (HBI . 16) 1 (1)
HBI, Harvey-Bradshaw Index; IQR, interquartile range; SD, standard deviation; TNF,
tumor necrosis factor.
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presentation (P ¼ 0.152 for MRS and P ¼ 0.316 for RS); and
disease behavior (P ¼ 0.779 for MRS and P ¼ 0.634 for RS).
With regard to smoking habits, we found a significant association
between active smoking and recurrent disease only when we
used the RS for classifying recurrent disease (P ¼ 0.012 for RS
and P ¼ 0.274 for MRS). Considering therapy at the time of
colonoscopy, being on 5-ASA, on corticosteroids or on anti-TNFa
agents was not significantly associated with endoscopic
recurrence, assessed by both scores. The use of immunomodula-
tors was associated with nonrecurrent disease only if we used the
RS (P ¼ 0.028 for RS and P ¼ 0.276 for MRS) (Table 3).
There was no statistical significant difference between
biomarkers (hemoglobin, CRP) and the HBI in patients with
endoscopic remission or in patients with endoscopic recurrence
assessed by both scores.
Modified Rutgeerts Classification and
Fecal Biomarkers
With regard to fecal markers, we found a positive corre-
lation between FC and FL (rs ¼ 0.558, P , 0.001), irrespective
of endoscopic recurrence, using the MRS. If we consider the
recurrent disease group, this correlation was found to be strong
(rs ¼ 0.729, P , 0.001). Fecal concentration of calprotectin and
lactoferrin was significantly higher in patients with endoscopic
recurrence ($i2b) in the neoterminal ileum than in those without
endoscopic recurrence (#i2a) (Median FC, 196.5 mg/g [IQR, 96–
634 mg/g] versus 42.1 mg/g [IQR, 19–91.60 mg/g; P , 0.001];
Median FL, 23.27 mg/g [IQR, 8.9–47.8 mg/g] versus 2 mg/g
[IQR, 0.9–7.26 mg/g]; P , 0.001). If we define endoscopic
recurrence as a Rutgeerts score$ i2, the median and interquartile
range concentrations of calprotectin and lactoferrin were also
higher in patients with endoscopic recurrence (FC, 95.1 mg/g
[IQR, 43.4–321 mg/g] versus 23.3 mg/g [IQR 9.85–66.7 mg/g;
P, 0.001]; FL, 8.6 mg/g (IQR 3.02–38.66 mg/g) versus 1.28 mg/
TABLE 2. Rutgeerts Score and Modified Rutgeerts
Score for Endoscopic Recurrence of CD After Ileocecal
Resection
Rutgeerts Score Modified Rutgeerts Score
n (%) n (%)
i0 19 (19) i0 19 (19)
i1 5 (5) i1 5 (5)
i2 51 (52) i2a 41 (42)
i2b 10 (10)
i3 11 (11) i3 11 (11)
i4 13 (13) i4 13 (13)
Endoscopic recurrence
No—i0, i1 24 (24) No—i0, i1, i2a 65 (66)
Yes—i2, i3, i4 75 (76) Yes—i2b, i3, i4 34 (34)
TABLE 3. Baseline Patients Characteristics According to Endoscopic Recurrence (Modified Rutgeerts Score and
Rutgeerts Score)
Endoscopic Recurrence
Rutgeerts Modified Rutgeerts
i0, i1, n (%) i2, i3, i4, n (%) P i0, i1, i2a, n (%) i2b, i3, i4, n (%) P
Age at diagnosis 0.316 0.152
A1 1 (4) 9 (12) 7 (11) 3 (9)
A2 21 (88) 54 (72) 52 (80) 23 (68)
A3 2 (8) 12 (16) 6 (9) 8 (23)
Disease behavior 0.634 0.779
B1 2 (8) 3 (4) 4 (6) 1 (3)
B2 13 (54) 37 (49) 33 (51) 17 (50)
B3 9 (38) 35 (47) 28 (43) 16 (47)
Smoking 0.012 0.274
Yes 1 (4) 21 (28) 13 (20) 9 (26)
Former 9 (38) 12 (16) 17 (27) 4 (12)
Therapy at time of colonoscopy
Mesalamine 6 (25) 29 (39) 0.327 21 (32) 14 (41) 0.507
Immunomodulators 20 (83) 43 (57) 0.028 44 (68) 19 (56) 0.276
Anti-TNF 5 (21) 25 (33) 0.313 16 (25) 14 (41) 0.109
Corticosteroids 2 (8) 5 (7) .0.999 4 (6) 3 (9) 0.689
TNF, tumor necrosis factor.
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g [IQR 0.55–4.64 mg/g; P , 0.001]) (Fig. 1). The 4 patients with
upper digestive tract disease had normal values of fecal markers.
A cutoff value of 7.25 mg/g for FL had a sensitivity of 85%,
a specificity of 74%, a positive predictive value (PPV) of 64%,
a negative predictive value (NPV) of 90%, and an accuracy of 77%
in detecting endoscopic recurrence, defined as an MRS$ i2b. The
calculated best cutoff level for FC in this study for predicting
recurrence was 100 mg/g, with a sensitivity of 74%, a specificity
of 75%, a PPV of 61%, an NPV of 91%, and an accuracy of 75%.
Table 4 shows the sensitivity, specificity, PPV, NPV, and accuracy
of FC and FL for predicting endoscopic recurrence (using Rut-
geerts and modified Rutgeerts scores) at different cutoff levels.
The area under the ROC curve (AUROC) for FC was 0.831
(95% CI, 0.752–0.911; P , 0.05) and for FL it was 0.842 (95%
CI, 0.763–0.920; P , 0.05) using the modified Rutgeerts score. If
recurrence was defined using the Rutgeerts score, the AUROC
was 0.757 (95% CI, 0.643–0.871; P , 0.05) for FC and 0.767
(95% CI, 0.657–0.877; P , 0.05) for FL (Figs. 2 and 3 compare
the ROC curves for FC [Fig. 2] and FL [Fig. 3] using the modified
Rutgeerts score [A] and the Rutgeerts score [B]).
FIGURE 1. FC (A) and FL (B) in endoscopic remission versus recurrence defined by the modified Rutgeerts score and the Rutgeerts score. Median
and interquartile range concentrations are presented.
TABLE 4. Sensitivity, Specificity, PPV, NPV and Accuracy of FC and FL in Identifying Endoscopic Recurrence
(Using Rutgeerts and Modified Rutgeerts Scores)
Sens (%) Specif (%) PPV (%) NPV (%) Accuracy (%) AUC (CI 95%)
Rutgeerts
Calprotectin 0.757 (0.643–0.871)
$50 72 71 89 45 72
$100 48 79 88 33 55
Lactoferrin 0.767 (0.657–0.877)
$7.25 55 79 89 37 60
Modified Rutgeerts
Calprotectin 0.831 (0.752–0.911)
$50 94 55 52 95 69
$100 74 75 61 91 75
Lactoferrin 0.842 (0.763–0.920)
$7.25 85 74 64 90 77
AUC, area under curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
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There was a poor correlation between both fecal markers
and HBI (FC, rs ¼ 0.096; FL, rs ¼ 0.146) and also between fecal
markers and CRP (FC, rs ¼ 0.251; FL, rs ¼ 0.230) at the time of
colonoscopy.
Follow-up
The median follow-up (FU) time since colonoscopy was
25 months (IQR, 22–34). At the end of FU, 95 patients were in
clinical remission (HBI , 5). Of the remaining patients, 3 pre-
sented with mild and 1 with moderate disease. Of these 4 patients
with clinically active disease, only 2 had recurrent endoscopic
disease with an MRS of i3 and i4, respectively. No patient
needed surgery during the FU period, and 33 patients underwent
changes in therapy (10 began immunomodulators, 13 began anti-
TNFa agents, 8 switched the anti-TNFa, and 2 began cortico-
steroids as the only therapy). A course of corticosteroids was
added to the therapy in 18 patients. Among the 33 patients that
intensified therapy, 20 (60.6%) intensified therapy due to endo-
scopic recurrence and clinical relapse and the remaining 13
(39.4%) intensified therapy based solely in endoscopic recur-
rence. We found that patients who needed therapy intensification
presented with significantly higher levels of FC and FL (FC,
191.0 mg/g [IQR, 95.6–726.5 mg/g] versus 51.9 mg/g [IQR,
23.4–118.5 mg/g; P , 0.001]; FL, 23.5 mg/g [IQR, 8.9–61.9 mg/
g] versus 2.5 mg/g [IQR, 1.1–8.4 mg/g]; P , 0.001). With regard to
endoscopic recurrence, patients with a modified Rutgeerts score $
i2b had intensified therapy more often than patients with a modified
Rutgeerts score # i2b (71.9% versus 13.8%, P , 0.001). Among
patients with clinical relapse during follow-up, 16 (80.0%) return
to clinical remission at the end of follow-up.
DISCUSSION
There is major scientific evidence to support early
endoscopic evaluation of the neoterminal ileum in CD in order
to predict the future clinical course and to adjust therapy
according to endoscopic findings.22–24 Recently, the POCER
study showed the short-term benefits of postoperative endoscopic
evaluation and treatment intensification in recurrent disease.25
Fecal markers have been attracting great interest in the post-
surgery setting despite the conflicting results and the small
number of patients enrolled in initial studies,18,26–29 thereby
postponing the establishment of a definitive role of FC and FL
in clinical management. In 2013, Yamamoto et al20 published
a pilot study demonstrating that both FC and FL levels corre-
lated with endoscopic scores and higher levels were predictors
of clinical recurrence in the 12-month follow-up. In recent
years, there have been some new publications supporting the
positive value of fecal markers in the evaluation of postoper-
ative recurrence of CD.25,21,30,31 The study of Wright et al21
evidenced the predictive value of serial monitoring of FC after
surgery for identifying patients likely to relapse and perform-
ing early endoscopic evaluation in order to intensify the ther-
apy if recurrence is diagnosed. All published series used the
FIGURE 2. ROC curves for FC for discriminating between endoscopic recurrence and remission after surgery (cutoff, 100 mg/g) using modified
Rutgeerts score (A) and Rutgeerts score (B).
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Rutgeerts score to classify endoscopic recurrence, which is
still an unvalidated score despite its widespread use in clinical
trials and clinical practice. This score lacks interobserver
agreement and has been a source of debate as it gathers in
the same category patients with lesions in the ileum and pa-
tients with lesions confined to the anastomosis. In this study,
the authors chose to use the modified Rutgeerts score as, from
a theoretical perspective (although again not yet validated), it
may be more accurate to define recurrence only when ileal lesions
are present (Rutgeerts $ i2b). With this score, stenosis and/or
ulceration of the anastomosis, which might simply be related to
ischemia or staples, do not define recurrent disease and have no
prognostic or therapeutic implications. This way, possible con-
founding factors for recurrent disease would be overcome by the
use of this modified score.
This is the first work, to the best of our knowledge, which
compares the performance of fecal markers with the 2 scoring
systems in predicting recurrent disease. We found that when using
the Rutgeerts score, a great number of patients were diagnosed as
having recurrent disease. This difference was mainly due to the
inclusion of patients with lesions concerning only the anastomosis
(either stenosis or ulceration) and no ileal disease (Rutgeerts i2
versus modified Rutgeerts i2a). In addition, the median values of
both FC and FL for recurrent disease with the Rutgeerts score
were lower than with the modified Rutgeerts score, with the
median FC below the cutoff value of 100 mg/g. This probably
reflects the subgroup of patients with normal FC and FL that
would have been classified as having endoscopic recurrence based
only on anastomotic disease. If we had used the Rutgeerts score,
the performance of both tests would have been jeopardized, with
a decrease in sensitivity from 74% to 48% and in NPV from 91%
to 33% with respect to FC, and from 85% to 55% and from 90%
to 37%, respectively, for FL. In terms of accuracy, for both tests,
we would have a decrease from 75% to 55% for FC and from 77%
to 60% for FL. Our findings also suggest, as in other studies, that
both FC and FL are sensitive enough to monitor CD recurrence
postoperatively, with a high NPV (91% and 90%, respectively),
which should reassure clinicians that few patients with endoscopic
recurrence will not be diagnosed using these tests. Both markers
not only had a good correlation between them but also correlated
significantly with the severity of endoscopic findings in the neo-
terminal ileum.
The presence of active disease elsewhere in the digestive
tract, besides the terminal ileum, is one of the major concerns over
the use of fecal markers for evaluating postoperative recurrence.
In this cohort, no patient presented with active colonic disease and
only 5 patients had active disease proximal to the neoterminal
ileum, as evaluated by capsule endoscopy, upper endoscopy, or
computed tomographic enterography (CTE) (data not shown).
We did not find either an association between CRP levels
or clinical symptoms and endoscopic findings, thereby con-
firming that this variable is not a good predictor of recurrent
disease, and that therapeutic options should not only be based
on this parameter. In this group, the majority of patients were
asymptomatic despite a third of them presenting with recurrent
disease.
FIGURE 3. ROC curves for FL for discriminating between endoscopic recurrence and remission after surgery (cutoff, 7.25 mg/g) using modified
Rutgeerts score (A) and Rutgeerts score (B).
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Selecting the most appropriate cutoff value for FC is critical
to its performance as a screening test. Such a value should have
a high NPV, so that few patients with active disease would be
missed for subsequent colonoscopy. In our analysis, the best
cutoff value for FC was 100 mg/g. Compared with 50 mg/g, the
value of 100 mg/g had a higher specificity, PPV, and accuracy in
diagnosing recurrent disease. If we had used the cutoff of 50 mg/g,
we would have increased the sensitivity (74% versus 94%) but
with less specificity (75% versus 55%) and accuracy (75% versus
69%). In this study, besides using FC, we decided to evaluate the
performance of FL in order to determine whether one marker
performed better than the other in diagnosing recurrence, and if
we could increase diagnostic accuracy by combining both. One
additional factor is the paucity of published data regarding the
utility of FL in this context. Although some authors have claimed
that FC performs better than FL in the evaluation of IBD,32 espe-
cially in limited ileal CD, the studies published in the literature
demonstrate that both markers are useful and comparable19,20,27
both in differentiating functional from organic disease and in
predicting disease activity and relapse.33–36 Possibly, the limited
use of FL relates to a more complex manipulation in the labora-
tory, bearing in mind the time limitation in the extraction process.
FL has also been evaluated in the postsurgery setting in CD, and
higher levels correlated with endoscopic recurrence. In our study,
FL performed extremely well with sensitivity, specificity, PPV,
NPV and accuracy of 85%, 74%, 64%, 90% and 77%, respec-
tively. FC and FL levels paralleled each other and endoscopic
findings, but their combined used did not improve diagnostic
accuracy (data not shown). Based on these results, it is our
conviction that there is no benefit in using both fecal markers
in combination because it does not bring any diagnostic
improvement.
The major strengths of this study are the following: (1) the
number of patients included in a single tertiary centre (99 patients
with simultaneous endoscopic assessment, fecal stool, and serum
markers evaluated); (2) endoscopic validation by only one
experienced operator, which obviates interindividual variation in
lesion classification and the definition of recurrence, overcoming
one of the major pitfalls when considering endoscopy; (3) the
exclusion of upper tract and colonic disease, which may affect
FC; and (4) the prospective design. However, we think that the
main limitations are the nonhomogeneous and variable time
between surgery and endoscopic recurrence evaluation, and the
use of a nonvalidated and less known endoscopic score (though
the Rutgeerts score has still not been validated either). It is our
opinion, supported by these findings, that the modified Rutgeerts
score should be preferred over the Rutgeerts score when
evaluating postoperative CD. Further studies are needed to
validate the modified Rutgeerts score and confirm its better
correlation with fecal markers.
In conclusion, fecal markers (FC and LF) are accurate
options for selecting patients for endoscopic (re-)evaluation in the
postoperative setting. They proved to be superior to clinical scores
or serum biomarkers as a screening test for endoscopic recurrence
of CD in the postoperative population. Their use should be
included in the management algorithm of asymptomatic postsur-
gery CD patients. Fecal markers performed significantly better
when the modified Rutgeerts score was used, suggesting that
endoscopic recurrence should only be considered for patients with
a modified Rutgeerts score . i2b (see Table, Supplemental Dig-
ital Content 1, http://links.lww.com/IBD/B294).
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Abstract
AIM
To evaluate the accuracy and best cut-off value of fecal 
calprotectin (FC) and fecal lactoferrin (FL) to predict 
disease recurrence in asymptomatic patients presenting 
with anastomotic strictures. 
METHODS
This was a longitudinal single tertiary center study 
based on prospectively collected data (recorded in a 
clinical database created for this purpose) performed 
between March 2010 and November 2014. Crohn’s 
disease (CD) patients with anastomotic stricture who 
submitted to postoperative endoscopic evaluation were 
included. Stools were collected on the day before bowel 
cleaning for FC and FL. Endoscopic balloon dilation 
(EBD) was performed if the patient presented an 
anastomotic stricture not traversed by the colonoscope, 
regardless of patients’ symptoms. Successful dilation 
was defined as passage of the colonoscope through 
the dilated stricture into the neotermimal ileum. 
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Postoperative recurrence was defined as a modified 
Rutgeerts score of ≥ i2b. 
RESULTS
In a total of 178 patients who underwent colonoscopy, 
58 presented an anastomotic stricture, 86% were 
asymptomatic, and 48 (54% male; median age of 46.5 
years) were successfully dilated. Immediate success 
rate was 92% and no complications were recorded. FC 
and FL levels correlated significantly with endoscopic 
recurrence (P  < 0.001) with an optimal cut-off value of 
90.85 µg/g (sensitivity of 95.5%, specificity of 69.2%, 
positive predictive value (PPV) of 72.4%, negative 
predictive value (NPV) of 94.7% and accuracy of 81%] 
for FC and of 5.6 µg/g (sensitivity of 77.3%, specificity 
of 69.2%, PPV of 68%, NPV of 78.4% and accuracy of 
72.9%) for FL.
CONCLUSION
Fecal markers are good predictors of CD endoscopic 
recurrence in patients with asymptomatic anastomotic 
stricture. FC and FL may guide the need for EBD in this 
context.
Key words: Crohn’s disease; Anastomotic strictures; 
Endoscopic balloon dilation; Fecal markers; Po-
stoperative recurrence
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This longitudinal study evaluated the accuracy 
of fecal calprotectin (FC) and fecal lactoferrin (FL) to 
predict disease recurrence in postoperative Crohn’s 
disease asymptomatic patients with an anastomotic 
stricture. FC and FL levels accurately predicted en-
doscopic recurrence in the presence of anastomotic 
stricture and thus may guide the need for endoscopic 
balloon dilation (EBD) in this context. A normal value of 
fecal markers can reassure clinicians and be safely used 
to avoid balloon dilation if we only aim to diagnose 
recurrence. A high value of fecal markers has a high 
likelihood of recurrence so EBD should be performed 
in order to provide adequate endoscopic therapy and 
adjust or optimize medical therapy. 
Lopes S, Andrade P, Rodrigues-Pinto E, Afonso J, Macedo G, 
Magro F. Fecal marker levels as predictors of need for endoscopic 
balloon dilation in Crohn´s disease patients with anastomotic 
strictures. World J Gastroenterol 2017; 23(35): 6482-6490 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v23/i35/6482.htm  DOI: http://dx.doi.org/10.3748/wjg.v23.
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INTRODUCTION
Crohn’s disease (CD) is a chronic inflammatory 
disorder with progression to penetrating or stricturing 
phenotype as part of the natural history. More than 
half of CD patients experience these complications 
during disease lifetime and will need surgery[1,2]. It 
is well known that disease recurrence proximal or at 
the anastomosis is almost universal, with progression 
to luminal narrowing and stricturing behavior[3]. It 
is known that despite the permanent reduction of 
luminal caliber and disease progression, the majority 
of patients remain asymptomatic, with normal 
biomarkers. As the primary therapeutic goal of CD has 
shifted from clinical remission to achieving mucosal 
healing[4,5], it may be important to access the mucosa 
proximal to strictures to evaluate disease recurrence 
and escalate therapy if needed. Over the last decade 
there is increasing evidence for endoscopic balloon 
dilation (EBD) as a safe and minimally invasive 
effective method for the treatment of stricturing 
disease[6-14]. Median technical success has been 
reported as 90%, with major complication rate around 
3%-10%[6,9,10]. Symptomatic recurrence is common, 
with a reported frequency ranging from 13% to 
100%[12]. However, it has been shown that repeated 
dilations do not reduce the efficacy of the procedure 
and may prevent surgery in compliant patients[8-12]. 
Fecal markers, namely fecal calprotectin (FC) and 
fecal lactoferrin (FL), have proved to be useful and 
accurate non-invasive tools in evaluating disease 
activity in CD. Recent works have also demonstrated 
their validity in diagnosing recurrence in the 
postoperative setting, suggesting that normal values of 
fecal biomarkers can obviate the need for endoscopic 
evaluation[15-18]. In patients with elevated levels of 
fecal biomarkers, endoscopy should be performed in 
order to confirm recurrence and escalate therapy if 
indicated[19]. To our knowledge there are no studies 
evaluating the performance of FC and FL in patients 
with asymptomatic anastomotic CD strictures and 
limited data is available on the long-term effect of 
medical therapy escalation after balloon dilation of 
anastomotic strictures. 
The aims of this study were, therefore, to evaluate 
the accuracy of FC and FL in the diagnosis of recurrent 
disease in the neoterminal ileum in asymptomatic/mild 
disease patients that had undergone bowel resection 
for CD and present with stricture of the anastomosis, 
to evaluate the best cut-off value of FC and FL to 
diagnose recurrence, and to evaluate the immediate 
technical success and safety rate of EBD.
MATERIALS AND METHODS
A longitudinal single tertiary center study based on 
prospectively collected data (recorded in a clinical 
database created for this purpose), was performed 
between March 2010 and November 2014. All patients 
gave informed written consent to participate in the 
study that was approved by the Ethics Committee 
of our Institution. From a cohort of consecutive CD 
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patients who submitted to postoperative endoscopic 
evaluation after ileocolectomy, we selected the group 
of patients with anastomotic stricture. All patients 
were followed at our inflammatory bowel disease (IBD) 
outpatient clinic and were referred for endoscopic 
evaluation at our institution. 
Inclusion criteria were definitive diagnosis of CD 
established by standard clinical, radiographic, endoscopic 
and histological criteria[20], previous ileocolectomy, and 
existence of an anastomotic stricture. Exclusion criteria 
were: age less than 18-years-old; strictures length 
greater than 6 cm; fistulae or deep ulceration of the 
strictured segment; technical impossibility of passing 
the catheter/balloon through the strictures; and active 
disease in the colon or upper digestive tract. 
Clinical disease activity was assessed on the day of 
endoscopic examination, according to the clinical criteria 
of the Harvey-Bradshaw index (HBI)[21,22]. Clinically 
inactive disease was defined as HBI < 5. All procedures 
were performed under propofol sedation, with CO2 
insufflation, by a single senior endoscopist (SL) and 
on an outpatient basis. Mechanical intestinal bowel 
preparation was done the day before colonoscopy 
with polyethylene glycol bowel preparation solution 
(Klean Prep®; Helsinn Birex Pharmaceuticals, Dublin, 
Ireland). Stool samples were collected the day 
before beginning bowel preparation (preferably from 
the first stool in the morning) and then kept in the 
refrigerator until being brought to the hospital. For 
FC, within a maximum 7 d after collection, stools were 
extracted in accordance with the manufacturer’s 
instructions, using the Fecal Sample Preparation 
Kit (Roche Diagnostics, Mannheim, Germany) and 
analyzed using immunoassay (EliA Calprotectin®; 
Thermo Fisher Scientific, Freiburg, Germany). For FL 
evaluation, stools were stored at -80 ℃ upon arrival 
at the laboratory, and samples were thawed and 
analyzed using a commercially available quantitative 
enzyme-linked immunoassay test (IBD-Scan®; Tech-
Lab, Blacksburg, VA, United States). The techniques 
for measurement of fecal markers followed the 
manufacturer´s guidelines.
Postoperative disease activity of the neoterminal 
ileum was evaluated according to the modified 
Rutgeerts score[23] (i0: no lesions in the distal ileum; 
i1: < 5 aphthous lesions in the distal ileum; i2a: 
lesions confined to the ileocolonic anastomosis, 
including anastomotic strictures; i2b: > 5 aphthous 
ulcers or larger lesions, with normal mucosa in 
between, in the neoterminal ileum, with or without 
anastomotic lesions; i3: diffuse aphthous ileitis with 
diffusely inflamed mucosa; i4: large ulcers with diffuse 
mucosal inflammation or nodules or strictures in the 
neoterminal ileum). Postoperative recurrence was 
defined as a modified Rutgeerts score of ≥ i2b. 
EBD was performed if the patient presented an 
anastomotic stricture not traversed by the colonoscope, 
regardless of the patient’s symptoms. All dilations 
were performed with the same type of colonoscope 
(Olympus® CF type H180AL; Tokyo, Japan) under 
fluoroscopic control to allow the endoscopist to 
characterize the strictures, exclude peristricture 
fistulae, evaluate the optimal diameter of the balloon 
to use and to prompt identify any complication 
during the procedure. Dilations were performed with 
a guidewire (Boston Scientific® Jagwire 0.035 in; 
Marlborough, MA, United States) placed through the 
strictures [after contrast instillation through a catheter 
(Olympus® Ball Tip/6Fr) over which a through-the-
scope balloon (Cook Medical®, Bloomington, IN, United 
States) was placed]. The balloon was inflated using 
contrast agent and the pressure maintained for 2 min, 
to a maximum diameter of 18 mm. 
The procedure could be repeated at the discretion 
of the endoscopist. Successful dilation was defined 
as passage of the colonoscope through the dilated 
stricture into the neotermimal ileum. Only patients with 
a successful dilation were analyzed, as progression 
to the neoterminal ileum was mandatory to evaluate 
disease recurrence. Major complications were defined 
as major bleeding requiring surgery, blood transfusion 
or hospital admission and perforation. Minor, self-
limited bleeding was not registered as a complication. 
Statistical analysis
SPSS 20.0 for Windows (SPSS, Chicago, IL, United 
States) was used for statistical analysis. Categorical 
variables were described as absolute frequencies (n) 
and relative frequencies (%); continuous variables were 
described as mean ± SD (parametric distributions) or as 
median and percentiles (non-parametric distributions). 
The normality of the continuous variables was tested 
using the Kolmogorov-Smirnov test and the respective 
histogram. Student’s t-test was used to compare 
quantitative variables with a normal distribution, and 
the Mann-Whitney U test was used to compare the 
quantitative variables without a normal distribution. 
Any groups with more than two quantitative variables 
were compared using the Kruskal-Wallis test. A 
Pearson χ 2 test was used to compare categorical 
variables. Kaplan-Meier analysis with log rank statistics 
was used to estimate event-free interval. A logistic 
regression was performed to assess predictors of 
disease recurrence and need for dilation. Statistical 
significance was set at P < 0.05. 
RESULTS
Patient characteristics 
One hundred and seventy-eight consecutive CD 
patients (51.7% male; median age 46.4 years) who 
previously submitted to right ileocolectomy were 
evaluated by colonoscopy. At the time of endoscopic 
evaluation, 31 (17.4%) patients complained of 
subocclusive symptoms, and 66.3% of patients were 
being treated with immunomodulators and 38.2% with 
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balloon diameter was used in 69.2% of the patients 
and the 15-mm diameter in 25.0%. Redilation was 
required in 14 patients (29.2%) during a median 
follow-up time of 34 mo (27.5-52.5 mo). During the 
follow-up period, only 2 patients needed surgery, both 
cases due to long strictures that did not allow EBD 
(Table 2).
Fecal markers and endoscopic recurrence
Of the 48 successfully dilated patients, 22 presented 
with endoscopic recurrence defined as modified 
Rutgeerts score of ≥ i2b. Of these, 16 patients 
presented with severe disease (i3 = 3 and i4 = 13). 
Recurrence was diagnosed only after dilation of the 
anastomotic stricture and intubation of the neoterminal 
ileum. Comparing FC and FL levels in patients with 
endoscopic recurrence and in patients with endoscopic 
remission we found a significantly higher level in 
patients with endoscopic recurrence [FC: 257.0 μg/g, 
interquartile range (IQR): 161.0-565.0 μg/g) vs 53.9 
μg/g, IQR: 23.9-146.0 μg/g; P < 0.001 and FL: 9.1 
biologics. 
Of the 178 evaluated patients, 58 (32.6%) pr-
esented with an anastomotic stricture. The majority 
were asymptomatic, with only 8 (13.8%) patients 
presenting with subocclusive symptoms. All patients 
were in clinical remission (HBI < 5 in 83.3%) or with 
mild clinical disease (HBI 5-7 in 16.7%). Among the 
58 patients presenting with anastomotic stricture, 52 
were dilated (6 were excluded due to deep ulceration, 
stricture size > 6 cm or technical inability). Of the total 
52 dilated patients, 4 were excluded as it was not 
possible to evaluate the neoterminal ileum (Figure 1). 
Baseline characteristics of the 48 successfully dilated 
patients are summarized in Table 1. The majority were 
men (54%) with a median age of 46.5 years. At the 
time of dilation, 42% of patients were being treated 
with biologics and 54% with immunomodulators.
EBD 
Overall, technical success rate was 92% (48/52) and 
no major complications were recorded. The 18-mm 
178 CD patients submitted to ileocolectomy
58 patients with anastomotic stricture
Dilation not performed (n  = 6)
3 deep ulceration, 2 strictures > 6 cm,
1 technical inability
52 dilated patients
Inability to passe into the neoileum (n  = 4)
48 patients successfully dilated in a total of 69 procedures
Success rate 92%
1 dilation
n  = 34
2 dilations
n  = 9
1 dilations
n  = 3
1 dilations
n  = 2
Figure 1  Study flowchart. CD: Crohn’s disease.
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μg/g, IQR: 5.5-27.8 μg/g vs 3.9 μg/g, IQR: 1.5-21.9 
μg/g; P = 0.042] (Figure 2). No other clinical variable 
or biomarker reached statistical difference between the 
two groups (Table 3).
The best calculated cut-off value for FC to predict 
recurrent disease was 90.85 µg/g, with a sensitivity 
of 95.5%, a specificity of 69.2%, a positive predictive 
value (PPV) of 72.4%, a negative predictive value (NPV) 
of 94.7% and an accuracy of 81%. The area under 
the ROC curve for diagnosing endoscopic recurrence 
was 0.786 (95%CI: 0.646-0.926, P < 0.05) for FC. 
Concerning FL, the best calculated cut-off was 5.6 µg/
g, with sensitivity of 77.3%, specificity of 69.2%, PPV 
of 68%, NPV of 78.4% and accuracy of 72.9%. The 
area under the ROC curve for diagnosing endoscopic 
recurrence was 0.672 (95%CI: 0.511-0.834, P = 
0.042) (Figure 3).
DISCUSSION
One of the major drawbacks of CD surgical therapy 
is the high recurrence rate of the disease at the 
anastomotic site or in the neoterminal ileum, with the 
development of stricture and bowel obstruction[8]. As 
the primary therapeutic goal of CD has shifted from 
clinical remission to achieving mucosal healing[4,5], 
it may be important to access the mucosa proximal 
to strictures to evaluate disease recurrence and 
escalate therapy if needed. The recently published 
POCER trial[16] demonstrated that initial postoperative 
treatment according to clinical risk stratification and 
early endoscopic evaluation and step-up therapy if 
there was recurrent disease was superior to standard 
medical therapy. 
In this study, endoscopy was the gold standard 
method to define recurrent disease. With respect to 
non-invasive methods, both serum biomarkers and 
clinical activity indexes have demonstrated a poor 
correlation with disease activity[24-26]. The use of fecal 
markers in the postoperative period has been studied 
in small groups of patients with variable results. 
Recently, however, some studies evaluated the value 
of fecal biomarker measurement after surgery for 
CD. In 2015, Wright et al[15] demonstrated that FC 
was sensitive enough to diagnosis CD recurrence in 
135 patients submitted to bowel resection with a high 
enough NPV to reassure clinicians that few patients 
with recurrence would be missed. More recently, 
Lopes et al[27] showed that both FC and FL strongly 
correlated with endoscopic findings in the evaluation of 
CD after surgery and accurately predicted endoscopic 
recurrence in 99 CD patients who submitted to ile-
ocolonic resection.
The results of both of these studies suggests 
that fecal biomarkers may be incorporated in the 
postoperative management algorithm, both to 
diagnose recurrence and to assess response to 
therapy. In our study, we evaluated if in asymptomatic 
CD patients with anastomotic strictures not traversed 
Lopes S et al. Fecal markers in CD anastomotic strictures
Table 1  Patient characteristics, n  = 48
Characterization n  (%)
Women, 22 (45.8)
Median time between diagnosis and surgery, mo 
(IQR)
36.0 (14.0-120.0)
Median time between surgery and endoscopic 
evaluation, mo (IQR)
114.5 (60.8-199.0)
Median age at endoscopic evaluation, yr (IQR) 46.5 (39.3-53.4)
Montreal classification
Age at diagnosis
   A1, ≤ 16 yr 6 (12.5)
   A2, 17-40 yr 33 (68.8)
   A3, > 40 yr 9 (18.8)
Location
   L1: ileal 30 (62.5)
   L3: ileocolonic 17 (35.4)
   L4: upper gastrointestinal tract 1 (2.1)
Behavior
   B1: non-stricturing, non-penetrating 1 (2.1)
   B2: stricturing 27 (56.2)
   B3: penetrating 20 (41.7)
Perianal disease 14 (29.2)
   Smoking
   Never 26 (54.2)
   Current 12 (25.0)
   Past 10 (20.8)
Concomitant treatment
   Corticosteroids 9 (18.8)
   Immunomodulators (Azathioprine/6MP/ 
Methotrexate)
26 (54.2)
   Biologics (Infliximab, adalimumab) 20 (41.7)
   5-ASA 17 (35.4)
   Median fecal calprotectin, μg/g (IQR) 134.0 (35.3-321.0)
   Median, fecal lactoferrin, μg/g (IQR) 6.2 (2.0-22.4)
Modified Rutgeerts score
   i0, i1, i2a 26 (54.2)
   i2b, i3, i4 22 (45.8)
   Subocclusive symptoms   8 (16.7)
Harvey-Bradshaw index
   Remission (HBI < 5) 40 (83.3)
   Mild disease (HBI 5-7)   8 (16.7)
   Need of redilation 14 (29.2)
   Surgery after dilation 2 (1.4)
   Median follow up, mo (IQR) 34.0 (27.5-52.5)
HBI: Harvey-Bradshaw index; IQR: Interquartile range.
Table 2  Characterization of the dilation procedure 
Characterization  n  (%)
Patients with stricture 58 (32.6)
Stricture type
   Anastomotic 58 (100)
   Dilated patients 52 (29.2)
Causes for non-dilation
   Length of stenosis   2 (33.3)
   Ulceration of mucosa   3 (50.0)
   Technical inability    1 (16.7)
Successful dilated patients
Balloon size, n = 52 48 (92.3)
   15 mm 13 (25.0)
   16.5 mm 3 (5.8)
   18 mm 36 (69.2)
Complications 0 (0.0)
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by the colonoscope, fecal markers perform as well 
as a predictor of disease recurrence, defining groups 
of patients that will need more invasive methods. In 
this series of 48 patients with strictures, only 18% 
complained of subocclusive symptoms. Similarly to 
what has been published[28-30], we also did not find 
any correlation between patient symptoms, serum bi-
omarkers and HBI and endoscopic or radiographic 
findings, supporting the belief that using only symptoms 
or C-reactive protein levels to inform treatment 
decisions may increase the risk of disease progression 
and complications. 
It is controversial whether or not asymptomatic 
strictures should be endoscopically treated. Despite 
being a safe and minimally invasive technique, there is 
a 3%-10%[6,9,10] described risk of major complications, 
especially in centers with limited procedural volume 
per year. Our data confirmed the safety and efficacy of 
EBD in the context of CD anastomotic strictures, with 
a technical success rate of 92%. We had no serious 
complications, which may be explained by several 
factors: careful patient selection; use of fluoroscopic 
image to evaluate, in real time, stricture characteristics 
and the therapeutic procedure indicated; maximum 
diameter of the balloon used (18 mm); use of carbon 
dioxide as type of insufflation; and experience of the 
endoscopist performing the technique with a uniform 
technical approach. The dilation of the anastomosis 
allowed the diagnosis of recurrence in 22 patients, that 
otherwise would have been missed if we only relied on 
symptoms or biochemical markers. 
We used the modified Rutgeerts score to diagnose 
endoscopic recurrence, although it is not yet validated. 
Despite being used for several decades in clinical 
trials and clinical practice, the Rutgeerts score is 
also an invalidated score. In this study, we chose to 
use the modified Rutgeerts score, as demonstrated 
in a previous work[27] as having a better correlation 
between the modified score and fecal markers to 
diagnose recurrent disease. Recurrence was defined by 
a modified Rutgeerts score of i2b, not considering the 
presence of only anastomotic stricture as a criterion, 
as many other factors may be implicated in stricture 
development[1,2]. In that paper[27] the calculated best 
cut-off level for FC for predicting recurrence was 100 
µg/g, with a sensitivity of 74% and a NPV of 91%. 
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Figure 2  Box plots of fecal markers according to endoscopic activity defined by the modified Rutgeerts score, in asymptomatic patients presenting with 
anastomotic strictures. A: Fecal calprotectin; B: Fecal lactoferrin.
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Figure 3  Receiver operating characteristic curves for fecal markers for discriminating between endoscopic recurrence and remission in asymptomatic 
patients presenting with anastomotic strictures. A: Fecal calprotectin; B: Fecal lactoferrin.
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This is in accordance with other studies[15] that defined 
in the post-operative setting a higher cut-off than 
that of 50 μg/g used to diagnose inflammatory bowel 
disease[31]. 
In the present study, both FC and FL were also 
significantly higher in patients with endoscopic 
recurrence, with an area under the receiver operating 
characteristic curve for detection of endoscopic 
recurrence of 0.786 for FC and of 0.672 for FL. The 
best cut-off value of FC as predictor of recurrence was 
90.85 μg/g, with sensitivity of 95.5%, NPV of 94.7% 
and accuracy of 81%. If we adopted the commonly 
used cut-off value of 7.25 μg/g for lactoferrin[32-34], 
we would have missed patients with recurrence (false 
negative results). The cut-off value of 5.6 μg/g had 
sensitivity of 77.3%, NPV of 78.4% and accuracy of 
72.9%. Our findings support the potential value of 
these two noninvasive markers in the monitoring of 
patients submitted to bowel resection and presenting 
with an anastomotic stricture. 
Indeed, a FC and/or FL concentration lower than 
90.85 μg/g and 5.6 μg/g respectively, have high 
accuracy to exclude disease recurrence, with no need 
to further therapeutic intervention. This may be of 
particular interest in centers with low expertise in 
EBD and/or with a lower procedural volume per year, 
in order to avoid complications and/or be used as an 
indication for referring patients to tertiary centers. If 
these results are reproduced and validated by others, 
in a large number of patients, this conservative 
strategy could be adopted, reserving balloon dilation 
for symptomatic patients and those with high levels of 
fecal markers, in order to facilitate step-up therapy.
To our knowledge this is the first report on the 
performance of FC and FL in the context of anastomotic 
strictures in CD. Our results suggest that low values 
of fecal markers can predict, with a great amount of 
certainty, disease remission. This may avoid application 
of endoscopic dilation in asymptomatic patients in 
centers with less endoscopic expertise, reassuring 
physicians that the use of fecal markers serves as a 
good indicator to monitor disease recurrence. The 
serial monitoring of FC and FL can help to make 
decisions in indeterminate results and a persistently 
elevated value may serve as another useful indicator 
when considering therapy intensification.
In conclusion, postoperative FC and FL levels 
accurately predicted endoscopic recurrence in the 
presence of anastomotic stricture. Considering that a 
significant number of patients remain asymptomatic, 
with normal serum biomarkers, despite the permanent 
reduction of luminal caliber, a normal value of fecal 
markers can reassure clinicians and be safely used 
to avoid balloon dilation if we only aim to diagnose 
recurrence. In asymptomatic patients with a high 
FC and/or FL level, there is a great chance of having 
disease activity proximal to the stricture, so EBD 
should be performed in order to provide adequate 
endoscopic therapy and adjust or optimize medical 
therapy.
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Background
Recurrent disease in the neoterminal ileum and anastomotic strictures are 
frequent complications of Crohn´s disease (CD). Despite the permanent 
reduction of luminal caliber and disease progression, the majority of patients 
remain asymptomatic. Fecal calprotectin (FC) and lactoferrin have been 
suggested as surrogate non-invasive markers for diagnosing postoperative 
disease recurrence. There are no studies evaluating the performance of fecal 
markers as predictors of disease recurrence in asymptomatic patients with an 
anastomotic stricture.
Research frontiers
The results demonstrated that FC and lactoferrin are good predictors of CD 
endoscopic recurrence in patients with asymptomatic anastomotic stricture and 
may guide the need for endoscopic balloon dilation in this context.
Innovations and breakthroughs
A normal value of fecal markers can reassure clinicians and be safely used 
to avoid balloon dilation if we only aim to diagnose recurrence. A high value 
of fecal markers has a high likelihood of recurrence, so endoscopic balloon 
dilation should be performed in order to provide adequate endoscopic therapy 
and adjust or optimize medical therapy. 
Applications
Fecal markers may avoid the need of endoscopic balloon dilation in 
asymptomatic patients with anastomotic stricture if we only aim to diagnose 
disease recurrence.
Terminology
Calprotectin is a protein complex, constituting up to 60% of neutrophil cytosol 
Table 3 Comparison between patients with and without 
endoscopic recurrence
Endoscopic 
recurrence, 
n  = 22
No endoscopic 
recurrence, 
n  = 26
P value
Sex, M:F 11:11 15:11 0.404
Median age, yr (IQR) 47.0 (35.5-53.3) 46.5 (39.8-54.8) 0.472
Median hemoglobin, 
g/dL (IQR)
13.8 (12.5-15.1) 13.9 (13.1-15.0) 0.715
Median albumin, g/L 
(IQR)
42.4 (36.1-45.9) 42.1 (39.8-44.6) 0.886
Median C-reactive 
protein, mg/L (IQR)
5.6 (1.6-8.2) 2.4 (0.9-9.9) 0.457
Median fecal calprotectin, 
μg/g (IQR)
257.0 
(161.0-565.0)
53.9 (23.9-146.0) < 0.001
Median fecal lactoferrin, 
μg/g (IQR)
9.1 (5.5-27.8) 3.9 (1.5-21.9) 0.042
Smoking, yes/no/past 3/13/6 9/13/4 0.196
Subocclusive symptoms, 
yes/no
2/20 6/20 0.183
HBI, remission/mild 17/5 24/2 0.145
Concomitant treatment
   Anti-TNF- α agents, 
yes/no
12/10 14/12 0.596
   Immunomodulators, 
yes/no
9/13 11/15 0.578
   Steroids, yes/no 4/18 5/21 0.611
HBI: Harvey-Bradshaw index; IQR: Interquartile range.
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protein that is released upon neutrophil activation. Lactoferrin, an iron-binding 
protein, is the main component of secondary granules that degranulate during 
inflammatory process. Both these proteins are remarkably stable and resistant 
to degradation, easily detected and have been proved to reflect endoscopic 
disease activity in CD, predicting endoscopic inflammation and being a 
surrogate marker of mucosal healing.
Peer-review
The authors have performed a very interesting and important study. They 
concluded that postoperative FC and FL levels accurately predicted endoscopic 
recurrence in the presence of anastomotic stricture.
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Abstract
AIM
To evaluate the incidence of anastomotic strictures after 
intestinal resection in Crohn’s disease (CD), demon-
strate long-term efficacy and safety of endoscopic 
balloon dilation (EBD) in CD strictures and its impact on 
the diagnosis of subclinical postoperative endoscopic 
recurrence. 
METHODS
Retrospective single tertiary center study based on 
prospectively collected data between 2010 and 2015 
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including anastomotic and non-anastomotic strictures. 
RESULTS
29% of 162 CD patients included developed an 
anastomotic stricture. 43 patients with anastomotic 
strictures and 37 with non-anastomotic strictures 
underwent EBD; technical success was 97.7% and 
100%, respectively, however, 63% and 41% needed 
repeat dilation during the 4.4-year follow-up. Longer 
periods between surgery and index colonoscopy and 
higher lactoferrin levels were associated with the 
presence of stricture after surgery. Calprotectin levels 
> 83.35 µg/g and current or past history of smoking 
were associated with a shorter time until need for 
dilation (HR = 3.877, 95%CI: 1.480-10.152 and HR = 
3.041, 95%CI: 1.213-7.627). Anastomotic strictures 
had a greater need for repeat dilation (63% vs  41%, 
P  = 0.047). No differences were found between 
asymptomatic and symptomatic cohorts. Disease recur-
rence diagnosis was only possible after EBD in a third 
of patients. 
CONCLUSION
EBD is an effective and safe alternative to surgery, 
with a good short and long-term outcome, postponing 
or even avoiding further surgery. EBD may allow to 
diagnose disease recurrence in patients with no clinical 
signs/biomarkers of disease activity.
Key words: Crohn’s disease; Endoscopic recurrence; 
Anastomotic strictures; Non-anastomotic strictures; 
Endoscopic balloon dilation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This study evaluated the incidence of anas-
tomotic strictures after intestinal resection in Crohn’
s disease (CD), the long-term efficacy and safety of 
endoscopic balloon dilation (EBD) in CD strictures and 
its impact on the diagnosis of subclinical postoperative 
endoscopic recurrence. Almost one-third of CD patients 
developed an anastomotic stricture after ileocecal 
resection/right hemicolectomy. EBD was an effective 
and safe alternative to surgery, with a good short 
and long-term outcome, postponing or even avoiding 
further surgery. EBD also allowed to diagnose disease 
recurrence in patients with no clinical signs/biomarkers 
of disease activity. Longer intervals after surgery 
and higher lactoferrin levels were associated with 
anastomotic strictures; time until dilation was lower 
in patients with calprotectin levels > 83.35 µg/g and 
current/past history of smoking.
Lopes S, Rodrigues-Pinto E, Andrade P, Afonso J, Baron TH, 
Magro F, Macedo G. Endoscopic balloon dilation of Crohn’
s disease strictures-safety, efficacy and clinical impact. World J 
Gastroenterol 2017; 23(41): 7397-7406  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i41/7397.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i41.7397
INTRODUCTION
Strictures in crohn’s disease (cD) develop during the 
course of the disease or as the presenting feature[1]. 
Up to 50% of cD patients undergo surgical resection 
within the first 10 years of diagnosis[2]. Disease 
recurrence often occurs at or above the anastomosis 
due to ongoing inflammatory activity[3,4]. This can result 
in luminal narrowing, and strictures (non-anastomotic 
and anastomotic), with up to 70% of patients requiring 
additional resection[5], though is unpredictable[6].
Medical therapy for stricture management is limited 
due to the fibrotic nature. Management includes surgical 
resection and stricturoplasty but with a high rate of 
recurrence and need for reoperation[7]. Increasing 
evidence supports endoscopic balloon dilation (EBD) as 
a safe and effective alternative to surgery, particularly 
for ileocecal and anastomotic strictures[8,9]. Technical 
and clinical success rates (resolution of obstructive 
symptoms) are seen in 73%-100% and 64%-70%, 
respectively, with a major adverse event (AE) rate 
of 2%-6.4%[1,10-12]. Balloon diameters of 25 mm are 
believed to increase risk of AEs[13]. During long-term 
follow-up patients needing surgery at 1, 3 and 5 years 
varies form 13%-17%, 28%-42%, and 36%-42% 
respectively. Strictures recur following dilation, and 
re-dilation may be required in up to 20% and 50% 
by 1 and 5 years, respectively[1,14,15]. The best results 
following dilation are obtained when stricture length is 
< 4 cm, and for anastomotic strictures when compared 
to de novo strictures[1,12,16].
Anastomotic strictures may represent disease 
recurrence, but data is limited and contradictory as 
to whether escalation of medical therapy following 
dilation may prevent the need for repeat dilation or 
surgery[10,12]. Other factors such as smoking status and 
disease activity status at the time of dilation may affect 
outcome of stricture dilation[12], though many studies 
are limited by short follow-up durations and small 
cohorts.
We sought to evaluate anastomotic stricture deve-
lopment after intestinal resection in cD and demonstrate 
long-term efficacy and safety of EBD in CD anastomotic 
and de novo strictures in a large referral centre cohort 
and determine the impact of dilation on the diagnosis of 
subclinical postoperative endoscopic recurrence.
MATERIALS AND METHODS
Retrospective single tertiary center study based on 
prospectively collected data from a clinical database 
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created for this purpose. Patients were treated 
from March 2010 to February 2015 including cD 
patients who had undergone ileocecal resection/right 
hemicolectomy. All patients were followed at our 
Inflammatory Bowel Disease (IBD) outpatient clinic 
and referred for endoscopic evaluation. Inclusion 
criteria were definitive diagnosis of cD established 
by clinical, radiographic, endoscopic, and histological 
criteria and previous surgery and surgical pathology. 
Exclusion criteria were previous EBD, age < 18 years, 
stricture length > 6 cm and fistulae or deep ulceration 
of the strictured segment.
clinical disease activity was assessed on the 
day of endoscopic examination, using the Harvey 
Bradshaw Index (HBI). clinically inactive disease was 
defined as a HBI < 5. Postoperative disease activity 
of the neoterminal ileum was evaluated according to 
the Modified Rutgeerts’ score[17]. Indication for EBD 
was to evaluate endoscopic recurrence or symptom/
biomarker-driven. 
cD patients with non-anastomotic strictures who 
underwent EBD during the study period were included 
as a control group (Figure 1).
All procedures were performed in an outpatient 
setting under propofol sedation, with cO2 insufflation, 
by one of two endoscopists (SL and ERP). Polyethylene 
glycol based bowel preparation was administered 
the day before colonoscopy. EBD was performed 
for strictures that would not allow passage with a 
colonoscope, regardless of patients’ symptoms. 
Dilations were performed endoscopically with a through-
the-scope balloon (Boston Scientific, Marlborough, MA), 
of 10-18 mm diameter and lengths of 55 mm. The 
balloon was filled with diluted contrast, with diameter of 
the balloon chosen according to endoscopist discretion. 
Inflation pressure was maintained for 2 min. 
Technical success was defined as the ability to 
pass the colonoscope through the stricture into the 
neoileum following dilation. clinical success was 
defined as improvement of obstructive symptoms (in 
symptomatic patients). Major AEs were defined as 
major bleeding (requiring surgery, blood transfusion or 
hospital admission) and perforation. Minor, self-limited 
bleeding was not considered an AE. All patients who 
underwent dilation were endoscopically reevaluated 
6-12 mo later. Long-term efficacy was defined as 
avoidance of surgical resection or repeat dilation 
after the initial dilation. Patients were followed until 
stricture resection, last clinic follow-up, or censor date 
of March, 2017. Escalation of medical therapy was 
defined as initiation of a thiopurine or anti-TNF within 6 
mo of first dilation, as determined by global physician 
assessment. 
All patients gave informed written consent to 
participate in the study that was approved by the 
Ethics committee of our Institution.
Statistical analysis
categorical variables were described through absolute 
and relative frequencies. continuous variables were 
described as median, minimum and maximum and 
dichotomized for analysis using the best cut-off on ROc 
analysis. Hypotheses were tested about the distribution 
of continuous variables with non-normal distribution, 
by using the nonparametric Mann-Whitney. The chi-
squared test and Fisher’s exact test were used for 
differences in proportions of patients experiencing a 
given outcome. Univariate and multivariate analysis by 
logistic regression was used to explore the correlation 
between predictor variables and need of dilation 
after surgery, as well as need to repeat dilation. To 
identify independent predictors of need of dilation 
after surgery, as well as need to repeat dilation, 
all significant variables evaluated in the univariate 
analysis were included. Kaplan-Meier survival analysis 
with log rank statistics was used to assess event-free 
survival, and cox conditional proportional hazards 
regression analysis was used to time-free survival. 
The results are shown as odds ratio (OR) and hazards 
ratio (HR) with 95% confidence intervals (CI). All the 
reported P values were two-sided, and P values of < 
0.05 were considered statistically significant. All data 
were arranged, processed and analyzed with SPSS® 
v.24.0 data (Statistical Package for Social Sciences).
RESULTS
Population
A total a 162 cD patients (52.5% males, n = 85) who 
had undergone ileocecal resection/right hemicolectomy 
were included; the mean age was 42.6 years (SD ± 
13.4 years). Baseline demographic characteristics are 
listed in Table 1. The median follow-up period since 
colonoscopy index was 4.4 years (1.3-6.8), with a 
median disease duration of 17.1 years (3.3-52.1). 
Median time between surgery and index colonoscopy 
was 7.7 years (range 0.3-37.6 years).
At the time of index colonoscopy, 82% of patients 
(n = 133) were receiving cD medication: 68.5% (n 
= 111) thiopurines and 36.4% (n = 59) anti-TNF 
medication; only 23% of the patients (n = 37) were 
on combination therapy. Seventeen percent of the 
patients (n = 27) had obstructive symptoms, with a 
median HBI of 1 (0-9). Median labs were: haemoglobin 
13.5 g/dL (9.6-18.3), albumin 42 g/dL (24.2-352), 
c-reactive protein 2.8 mg/L (0.1-105.3), median 
lactoferrin 4.7 µg/g (0.4-216) and median calprotectin 
68.5 µg/g (0.5-2051). 
Anastomotic strictures
Twenty-nine percent of patients (n = 47) had an 
anastomotic stricture (17 symptomatic), with 4 also 
having a non-anastomotic stricture; dilation wasn’t 
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= 2.6, 95%cI: 1.3-5.3, P = 0.007), longer duration 
between surgery and index colonoscopy [132 mo 
(9-439) vs 71 mo (3-415), P = 0.001], older age [47 
years (16-72) vs 39 years (18-77), P = 0.031] and 
lower c-reactive protein levels [2.65 mg/L (0.3-21.9) 
vs 2.85 mg/L (0.1-105.3), P = 0.045]. 
On univariate analysis, the presence of stricture 
after surgery was associated with longer periods 
between surgery and index colonoscopy (OR = 
1.006, 95%cI: 1.003-1.010, P = 0.001), higher 
lactoferrin levels (OR = 1.010, 95%cI: 1.000-1.021, 
P = 0.049), obstructive symptoms (OR = 6.155, 
95%cI: 2.546-14.880, P < 0.001), no medication 
with thiopurines (OR = 2.611, 95%cI: 1.282-5.319, 
P = 0.008) and older age at index colonoscopy (OR 
= 1.028, 95%cI: 1.002-1.055, P = 0.033) (Table 2). 
On multivariate analysis, only longer periods between 
surgery and index colonoscopy (OR = 1.007, 95%cI: 
1.001-1.013, P = 0.027) and higher lactoferrin levels 
(OR = 1.012, 95%cI: 1.000-1.024, P = 0.043) were 
associated with the presence of stricture (Table 2). 
In the cox regression univariate analysis, time 
until dilation was longer in patients on medication 
with thiopurines or anti-TNF (HR = 0.476, 95%CI: 
0.239-0.946, P = 0.034); in further subgroup analysis, 
thiopurine treatment was the only medication found 
to be significantly associated with a longer time to 
dilation (HR = 0.493, 95%cI: 0.275-0.883, P = 0.017). 
Obstructive symptoms and calprotectin levels higher 
than 83.35 µg/g, on the other hand, were associ-
ated with a shorter time until dilation (HR = 2.976, 
95%cI: 1.622-5.460, P < 0.001 and HR = 3.444, 
95%cI: 1.391-8.526, P = 0.008, respectively). There 
was a trend for current or past history of smoking 
being associated with a shorter time to dilation 
in the univariate analysis (HR = 1.752, 95%cI: 
0.964-3.185, P = 0.066). In the cox multivariate 
analysis, calprotectin levels > 83.35 µg/g and current 
performed in 4 patients: 1 due to stricture length > 6 
cm, 2 due to marked ulceration and 1 due to unstable 
scope position. 
The presence of stricture after surgery was 
associated with presence of obstructive symptoms 
(37% vs 9%, OR = 6.3, 95%cI: 2.5-14.9, P < 0.001), 
no medication with thiopurines (74.8% vs 53.2%, OR 
CD patients with prior ileocecal 
resection/hemicolectomy 
(n  = 162)
Anastomotic stricture 
(n  = 47)
Anastomosis without stricture 
(n  = 115)
CD patients with non-
anastomotic stricture 
(n  = 37)
Not dilated (n  = 4)
- Stricture length > 6 cm (n  = 1)
- Scope unstable position (n = 1)
- Marked ulceration (n  = 2)
Balloon dilation 
(n  = 43)
Balloon dilation 
(n  = 37)
Repeat dilation 
(n  = 27)
No further 
dilation 
(n  = 16)
Repeat dilation 
(n  = 15)
No further dilation 
(n  = 22)
Figure 1  Flowchart with study design.
Table 1  Baseline characteristics of crohn’s disease patients 
with prior ileocecal resection/right hemicolectomy
Characteristic CD (n  =  162)
Female/male (n) 77/85
Disease duration in years (median; min-max) 17.1 (3.3-52.1)
Follow-up time in years (median; min-max) 4.4 (1.3-6.8)
Time between surgery and index colonoscopy in years 
(median; min-max)
7.7 (0.3-37.6)
Age at index colonoscopy (mean; standard deviation) 42.6 (± 13.4)
Montreal classification (n; %)
   Age at diagnosis
      A1 25 (15.5)
      A2 116 (72)
      A3 20 (12.4)
   Disease location
      L1 89 (54.9)
      L2 9 (5.6)
      L3 55 (34)
      L1-4 7 (4.3)
      L3-4 2 (1.2)
   Behavior
      B1 6 (3.7)
      B2 77 (47.5)
      B3 79 (48.8)
   Perianal disease 38 (23.5)
Smoking habits (n; %)
   Non-smoker 86 (55.1)
   Ex-smoker 34 (21.8)
   Current smoker 36 (23.1)
Medication at index colonoscopy
   Thiopurines 111 (68.5)
   Anti-TNFα 59 (36.4)
TNFα: Tumor necrosis factor α.
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or past history of smoking were associated with a 
shorter duration to dilation (HR = 3.877, 95%cI: 
1.480-10.152, P = 0.006 and HR = 3.041, 95%cI: 
1.213-7.627, P = 0.018) (Figure 2).
Endoscopic balloon dilation
EBD was performed in 26.5% (n = 43) of patients 
(Table 3). Technical success was achieved in 97.7% (n 
= 42). Repeat dilation was required in 62.8% (n = 27) 
of patients (long-term efficacy: 37.2%), with a total of 
85 dilations being performed during the study period 
[median: 2 (1-5)], with a median balloon dilation of 
18mm (range 10-18). Technical success was achieved 
in 95.3% (n = 81) without major AEs, and only one 
episode of self-limited bleeding (1.2%). All patients 
(n = 17) had improvement of obstructive symptoms. 
Median time to second dilation was 453.5 d (range: 
152-1362).
Endoscopic recurrence, defined as modified Rut-
geerts score ≥ i2b was present in 60 patients (37.7%), 
of which 20 (33%) were diagnosed only after dilation 
of the anastomotic stricture. Following initial endoscopy 
and dilation, medical therapy was escalated in 38.5% 
of patients (n = 15; 3 began thiopurines and 14 began 
anti-TNF); however, escalation of medical therapy 
was probably driven by endoscopic recurrence (87%, 
n = 13) and not by anastomotic stricture presence, 
as suggested by escalation of therapy in 53% (n 
= 21) of the patients with endoscopic recurrence 
and no anastomotic stricture. No agreement was 
found between endoscopic recurrence and presence 
of stricture (K = 0.085, P = 0.273). Escalation of 
medical therapy did not decrease the need for repeat 
dilation; no other risk factors (gender, age, Montreal 
classification, perianal disease, smoking habits, 
previous medical therapy, presence of obstructive 
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Figure 2  Kaplan-Meier curves showing time from surgery to dilation (in mo) considering calprotectin levels (A) and smoking status (B).
Table 2  Univariate and multivariate analysis of risk factors for need for dilation after surgery
Risk factors Univariate analysis Multivariate analysis
OR 95%CI P  value OR 95%CI P  value
Significant in univariate and multivariate analysis  
   Time between surgery and index colonoscopy 1.006 1.003-1.010 0.001 1.007 1.001-1.013 0.027
   Lactoferrin levels 1.010 1.000-1.021 0.049 1.012 1.000-1.024 0.043
Significant in univariate analysis
   Subocclusive symptoms 6.155 2.546-14.880 < 0.001 - - 0.180
   No medical treatment with thiopurines 2.611 1.282-5.319 0.008 - - 0.500
   Age at index colonoscopy 1.028 1.002-1.055 0.033 - - 0.932
Not significant in univariate nor multivariate analysis
   Smoking status 1.877 0.912-3.861 0.087
      B2 behavior 1.221 0.619-2.408 0.565
      B3 behavior 0.895 0.454-1.767 0.750
      Perianal disease 1.376 0.632-2.996 0.421
   Anti-TNF therapy 0.893 0.443-1.799 0.751
   C-reactive protein levels 0.975 0.935-1.016 0.229
   Calprotectin levels 1.001 1.000-1.002 0.125
   Harvey-Bradshaw index 1.111 0.936-1.318 0.229
   Disease duration 1.002 1.000-1.005 0.089
OR: Odds ratio; CI: Confidence interval; B1: Non-stenosing and non-penetrating behaviour; B2: Stenosing behaviour; B1: Penetrating behaviour; TNF: 
Tumor necrosis factor.
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symptoms, serum/fecal biomarkers) were found to 
influence need for repeat dilation. After initial dilation, 
4.6% of the patients (n = 2) required anastomotic 
stricture resection due to worsening or recurrence of 
symptoms. The median time to progression to surgery 
was 35 mo (33.4-36.7).
Non-anastomotic strictures
During the study period, a total of 37 cD patients 
(40.5% males, n = 15) underwent a total of 59 EBD 
sessions of non-anastomotic strictures (17 in the 
ileum, 13 in the ileocecal valve, 2 in the ascending 
colon, 1 in the transverse colon, 3 in the descending 
colon and 1 in the sigmoid colon) (Table 3). Twenty-
seven percent of the patients (n = 10) had obstructive 
symptoms, with a median HBI of 1 (0-10). Technical 
success was achieved in all patients (n = 37). Repeat 
dilation was required in 40.5% (n = 15) of patients 
(long-term efficacy: 59.5%), with a median balloon 
dilation of 16.5mm (range 10-18). Technical success 
and improvement in obstructive symptoms were 
achieved in all patients without AEs. Following EBD, 
medical therapy was escalated in 18.9% of patients 
(n = 7; 4 began thiopurines and 6 began anti-TNF). 
Median time to second dilation was 368 d (range: 
157-1705). Only 1 patient (3%) required surgical 
resection. No risk factors were found to influence need 
for repeat dilation.
Anastomotic strictures vs non-anastomotic strictures
Baseline characteristics of patients with anastomotic 
and non-anastomotic strictures are shown in Table 
3. Follow-up since 1st dilation was longer in patients 
with anastomotic strictures. Patients with anastomotic 
strictures had a greater recurrence of stenosis (63% vs 
41%, P = 0.047). In the univariate analysis, absence 
of thiopurine medication (OR = 3.1, 95%cI: 1.2-7.9, 
P = 0.019) and anastomotic strictures (OR = 2.5, 
95%cI: 1.01-6.1, P = 0.049) were the only factors 
found to influence need for repeat dilation.
Asymptomatic and symptomatic cohorts 
No statistical significant differences were found 
between asymptomatic and symptomatic cohorts 
when comparing baseline disease characteristics, 
medical therapy at time of dilation, disease activity, 
Table 3  Baseline characteristics comparison between anastomotic and non-anastomotic strictures n  (%)
Characteristic Anastomotic strictures (n  = 43) Non-anastomotic strictures (n  = 37) P  value
Female/male (n) 19/24 22/15 0.173
Disease duration in years (median; min-max) 19.2 (5.7-52.1) 16.3 (3.0-45.3) 0.236
Follow-up since 1st dilation in years (median; min-max) 4.4 (1.3-6.8) 2.9 (1.2-6.5) < 0.001
Time between 1st and 2nd dilation in days (median; min-max) 453.5 (152-1362) 368 (157-1705) 0.796
Age at index colonoscopy (mean; standard deviation) 44.9 (± 12.2) 39 (± 12.2) 0.035
Montreal classification
   Age at diagnosis 0.368
      A1 6 (14) 4 (12.9)
      A2 29 (67.4) 25 (80.6)
      A3 8 (18.6) 2 (6.5)
   Disease location 0.057
      L1 23 (53.5) 9 (29)
      L2 1 (2.3) 4 (12.9)
      L3 17 (39.5%) 14 (45.2%)
      L1-4 2 (4.7%) 3 (9.7%)
      L3-4 - 1 (3.2%)
   Behavior
      B1 1 (2.3) 4 (12.9) 0.071
      B2 22 (51.2) 19 (61.3) 0.387
      B3 20 (46.5) 8 (25.8) 0.07
   Perianal disease 12 (27.9) 9 (29) 0.916
Smoking habits 0.635
   Non-smoker 22 (52.4) 11 (44)
   Ex-smoker 8 (19) 9 (36)
   Current smoker 12 (28.6) 5 (20)
Medication at index colonoscopy
   Thiopurines 23 (53.5) 25 (67.6) 0.200
   Anti-TNFα 17 (39.5) 19 (51.4) 0.289
Obstructive symptoms 15 (35.7) 10 (27.8) 0.454
C-reactive protein 2.8 (0.3-18.4) 6.95 (0.2-35.5) 0.126
Calprotectin 103.5 (5.9-1356) 283 (166-321) 0.789
Lactoferrin 7.66 (1.05-204.4) 10.7 (7.1-22.7) 0.429
Need to repeat dilation 27 (62.8) 15 (40.5) 0.047
TNFα: Tumor necrosis factor α.
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EBD procedure, need for further dilations, escalation of 
medical therapy and need for surgery (Table 4).
DISCUSSION
cD is characterized by chronic, recurrent, transmural 
inflammation; intestinal strictures are believed to 
result from partial healing and localized fibrosis[18]. 
Strictures develop unpredictably after surgery[6]. EBD 
has emerged as a bridging tool for management of cD 
strictures with favorable success rates and efficacy[10].
In this study, we found that almost one-third of cD 
patients develop an anastomotic stricture after ileocecal 
resection/right hemicolectomy. The mean age at first 
dilation was 42.6 years, which reflects their etiology 
as a complication of the surgery. Longer intervals after 
surgery and higher lactoferrin levels were associated 
with anastomotic strictures; time until dilation was 
lower in patients with calprotectin levels > 83.35 µg/g 
and current/past history of smoking. Previous studies 
have not studied the development of anastomotic 
strictures after surgery, however, as a progressive 
disease, anastomotic strictures will be more likely over 
time. Both anastomotic and de novo strictures have 
either inflammatory and/or fibrotic elements. Healing 
occurs in a defined pattern during bouts of activity 
and remission, with progression to luminal narrowing 
leading to stricture formation[17]; on the other hand, 
elevated serologic markers probably reflect the 
inflammatory component of the neo terminal ileum 
instead of the presence of an anastomotic stricture. 
While there is controversy regarding the effect of 
smoking on the disease phenotype, literature supports 
smoking as a factor in complicated disease[19].
Regarding EBD, our technical success was 97.7%, 
similar to literature (88%-100%)[20] and similar to non-
Table 4  Baseline disease characteristics, endoscopic balloon dilation procedure, need for further dilations, escalation of medical 
therapy and need for surgery between asymptomatic and symptomatic cohorts n  (%)
Characteristic Asymptomatic strictures1 (n  = 53) Symptomatic strictures1 (n  = 25) P  value
Female/male (n) 25/28 16/9 0.165
Disease duration in years (median; min-max) 17.9 (2.9-45.3) 19.9 (5.3-52.1) 0.955
Follow-up since 1st dilation in years (median; min-max) 3.1 (1.3-6.8) 3.9 (2.1-6.7) 0.068
Time between 1st and 2nd dilation in days (median; min-max) 668 (157-2074) 877 (152-2242) 0.790
Age at index colonoscopy (mean ± SD) 41.7 ± 13.8 43 ± 9.3 0.425
Montreal classification 
   Age at diagnosis 0.998
      A1 7 (14) 3 (13.6)
      A2 36 (72) 16 (72.7)
      A3 7 (14) 3 (13.6)
   Disease location 0.319
      L1 22 (44) 9 (40.9)
      L2 5 (10) -
      L3 21 (42) 9 (40.9)
      L1-4 1 (2) 4 (18.2)
      L3-4 1 (2) -
   Behavior 0.833
      B1 4 (8) 1 (4.5)
      B2 28 (56) 12 (54.5)
      B3 18 (36) 9 (40.9)
   Perianal disease 15 (30) 6 (27.3) 0.815
Smoking habits 0.761
   Non-smoker 24 (52.2) 8 (42.1)
   Ex-smoker 8 (17.4) 4 (21.2)
   Current smoker 14 (30.4) 7 (36.8)
Previous surgery (ileocecal resection/right hemicolectomy) 27 (50.9) 15 (60) 0.454
Medication at index colonoscopy
Thiopurines 33 (62.3) 13 (52) 0.390
   Anti-TNFα 21 (39.6) 14 (56) 0.175
   Combo 13 (24.5) 9 (36) 0.293
C-reactive protein 6.2 (0.2-35.5) 3.2 (0.3-19.4) 0.351
Calprotectin 107 (18.2-837) 340 (5.9-1356) 0.449
Lactoferrin 7.1 (1.1-102.6) 37.6 (4.0-204) 0.071
Therapeutic success 52 (98.1) 25 (100%) 0.377
Balloon diameter (median; min - max) 18 (10-18) 18 (13.5-18) 0.201
Adverse events 0 (0) 1 (4) 0.129
Need to repeat dilation 27 (50.9) 15 (60) 0.454
Number of dilations (median; min - max) 2 (1-5) 2 (1-5) 0.463
Escalation of medical therapy after dilation 13 (27.7) 8 (34.8) 0.541
Need for surgery after dilation 2 (4) 1 (4.2) 0.973
1Two patients had no information regarding presence of obstructive symptoms (one in each group). TNFα: Tumor necrosis factor α.
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anastomotic strictures (100%), however, this was 
not associated with a permanent stricture dilation, as 
63% of patients with anastomotic strictures and 41% 
of those with non-anastomotic strictures required 
additional dilation over a 4.4-year period. The fibrotic 
pathology of anastomotic strictures may be responsible 
for the lower response rate of EBD for non-anastomotic 
strictures. Re-dilation was as technically successful, 
supporting the evidence that repeated dilations do 
not reduce the procedural efficacy[20,21]. The rate of 
major AEs, including bowel perforation and significant 
bleeding, has been reported to be between 2%-6%[1,8]. 
AEs have been attributed to balloon size (25 mm 
diameter), pressure used to dilate and number of 
dilations per session. Our data confirm safety of 
EBD for cD strictures. We had no serious AEs, which 
may be explained by the careful patient selection, 
fluoroscopy to evaluate stricture characteristics and 
monitoring, maximum balloon diameter of 18 mm, use 
of cO2 insufflation, and endoscopists experience.
Long-term outcome following EBD varies. In our 
study, a long-term efficacy of 37.2% for anastomotic 
strictures and 59.5% for non-anastomotic strictures 
was achieved during a follow-up period of 4.4 years. 
Even though follow-up was longer, results were 
somewhat inferior to previous studies (52%-69%) 
when considering only anastomotic strictures. 
However, EBD in previous studies was symptom-
driven, while in ours, EBD was performed for strictures 
that did not allow passage with a colonoscope, 
regardless of patients’ symptoms. Besides, EBD 
delayed time until surgery, with only 3 patients (2 with 
anastomotic and 1 with non-anastomotic strictures) 
requiring surgery during follow-up period, suggesting 
a benefit of EBD. A recent pooled analysis reported 
a technical success, clinical success, long-term 
symptomatic and surgical recurrence rates of 89%, 
81%, 48% and 29%, respectively[22]; these data are 
almost exclusively derived from retrospective cohort 
studies and may somewhat overestimate the actual 
benefit. In 2013, the European crohn’s and colitis 
Organisation stated that EBD was safe and effective 
and allowed surgery to be avoided in cD patients 
with anastomotic strictures[23]. The overall technical 
success rate in the meta-analysis performed by Hassan 
et al[8] was 86% (71%-100%), while 41% of patients 
required repeated EBD allowing an overall long-term 
clinical efficacy (avoidance of surgery) rate of 58% 
during a median follow up of 33 mo. 
Risk factors associated with need for subsequent 
dilation have been inconsistent. Longer disease 
duration was associated with a shorter time to repeat 
dilation[12]; technical success of dilation[8,24,25], length 
of stricture[8,26], and non-ulcerated stricture[27] were 
found to be associated with a successful procedure. 
In our study, the only factors found to influence need 
for repeat dilation (in the univariate analysis) were 
absence of thiopurine medications and anastomotic 
strictures. Escalation of medical therapy did not 
decrease the need for repeat dilation. considering 
therapeutic strategy, Thienpont et al[10] reported no 
significant effect of systemic medical therapy after 
dilation on redilation or surgery, while Honzawa et al[28] 
found that prior use of immunomodulatory drugs 
improved the clinical outcome of EBD for intestinal 
strictures in patients with cD. Patients in our study may 
also have had more severe disease, as demonstrated 
by the majority receiving immunossupressants at 
the time of index colonoscopy (immunomodulators: 
68.5%; biological therapy: 36.4%), as well as the 
high rate of repeat dilation. Despite the well-known 
deleterious association between tobacco use and cD 
activity, with increased risk of recurrence after surgery 
and EBD, we did not find any association between 
smoking and long-term outcome of EBD. Disease 
activity assessed by serologic markers, endoscopy, 
and clinical variables such as HBI, disease duration or 
time between surgery and dilation did not predict the 
need for repeat dilation, in accordance with previously 
published data[10,21].
It is controversial whether asymptomatic stric-
tures should be endoscopically treated. Previous 
studies have found no correlation between patient
´s symptoms and clinical scores and endoscopic/
radiographic findings after intestinal resection[29-31]. 
In our study, only 2 patients presented with an HBI 
> 7 and only 27 patients complained of obstructive 
symptoms, despite 47 having an anastomotic stricture. 
Serum biomarkers did not correlate with endoscopic 
recurrence or presence of strictures, supporting the 
belief that using only symptoms or c-reactive protein 
levels to make treatment decisions may increase the 
risk of disease progression and AEs. Our group believes 
that dilation of strictures, despite symptoms, has 
impact on patients’ management and disease course, 
allowing evaluation of disease activity and therapeutic 
adjustments. If EBD was not performed, a diagnosis of 
endoscopic recurrence would not have been possible 
in 33% of patients, all with normal biomarkers. On the 
other hand, we did not find any differences between 
asymptomatic and symptomatic cohorts regarding 
disease characteristics as well EBD peculiarities.
Limitations of our study include its retrospective 
nature, being conducted in a tertiary referral center 
(with referral or selection bias), lack of a control group 
(medical and surgical therapy), uncertainty of the 
degree of luminal narrowing caused by inflammation 
vs fibrosis and escalation of medical treatment biased 
toward those having active IBD. 
In conclusion, smoking habits and longer disease 
duration after surgery are associated with a higher risk 
of anastomotic strictures. EBD is a feasible, simple, 
effective and safe alternative to surgery, with the 
possibility of being repeated as needed, with excellent 
symptomatic response, as well as good short-term and 
long-term outcomes, postponing or avoiding surgery. 
Considering that a significant number of patients with 
significant strictures remain asymptomatic with normal 
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biomarkers, and the fact that the disease continues 
to evolve proximal to the strictures, we believe EBD 
should be considered for all strictures not transposable 
by a colonoscope, regardless of the presence or 
absence of symptoms, in order to adjust treatment in 
an attempt to alter the natural history of the disease. 
Thus, EBD is useful not only for symptom resolution 
but also for evaluating mucosal healing.
ARTICLE HIGHLIGHTS
Research background
Strictures in crohn’s disease (cD) develop during the course of the disease 
or as the presenting feature. More than half of cD patients will need surgery 
within the first 10 years of diagnosis. Medical therapy for stricture management 
is limited due to the fibrotic nature. Endoscopic balloon dilation (EBD) has been 
proposed as a safe and effective therapeutic intervention for cD strictures, 
particularly for ileocecal and anastomotic strictures. 
Research motivation
Data on long term efficacy and safety of EBD are limited due to lack of long-
term outcome and small cohorts. Up to now there are also some uncertainties 
regarding the factors associated with long term success rate. Smoking status 
and disease activity status at the time of dilation may affect outcome of stricture 
dilation, though many studies are limited by short follow-up durations and small 
cohorts. Furthermore, as the primary therapeutic goal of CD has shifted from 
clinical remission to achieving mucosal healing, it may be important to access 
the mucosa proximal to strictures to evaluate disease recurrence and escalate 
therapy if needed.
Research objectives
This study aimed to evaluate anastomotic stricture development after intestinal 
resection in CD and demonstrate long-term efficacy and safety center of EBD 
in CD anastomotic and de novo strictures in a large referral centre cohort and 
determine the impact of dilation on the diagnosis of subclinical postoperative 
endoscopic recurrence.
Research methods
CD patients who had undergone ileocecal resection/right hemicolectomy 
referred for endoscopic evaluation between March 2010 to February 2015 
were included in this study. CD patients with non-anastomotic strictures 
who underwent EBD during the study period were included as a control 
group. EBD was performed for strictures that would not allow passage with a 
colonoscope, regardless of patients’ symptoms. Technical success was defined 
as the ability to pass the colonoscope through the stricture into the neoileum 
following dilation. Clinical success was defined as improvement of obstructive 
symptoms (in symptomatic patients). All patients who underwent dilation were 
endoscopically reevaluated 6-12 mo later. Long-term efficacy was defined 
as avoidance of surgical resection or repeat dilation after the initial dilation. 
Patients were followed until stricture resection, last clinic follow-up, or censor 
date of March, 2017. Escalation of medical therapy was defined as initiation 
of a thiopurine or anti-TNF within 6 months of first dilation, as determined by 
global physician assessment. 
All data were prospectively collected in a database created for this 
purpose. After a 5 year follow up period all data were arranged, processed and 
analyzed with SPSS® v.24.0 data (Statistical Package for Social Sciences).
Research results
In this study we found that almost one-third of CD patients developed an 
anastomotic stricture after ileocecal resection/right hemicolectomy. Longer 
periods between surgery and index colonoscopy and higher lactoferrin levels 
were associated with the presence of stricture after surgery. calprotectin levels 
> 83.35 µg/g and current or past history of smoking were associated with a 
shorter time until need for dilation (HR = 3.877, 95%CI: 1.480-10.152 and 
HR = 3.041, 95%CI: 1.213-7.627). Technical success of EBD was 97.7% and 
100% for anastomotic and non-anastomotic strictures, respectively, and 63% 
and 41% of the patients needed repeat dilation during the 4.4-year follow-up. 
Anastomotic strictures had a greater need for repeat dilation (63% vs 41%, P 
= 0.047). No differences were found between asymptomatic and symptomatic 
cohorts. Disease recurrence was diagnosed only after EBD in a third of 
patients. 
Research conclusions
EBD is a feasible, simple, effective and safe alternative to surgery, with the 
possibility of being repeated as needed, with excellent symptomatic response, 
as well as good short-term and long-term outcomes, postponing or avoiding 
surgery. Considering that a significant number of patients with significant 
strictures remain asymptomatic with normal biomarkers, and the fact that the 
disease continues to evolve proximal to the strictures, we advocate EBD for 
all strictures regardless of the presence or absence of symptoms, in order to 
adjust treatment in an attempt to alter the natural history of the disease. Thus, 
EBD is useful not only for symptom resolution but also for evaluating mucosal 
healing.
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 The treatment goal of Crohn´s disease (CD) has moved towards achieving 
mucosal healing, resolution of transmural inflammation and normalization of biomarkers. 
The purpose of this study was to evaluate how well CT enterography (CTE) and fecal 
calprotectin (FC) correlated with endoscopic activity, in newly diagnosed CD patients and 
after one year of therapy.  
 Consecutive patients with newly diagnosed CD diagnosis were evaluated by 
endoscopy, CTE and FC at diagnosis and 12 months after beginning immunosuppression. 
Endoscopic severity was assessed using the simplified endoscopic score for Crohn´s disease 
(SESCD). Biomarkers, clinical indexes, and fecal calprotectin were recorded on the day of 
ileocolonoscopy at diagnosis and oneyear after diagnosis. We adapted a CTE score for 
disease activity based on radiological signs of inflammation (mural thickness, mural 
hyperenhancement, mesenteric fat proliferation, mesenteric fat densification, comb sign, 
presence of strictures, fistulas, abscesses, ascites and lymphadenopathy). Correlations 
between endoscopy, CTE, and FC were assessed using Spearman’s rank correlation. 
Twentynine patients (48% female; men age 30 ±  9.5 years) were included in this 
prospective cohort. CTE findings significantly correlated with endoscopic findings. 
Endoscopic remission at oneyear followup significantly correlated with improvement in 
mural hyperenhancement (=0.004), mesenteric fat densification (=0.001), comb sign 
(=0.004), and strictures (=0.008) in CTE. None of the CTE findings improved in patients 
without endoscopic remission. FC correlated with SESCD (r=0.696, p<0.001) and with CTE 
features of inflammation (r=0.596, p<0.001). A cutoff of 100 ug/g predicted endoscopic 
remission with 92% sensitivity, 65% specificity and 83% accuracy (AUC 0.878, <0.001).  
CTE findings and FC levels correlated with endoscopic activity in CD both at 
diagnosis and at oneyear followup. These two noninvasive markers of disease activity may 
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be used as an alternative to endoscopy to monitor disease response to therapy.

 Crohn’s disease; ileocolonoscopy; fecal calprotectin; CT Enterography; 
mucosal healing; disease monitoring



Crohn’s disease (CD) is a chronic relapsing inflammatory bowel disease (IBD) characterised 
by transmural inflammation often affecting multiple sites of the gastrointestinal tract (1).  In 
recent decades, treatment goals in CD have evolved greatly (2); although symptomatic 
control was once considered the goal of therapy, with the introduction of antitumour 
necrosis factor (TNF)α agents in the 1990’s, endoscopic remission (ER) and histological 
remission (HR) both reflecting mucosal healing have become accepted therapeutic targets (3, 
4). A wealth of data suggests that mucosal healing may alter the natural course of disease by 
decreasing the rates of hospitalisation and reducing the need for surgery (5, 6).  However, 
since CD often affects the small bowel beyond the terminal ileum, ileocolonoscopy alone 
may be inadequate for the correct evaluation of mucosal inflammation in CD (7).  
Crosssectional imaging including computed tomography enterography (CTE) and magnetic 
resonance enterography (MRE) have been recently introduced into clinical practice and have 
emerged as preferred modalities for the evaluation of small bowel involvement in CD (8). 
These imaging modalities not only allow the accurate assessment of small bowel disease 
activity, extent, and location, but also aid in diagnosing extraluminal manifestations and CD 
complications during a single examination (8, 9). CTE and MRE perform similarly in the 
assessment of disease (10), but interobserver agreement and image quality may be superior 
with CTE (11, 12). In a preliminary study, Hara et al have reported that CTE may also have 
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the potential for longitudinal disease monitoring, noting its reliability to predict CD 
progression or regression (13). In addition, a more recent retrospective study showed that 
63% of patients had a significant radiological response to antiTNFα agents as assessed by 
serial CTEs (14).  However, this study was marred by its retrospective nature and by the fact 
that repeated CTE was performed in symptomatic patients only (14), and therefore the real 
accuracy of CTE to assess therapeutic responses remains to be prospectively assessed. 
Fecal calprotectin (FC), a 36kDa calcium and zincbinding protein complex derived from 
leukocytes infiltrating the intestinal wall, has recently emerged as a noninvasive biomarker of 
intestinal inflammation (15). Several studies have shown that FC reflect endoscopic disease 
activity in CD, predicting endoscopic inflammation and being a surrogate marker of mucosal 
healing (16, 17). However, the most appropriate cutoff value for FC to predict endoscopic 
activity in patients with clinical remission has yet to be determined.  
Despite their widespread availability in clinical practice, the performance of CTE and FC 
compared to endoscopy as diagnostic tools and/or as measures to evaluate therapeutic 
response in CD are yet to be determined. This prospective study was designed to evaluate the 
correlation between endoscopic disease activity, fecal markers and CTE findings of 
inflammatory activity in newly diagnosed CD patients and one year after initiation of 
immunosuppressive therapy.  
 
 


Consecutive newly diagnosed adult CD patients were prospectively enrolled between January 
2013 and October 2014 at Centro Hospitalar Sao Joao (Porto, Portugal). Patients were 
included if the following criteria were met: 1. presence of a definitive diagnosis of CD based 
on accepted clinical, radiological, endoscopic and histological criteria criteria (18) ; 2. 
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requiring therapy with steroids, azathioprine, and/or antiTNFα agents; and 3. presence of 
endoscopic activity, defined by a Simplified Endoscopic Activity Score for CD (SESCD) ≥ 
3 (19). Patients younger than 18 yearsold, who were pregnant, needed immediate surgery, or 
did not have endoscopically active disease at the time of enrollment were excluded. 
Eligible patients underwent ileocolonoscopy, CTE, and FC determination at diagnosis and at 
1 year of followup. Time between ileocolonoscopy and CTE was less than 4 weeks and no 
therapeutic changes were performed during that time period. Considering strict inclusion and 
exclusion criteria, sample size at the end of recruitment period was 29 patients.  
Disease phenotype was determined according to Montreal classification, based on age at 
onset, location and behaviour, with perianal and upper gastrointestinal tract involvement as 
additional modifiers (20). Gender, age, age at onset, disease location, disease behaviour, 
perianal disease, smoking habits, HarveyBradshaw index (HBI) and laboratory workup at 
diagnosis and at 1 year of followup were recorded. A HBI of less than 5 was considered as 
clinically inactive disease, and a 2 points drop on HBI was considered as disease 
improvement. 


Ileocolonoscopy was performed under propofol sedation by a single boardcertified 
gastroenterologist (SL) experienced in the endoscopic examination of CD patients. All 
patients had the distance of the ileum scoped specified in their endoscopic report, with a 
median distance of 10 cm. A solution of polyethyleneglycol was used on the night before, for 
bowel preparation. Endoscopic lesions were assessed using the SESCD (19). Endoscopic 
remission was defined in the protocol as a SESCD ≤ 3.  


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All CTE were performed at our institution, using a 64 rowmultidetector CT Siemens 
Somaton Sensation (Erlangen, Germany) scanner under American College of Radiology 
guidelines  for CT enterography. Axial, coronal and sagittal images 2 mm in thickness were 
obtained.  
Patients were asked to be nil by mouth for 6 hours before the procedure. Just before the 
scanning patients were asked to drink 2000 mL of water with 40g of mannitol (200 ml of 
Baxter solution with 20% of mannitol diluted with 1800 cc of water), over 60 minutes, at a 
steady rate of approximately 500ml every 15 minutes. Contrast enhanced CT images were 
acquired at enteric phase 50 seconds after intravenous injection of 80 mL of ioversol (Optiray 
320; Mallinckrodt Canada, Quebec, Canada). CTE images were analysed using transverse 
and multiplanar views. Multiplanar images were reconstructed with 2 mm of slice thickness.  


Images were evaluated using the PACS system (SECTRA AB, Sweden). Radiological 
interpretation and scoring was performed by a senior radiologist with more than 8 years of 
experience dedicated to IBD imaging. He was blinded to all the clinical, laboratory and 
endoscopic data and was asked to identify all bowel segments with signs of inflammation. 
Six CT signs of active CD (mural thickness, mural hyperenhancement, mesenteric fat 
proliferation, mesenteric fat densification, comb sign, presence of strictures) were evaluated 
in 5 predefined ileocolonic segments (ileum, right colon, transverse colon, left colon and 
rectum) (21). 
Mural thickening was assumed for a small bowel wall thickness of greater than 3 mm in a 
distended loop. Stenosis were suggested when there is visual luminal narrowing and upstream 
bowel dilation >30 mm. Each variable was scored as either 0 (absent) or 1 (present) per 
segment. In addition, fistulas, abscesses, ascites and lymphadenopathy were globally scored 
as either 0 (absent) or 1 (present). Thus, the total CTE score was 34.  
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
 
Stool samples were collected the day before beginning bowel preparation (preferably from 
the first stool in the morning) and then kept in the fridge until being brought to the hospital. 
Within a maximum of 7 days after collection, stools were extracted in accordance with the 
manufacturer’s instructions, using a “Faecal sample preparation kit” (Roche Diagnostics, 
Mannheim, Germany). Sample extracts were stored at 80ºC until the assays were performed 
at the Department of Pharmacology and Therapeutics, Faculty of Medicine of the University 
of Porto. Samples were thawed and analyzed using a commercially available fluoroenzyme 
immunoassay (EliA Calprotectin®; Thermo Fisher Scientific, Freiburg, Germany).  

 
Categorical variables were described through absolute and relative frequencies and 
continuous variables were described as mean and standard deviation, median, percentiles, 
minimum and maximum. McNemar tests were used to compare paired samples. The 
Spearman’s rank correlation coefficient was applied for assessing the correlations between 
CTE score and SESCD, HBI, FC as well as other laboratory parameters.  
Receiver operating characteristic (ROC) analysis was applied for determining the optimal 
cutoff values with the sensitivity and specificity based on the endoscopic remission (SES
CD≤3). All the reported  values were twosided, and  values of <0.05 were considered 
statistically significant. All data were arranged, processed and analysed with Statistical 
Package for Social Sciences (SPSS ®) v.20.0 data (SPSS Inc., Chicago, IL, USA). 


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This study was conducted according to the Declaration of Helsinki. The study protocols were 
approved by the Ethics Committee of Centro Hospitalar São João, Porto, Portugal on 27th 
February 2012 (ethics approval number 145/12 and 84/12). All patients gave informed 
consent to participate in this study in accordance with the local institutional board 
regulations.  
 


A total of 29 newly diagnosed CD patients were enrolled. Table 1 depicts baseline 
demographic characteristics. Fourteen (48%) patients were female with a mean age of age 30 
±  9.5 years. At diagnosis, nearly all patients (n=28, 97%) were aged between 17 and 40 
yearsold. Nineteen (65.6%) patients had exclusively ileal involvement (L1) and 14 (48%) 
had nonstricturing nonpenetrating behaviour (B1). Seven (24%) had evidence of perianal 
disease. Ten (34%) patients were smokers while 2 (7%) were former smokers. All patients 
had clinical and endoscopically active disease at baseline, with a median SESCD score of 10 
(7–16). 
All patients received systemic steroids (equivalent to prednisolone 1mg/Kg) at diagnosis after 
all the contraindications were solved (e.g. abscesses in 3 patients). 97% (n=28) of patients 
were started on azathioprine, while 59% (n=17) started biologic therapy (infliximab: 11; 
adalimumab: 6), having started them at median of 9 and 162 days after diagnosis, 
respectively.  
At oneyear followup 24 (83%) patients were in clinical remission, with a median HBI of 1 
(0.02.0) and 19 (66%) patients were in endoscopic remission. Compared to baseline, median 
values of haemoglobin and albumin were significantly higher at 1year of followup, while 
Creactive protein levels were significantly lower (Table 2). 
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
At baseline, all patients had ileal involvement at CTE, with 59% (n=17) having exclusively 
ileal involvement, while 24% (n=7) had two different locations involved, 10% (n=3) three 
different locations involved and 7% (n=2) 4 different locations involved. Seventeen percent 
of the patients (n=5) had disease proximal to the reach of the colonoscope. 
CTE findings at baseline showed bowel thickening and hyperenhancement in 29 (100%) and 
28 (97%) patients, respectively. Twentyone (72%) patients presented fat densification and 
comb sign of at least one bowel segment. Strictures were observed in 18 (62%) patients. 
Fistulas were identified in 9 (31%) patients and abscesses in 3 (10%). 
Most of the CTE findings improved at one year of followup. Baseline and at one year of 
followup individual CTE findings are shown in Table 3. An example of a patient’ 
endoscopic findings and corresponding CTE images at baseline and at one year of followup 
is shown in figure 2 and 3, respectively.  
Endoscopic remission at oneyear follow up was significantly associated with improvement 
in mural hyperenhancement (=0.004), mesenteric fat densification (=0.001), comb’s sign 
(=0.004), and strictures (=0.008) in CTE. None of the CTE findings improved in patients 
without endoscopic remission (Table 3). Five patients in endoscopic remission showed 
complete disappearance of disease signs at CTE.  
 

At diagnosis, the median CTE score was 7.0 (4.510.0), while at 1year followup it 
decreased to 3.0 (0.06.5; <0.001). When considering examinations both at baseline and 1
year followup together (totalling 58 of each procedures), the median value of CTE was 5.5 
(2.8 – 8.0). The CTE score level showed significant correlation with either HBI (rs=0.787, 
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p<0.001), SESCD score (rs=0.746, p<0.001), Creactive protein (rs=0.671, p<0.001), and 
haemoglobin (rs=0.580, p<0.001).  
 

At diagnosis, the median FC value was 986.5 (361.83175.8), while at 1year followup it decreased 
to 53.0 (23.8648.5; <0.001). When considering FC determinations both at baseline and 1year 
followup together (totalling 58 determinations), the median value of FC was 499.0 (52.7 – 1537.5). 
FC significantly correlated with HBI (rs=0.450, p=0.001), SESCD score (rs=0.696, p<0.001), C
reactive protein (rs=0.609, p<0.001), CTE score (rs=0.596, p<0.001) and haemoglobin (rs=0.383, 
p=0.003). The location of the disease did not influence the accuracy of FC (L1 [rs=0.695, p<0.001] 
and L3 [rs=0.678, p<0.001]).  We found that FC significantly correlated with the same CTE variables 
that reflected endoscopic activity: bowel hyperenhancement (rs=0.458, p<0.001), fat densification 
(rs=0.508, p<0.001), comb´s sign (rs=0.437, p=0.001), and strictures (rs=0.329, p=0.012); in addition, 
FC also correlated with the presence of lymphadenopathy (rs=0.426, p=0.001). CTE findings 
distributed per ileocolonic segments at baseline and after 1 year of followup are depicted in a 
supplementary table. 
Higher values of FC significantly correlated with a higher number of CTE findings per ileocolonic 
segment (rs=0.521, p<0.001). 
 

Nineteen patients were in endoscopic remission at oneyear followup. Patients in endoscopic 
remission had lower Creactive protein levels (3mg/L [0.216.4]  20.1mg/L [0.7125.7], 
p<0.001), lower calprotectin levels (42.1 [2.61208]  857 [26.710600], p<0.001), a HBI ≤4 
(94.7%  15.4%, p<0.001) and a CTE score ≤3 (73.7%  12.8%, p<0.001).  
In ROC analyses (Figures 1&2), endoscopic remission at ileocolonoscopy was predicted by a 
CTE score ≤3 with 87.2% sensitivity, 73.7% specificity, 87.2% positive predictive value 
(PPV), 73.7% negative predictive value (NPV) and 82.8% accuracy (AUCROC 0.866, 
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p<0.001 95%CI 0.7610.970) and by a calprotectin value<100 ug/g with 92.1% sensitivity, 
65.0% specificity, 83.3% PPV, 81.3% NPV and 82.7% accuracy (AUCROC 0.878, p<0.001 
95%CI 0.7810.976). 
With the aim of simplifying the application of these results on a daily basis so a likelihood of 
endoscopic remission at ileocolonoscopy could be achieved, a model combining FC value 
and CTE score was created by applying the following logistic function: 
 
exp (14.685 + 1.227 * Haemogl. level – 0.004 * Calprot. level – 2.422 * CTE score) 
1 + exp (14.685 + 1.227 * Haemogl. level – 0.004 * Calprot. level – 2.422 * CTE score) 
 
Assuming a sensitivity of 89.5% and a specificity of 89.7%, we consider the cutoff of 
0.3146 as clinically relevant, with a PPV of 94.6%, a NPV of 80.9% and an accuracy of 
89.6%, regarding likelihood of endoscopic remission at ileocolonoscopy (AUROC 0.946; 
95% CI [0.892–1.000]). 
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
In this study we show that CTE findings and FC levels mirror endoscopic activity in newly 
diagnosed CD patients.  In addition, both CTE findings and FC levels are able to predict 
endoscopic remission one year after therapy, suggesting that these two noninvasive markers 
of disease activity may be used as an alternative to endoscopy to monitor disease response to 
therapy. 
As the paradigm in CD treatment has shifted from clinical response to “bowel healing” 
(mucosal and transmural healing), it is now essential to define the best way to monitor 
disease activity. Attempts to correlate outcomes with radiological signs of inflammation have 
produced variable findings (2226). However, most studies focused on mural findings rather 
than on mesenteric signs of inflammation(12). It is known that at least some of the mural 
thickening observed despite endoscopic remission may not be due to active inflammation, but 
rather histological alterations secondary to transmural healing (27, 28). We have therefore 
adapted a CTE scoring system that factored also features such as mural hyperenhancement, 
mesenteric fat proliferation and densification, and the comb sign, since these CTE findings 
are closely related to inflammation (9).  In this work we were able to establish a strong 
correlation not only between mural findings but also mesenteric findings of inflammation 
(comb sign and fat densification) and endoscopic activity defined by SESCD. Previous 
studies (25, 27) have also described the comb sign, enlarged lymph nodes and increased fat 
density as good markers of endoscopic and histological activity. These studies suggested that 
the CTE variables associated with more severe endoscopic disease were mesenteric in origin 
rather than mural. In line with these findings, here we shown that fat densification, comb 
sign, and mural hyperenhancement are the best predictors of disease activity in CD. In 
addition, we found a significant reversal in CTE signs of inflammation one year after 
treatment, reflecting disease response to immunosuppressive therapy. This radiological 
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improvement correlated significantly with clinical response as assessed by the HBI. Lastly, 
CTE score accurately predicted endoscopic remission.  
On the other hand, FC has proved to correlate with disease activity and to be a good predictor 
of disease relapse and recurrence (2931). A better correlation between SESCD and FC than 
with serological markers has also been demonstrated (17, 32). Our group has recently shown 
that FC performed better than Creactive protein in predicting endoscopic activity in the post
operative setting (33). In the current study, we show that FC significantly correlated with 
both endoscopic activity and CTE findings. Defining endoscopic remission as a SESCD ≤3 , 
we found FC to have 92% sensitivity and 65% specificity for predicting endoscopic 
remission at a cutoff value of 100 ug/g. Interestingly, disease location seemed not influence 
the diagnostic performance of FC.  
One limitation that could be pointed out to this study is the use of CTE to monitor CD, 
regarding radiation concern. Although MRE has emerged as a nonionizing alternative 
method to CTE (34) not all centers have MRE readily available. CTE is cheaper, more 
readily accessible, faster, with higher spatial resolution and better tolerated by patients. CTE 
may even be superior compared to MRE in terms of image quality and interobserver 
agreement. Nowadays there are several strategies available to reduce radiation dose exposure, 
with no compromise of diagnostic accuracy. Nevertheless, cumulative radiation exposure of 
CD patients undergoing repeated CT examination needs to be carefully considered. 
Another limitation of this study is the single reader analysis of CTE images, as we know that 
CTE interpretation is subjected to interobserver variation, the use of a CTE score that was not 
yet validated (but actually no CTE score is validated) and also the relative small simple size. 
In conclusion, FC and CTE are good markers of disease activity in CD. In this group of 
newly diagnosed patients we found a good correlation between FC and SESCD and CTE 
score, and between SESCD and CTE score. Both FC and CTE score significantly improved 
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at one year of followup after beginning immunosuppressive therapy and strongly correlated 
with endoscopic findings. A CTE score ≤ 3 points and a FC < 100 ug/g accurately predicted 
endoscopic remission at one year follow up. Therefore, CTE and FC could be used as 
alternatives to endoscopic evaluation in newly diagnosed CD patients to monitor response to 
therapy. 
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
: Study flowchart. 
ADA: adalimumab; CD: Crohn’s disease; IFX: infliximab; TNF: tumor necrosis factor; 
 
Endoscopic findings at baseline (A and B) and corresponding CTE images (C, D, E 
and F).  

Endoscopic findings after one year of follow up (A and B) and corresponding CTE 
images (C and D). 
 
: ROC curves for CTE score (A) and FC (B) for discriminating between endoscopic 
recurrence and remission. 
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
 



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   
   
   
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
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Supplementary table: CTE findings distributed per ileocolonic segments at baseline and after 1 year of follow-up  
 Ileum n(%) Right colon n(%) Transverse colon n(%) Left colon n(%) Rectum n(%) 
 Baseline 1 year of FU Baseline 1 year of FU Baseline 1 year of FU Baseline 1 year of FU Baseline 1 year of FU 
Mural thickness 29 (100.0) 23 (79.3) 3 (10.3) 2 (6.9) 4 (13.8) 2 (6.9) 5 (17.2) 1 (3.4) 0 (0.0) 0 (0.0) 
Mural 
hyperenhancement 
28 (96.6) 18 (62.1) 3 (10.3) 2 (6.9) 4 (13.8) 2 (6.9) 5 (17.2) 1 (3.4) 0 (0.0) 0 (0.0) 
Mesenteric fat 
proliferation 
19 (65.5) 17 (58.6) 0 (0.0) 1 (3.4) 1 (3.4) 1 (3.4) 3 (10.3) 1 (3.4) 0 (0.0) 0 (0.0) 
Mesenteric fat 
densification 
21 (72.4) 6 (20.7) 3 (10.3) 0 (0.0) 3 (10.3) 1 (3.4) 3 (10.3) 1 (3.4) 0 (0.0) 0 (0.0) 
Comb’s sign  21 (72.4) 10 (34.5) 2 (6.9) 0 (0.0) 4 (13.8) 0 (0.0) 5 (17.2) 0 (0.0) 0 (0.0) 0 (0.0) 
Strictures 18 (62.1) 9 (31.0) 1 (3.4) 0 (0.0) 2 (6.9) 0 (0.0) 3 (10.3) 0 (0.0) 0 (0.0) 0 (0.0) 
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Transmural healing in Crohn’s disease: Beyond
mural findings
Dear Editor,
We read with great interest the article by Castiglione et al.
[1] reporting the rate of transmural healing (TH) in Crohn’s dis-
ease (CD) patients onmaintenance treatmentwith anti-TNF agents.
After two years of biologic treatment, transmural healing (TH) was
achieved in about 25% of patients. Diagnostic criteria for THwere a
bowelwall thickening (BWT)≤3mmusingbowel sonographyanda
BWT≤3mmwithout signs of hypervascularization using magnetic
resonance enterography. It should be noted that this study focused
onmural findings rather than onmesenteric signs of inflammation.
Herein, we report an interim analysis of our prospective tertiary
center study aiming to evaluate the correlation between endo-
scopic disease activity, fecal markers and Computed Tomography
Enterography (CTE) findings of inflammatory activity at diagno-
sis and one year after initiation of immunosuppressive therapy.
Consecutive patients with newly diagnosed CD were evaluated
by endoscopy, CTE and fecal calprotectin at diagnosis and 12
months after beginning immunosuppression. Endoscopic severity
Table 1
Changes in CTE findings between baseline and 1year of follow-up considering endoscopic activity.
All patients (n =29) Endoscopic remission (n=19) Endoscopic activity (n =10)
Baseline 1year of FU p-Value Baseline 1year of FU p-Value Baseline 1year of FU p-Value
Mural thickness 100% (n=29) 79.3% (n=23) – 100% (n=19) 68.4% (n=13) – 100% (n=10) 100% (n=10) 1
Mural hyperenhancement 96.6% (n=28) 62.1% (n=18) 0.002 94.7% (n=18) 47.4% (n=9) 0.004 100% (n=10) 100% (n=10) 1
Mesenteric fat proliferation 65.5% (n=19) 58.6% (n=17) 0.687 57.9% (n=11) 47.4% (n=9) 0.687 80% (n=8) 80% (n=8) 1
Mesenteric fat densification 72.4% (n=21) 20.7% (n=6) <0.001 68.4% (n=13) 10.5% (n=2) 0.001 80% (n=8) 40% (n=4) 0.219
Comb’s sign 72.4% (n=21) 34.5% (n=10) 0.001 63.2% (n=12) 15.8% (n=3) 0.004 90% (n=9) 70% (n=7) 0.5
Strictures 62.1% (n=18) 31% (n=9) 0.004 57.9% (n=11) 15.8% (n=3) 0.008 70% (n=7) 60% (n=6) 1
Lymphadenopathy 27.6% (n=8) 13.8% (n=4) 0.125 10.5% (n=2) 0% (n=0) – 60% (n=6) 40% (n=4) 0.5
Fistulas 31% (n=9) 10.3% (n=3) 0.031 31.6% (n=6) 10.5% (n=1) 0.125 30% (n=3) 10% (n=1) 0.5
Ascites 10.3% (n=3) 0% (n=0) – 5.3% (n=1) 0% (n=0) – 20% (n=2) 0% (n=0) –
Abscesses 10.3% (n=3) 0% (n=0) – 5.3% (n=1) 0% (n=0) – 20% (n=2) 0% (n=0) –
p<0.05.
DOIs of original articles:http://dx.doi.org/10.1016/j.dld.2017.09.136, http://dx.
doi.org/10.1016/j.dld.2017.02.014.
was assessed using the simplified endoscopic score for Crohnı´s dis-
ease (SES-CD). Biomarkers, clinical indexes, and FC were recorded
on the day of ileocolonoscopy at diagnosis and one-year after diag-
nosis. Radiological signs of inflammation evaluated were: mural
thickness, mural hyperenhancement, mesenteric fat proliferation,
mesenteric fat density, comb sign, presence of strictures, fistulas,
abscesses, ascites and lymphadenopathy. These findingswere eval-
uated in 5 predefined ileocolonic segments such as SES-CD, and
each variable was scored as either 0 (absent) or 1 (present).
A total of 29 newly diagnosed CD patients have been enrolled
[48% women, median age at diagnosis 30.0 (24.5–35.5) years].
At diagnosis, nearly all patients (n =28, 97%) were aged between
17 and 40 years-old. Nineteen (65.6%) patients had exclusively
ileal involvement (L1) and 14 (48%) had non-stricturing non-
penetratingbehaviour (B1). All patients had clinical andendoscopic
active disease at baseline, with a median Harvey-Bradshaw Index,
FC and SES-CD score of of 7.0 (6.0–9.0), 986.5 (361.8–3175.8) and
10.0 (7.0–16.0), respectively.Atbaselineall patientspresentedBWT
and 97% presented mural hyperenhancement. Twenty-one (72%)
patients presented increased fat density and hypervascularity and
18 (62%) strictures of at least one bowel segment (Table 1). Twenty-
eight (97%) of patients were started on azathioprine, while 59%
(n=17) started biologic therapy (infliximab 11; adalimumab 6). At
one-year follow-up, 24 (83%) patients were in clinical remission
and 19 (66%) patients were in endoscopic remission. In contrast
to Castiglione findings, in our cohort there was not a significant
improvement in BWT at one year follow-up (Table 1). Indeed,
endoscopic remission at one-year follow up only significantly cor-
relatedwith improvement inmural hyperenhancement (p=0.004),
mesenteric fat density (p=0.001), comb’s sign (p=0.004), and stri-
ctures (p=0.008) (Table 1). It is known that at least some of the
mural thickening observed despite endoscopic remission may not
be due to active inflammation, but rather histological alterations
secondary to transmural healing and it has been suggested that
mesenteric findings may be better predictors of active disease
[2–4]. According to that, our findings also suggest that an accurate
diagnosis of transmural healing should be made based not only on
mural findings but also on mesenteric signs of inflammation.
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Transmural healing in Crohn’s disease: Beyond
mural findings – Authors’ reply
Dear Editor,
We sincerely appreciated the interest and the comments on our
paper by Lopes et al. [1,2]. The authors refer about their inter-
esting study including 29 newly diagnosed patients with active
Crohn’s disease (CD), all performing endoscopy and computed
tomography enterography (CTE). After one year of follow-up, 6
out of 29 patients (20.7%) achieved the transmural healing (TH).
Particularly, the authors put their attention on a new, interest-
ing but unexplored, endpoint: the “extramural healing”, defined
as the radiological remission of all signs of inflammation beyond
mural findings (e.g. increased mesenteric fat density, mesenteric
fat proliferation, comb’s sign, lymphadenopathies). In effect, Lopes
et al. found that endoscopic remission at one-year follow-up
significantly correlated only with improvement in mural hyper-
enhancement (p =0.004), mesenteric fat densification (p=0.001),
DOI of original article: http://dx.doi.org/10.1016/j.dld.2017.02.014.
comb’s sign (p=0.004), and strictures (p =0.008), but they did not
find any significant improvement in bowel wall thickness (BWT).
However, it is important to note that in their study no statisti-
cally significant improvement was observed either in mesenteric
fat proliferation (p=0.6) or in presence/features of lymphadeno-
pathy (p=0.1), that are considered two important signs of active
inflammation.
Moreover, it appears quite difficult to compare our results [2] to
those by Lopes et al. [1]: in effect, we enrolled only patients who
completed a 2-years period of treatmentwith anti-TNF, while their
study ended at one year; this aspect could justify the lower rate of
TH obtained in their series (20.7%). Furthermore, only 17 subjects
(59%) in Lopes et al. series started an anti-TNF treatment, while the
remaining CD population was put on thiopurines. About this topic,
we previously reported [3] that TH can be achieved after two years
in 25% of patients treated with anti-TNF and in only 4% of subjects
treated with thiopurines (p =0.01; OR 6.2), thus concluding that
only biologics are able to achieve this strong outcome. It would be
interesting to know if patients who achieved TH at one year in the
study by Lopes et al. [1] were on anti-TNF or on thiopurines.
A recent study by Fernandes et al. [4] reported that patients
presenting TH (defined as normalization of BWT) had lower rates of
hospitalization, surgery, and therapy escalation than patients with
only mucosal healing or no healing. Interestingly, comb’s sign was
used as additional feature for assessment of disease activity only in
inconclusive cases.
Deepak et al. [5] reported that radiological response (using
MRI or CTE) was highly predictive of reductions in long-term risk
of hospitalization, surgery, or steroids use among patients with
small bowel CD. Remarkably, they considered also comb’s sign and
mesenteric edema in their radiological protocol. However, themost
impressive outcomes were correlated to BWT and bowel enhance-
ment.
In conclusion, we agree with Lopes et al. that the evaluation
of extramural signs of inflammation (by MRI, CTE or ultra-
sonography) should be carefully evaluated and interpreted by
radiologists/gastroenterologists. At the same time, further stud-
ies are needed in order to evaluate the prognostic role of residual
mesenteric findings in patients achieving TH.
We strongly encourage further studies, like that by Lopes et al.,
attempting to evaluate, characterize and better define the concept
of “transmural healing” as new promising therapeutic target in CD.
Guarantor of article
Prof Fabiana Castiglione.
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Abstract
AIM: To analyze therapeutic changes in Crohn’s disease 
(CD) patients following video capsule endoscopy (VCE) 
and to assess the usefulness of Lewis score and the 
Patency Capsule.
METHODS: Patency Capsule was performed in every 
patient that had indication for VCE, and those with 
negative patency did not undergo VCE. Patients with 
established CD that underwent VCE between January 
2011 and February 2014 were selected for this study; 
those with suspected CD were excluded, independent 
of VCE results, since our purpose was to address 
differences in therapeutic regimen in CD patients before 
and after VCE. Patients with inconclusive VCE were 
also excluded. Patients had to be free of non-steroidal 
anti-inflammatories for at least 1 mo. Those patients 
who met these criteria were allocated into one of three 
groups: Staging group (asymptomatic CD patients 
that underwent VCE for staging of CD), Flare group 
(patients with active CD), or Post-op group (CD patients 
evaluated for post-operative recurrence). Lewis score 
was calculated for every VCE procedure. Statistical 
Observational Study
ORIGINAL ARTICLE
R
es
ul
ts
 - 
Pu
bl
ic
at
io
ns
140
analysis was performed to address the impact of VCE 
findings on the therapeutic management of CD patients 
and to evaluate the utility of the Lewis score.
RESULTS: From a total of 542 VCEs, 135 were 
performed in patients with CD. Patency capsule excluded 
nearly 25% of the patients who were supposed to 
undergo VCE. No videocapsule retention during VCE 
was reported. From these 135 patients, 29 were 
excluded because CD diagnosis was not established at 
the time of VCE. Therefore, a total of 106 patients were 
included in the final analysis. From these, the majority 
were in the Staging group (n  = 73, 69%), and the 
remaining were in the Flare (n  = 23, 22%) or Post-op (n  
= 10, 9%) group. Median time between diagnosis and 
VCE was 5.5 years. Overall, VCE determined changes in 
the treatment of 40% of patients: only 21% remained 
free of immunosuppressors after VCE compared to 44% 
before VCE (P  < 0.001). The differences in therapy 
before and after VCE achieved statistical significance 
in the Staging and Flare groups. In addition, patients 
were significantly different when stratified regarding 
time since diagnosis to the date of VCE. A higher Lewis 
score was associated with therapeutic modifications (P 
< 0.0001); where a score higher than 1354 was related 
to 90% probability of changing therapy [area under the 
receiver operative characteristic (AUROC) 0.80 (95%CI: 
0.69-0.88)]. 
CONCLUSION: VCE significantly changed the thera-
peutic management of CD patients, even in those with 
long-term disease. Systematic use of Patency capsule 
allowed for no videocapsule retention.
Key words: Capsule enteroscopy; Crohn’s disease; 
Treatment modification; Patency capsule; Lewis score
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Our work analyzed the therapeutic mana-
gement of patients with Crohn’s disease (CD) and 
concluded that a very significant proportion of patients 
modify their therapeutic regimens after performing 
video capsule endoscopy (VCE), even in those with 
long-term disease or those without symptoms. This 
finding highlights the importance of this procedure 
in the management of CD. The systematic use of 
Patency capsule is controversial; however, we showed 
in our study that after excluding patients with negative 
patency, who did not undergo VCE, none of the patients 
had video capsule retention during VCE, highlighting 
the importance of Patency capsule in this setting.
Santos-Antunes J, Cardoso H, Lopes S, Marques M, Nunes ACR, 
Macedo G. Capsule enteroscopy is useful for the therapeutic 
management of Crohn’s disease. World J Gastroenterol 2015; 
21(44): 12660-12666  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v21/i44/12660.htm  DOI: http://dx.doi.
org/10.3748/wjg.v21.i44.12660
INTRODUCTION
Crohn’s disease (CD) is a chronic inflammatory disease 
associated with mucosal and transmural inflammation 
of the bowel wall, and its diagnosis relies on the 
combination of clinical, endoscopic, radiologic and 
histopathological features. 
Regarding endoscopic assessment, ileocolonoscopy 
is the first procedure for the establishment of 
the diagnosis. However, evaluation of the entire 
small bowel is mandatory, since it can change the 
therapeutic approach used and overall prognosis[1]. 
In this setting, international guidelines[1] regard 
cross-sectional studies, such as entero-computed 
tomography (CT) scan or magnetic resonance imaging 
(MRI), as first line tools, since they can evaluate extra-
luminal features and characterize intra-abdominal 
adverse events related to CD, such as abscesses or 
fistulas. Video capsule endoscopy (VCE) is considered 
a second-line tool in those CD patients with atypical 
symptoms, in which imaging was negative[1].
Nevertheless, VCE is often used as a first-line study 
in the suspicion of CD, after ileocolonoscopy[2,3]. Its 
efficacy in detecting lesions in the upper small bowel 
seems higher than entero-CT or MRI, with similar 
accuracy for distal lesions[4-6]. 
Since the role of VCE in established CD is not 
completely defined, namely whether VCE is useful for 
treatment guidance, a few studies tried to evaluate 
its impact on determining treatment guidance and 
analyzing the therapeutic changes attributed to 
VCE[7-11]. However, some of these previous studies 
included a very low number of patients or had very 
short disease duration at the time of VCE, thereby 
compromising the interpretation of the results. 
Evaluation of possible changes in management 
includes searching for changes in inflammatory bowel 
disease (IBD) specific modification strategies, further 
radiologic or endoscopic studies, or even surgical 
interventions. 
In this study, our main goal was to analyze the 
changes in the therapeutic regimen of patients with 
long-term CD after undergoing VCE. Additionally, 
we studied the impact of Lewis score in this setting 
and the number of videocapsule retentions with the 
systematic use of Patency capsule.
MATERIALS AND METHODS
All patients with established CD that underwent VCE 
since January 2011 to February 2014 were included 
in the study. Patients were assigned to one of three 
groups. The first group (Staging group) included 
patients with clinical remission who underwent VCE to 
assess disease extent or small bowel re-evaluation. 
The second group (Flare group) included patients 
who were undergoing re-evaluation because of a flare 
and had clinical deterioration or raised inflammatory 
markers. The third group (Post-op group) included 
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Table 1  Baseline characteristics of the patients included in 
the study  n  (%)
patients who were being evaluated for post-operative 
recurrence. 
Patients with suspected CD in which VCE did not 
confirm the diagnosis or those with VCE considered 
inconclusive were excluded from the study. Also, 
patients with suspected CD in which VCE confirmed 
the diagnosis were also excluded, since our main goal 
was to evaluate changes in therapeutic regimens for 
CD before and after VCE. Patients had to be free of 
non-steroidal anti-inflammatories for at least 1 mo.
All the VCEs were performed after confirming small 
bowel patency using Agile Patency capsules (Given®, 
Imaging Ltd. Yoqneam, Israel), which were read 30 h 
after ingestion. VCEs were performed using PillCam® 
SB2 or SB3 capsules (Given®, Imaging Ltd.). On the 
previous day, patients were asked to follow a liquid diet 
and to perform a bowel preparation. On the day of the 
procedure, patients were on a clear-liquid diet for 6 h 
after swallowing the capsule. RAPID® Real-Time Viewer 
was performed in all patients after 2 h of ingestion, 
and domperidone 10 mg was prescribed if the 
capsule remained in the stomach. A new evaluation 
was performed 1 h later, and if the capsule was still 
retained in the stomach, a new dose of domperidone 
10 mg was administered. If the medication failed, an 
upper endoscopy was performed to place the device in 
the duodenum. 
All the exams were read by two experienced 
gastroenterologists using RAPID Reader®. Lewis score 
was calculated in order to assess the severity of the 
disease in all procedures, being classified as normal 
or clinical insignificant if lower than 135 points, mild 
disease between 135 and 790, and moderate/severe 
disease above 790, as described elsewhere[12].
In addition to demographic, clinical, and analytical 
data, medical therapy at the time of VCE and therapy 
modifications due to VCE were recorded. In order 
to simplify the results, the “Anti-tumor necrosis 
factor (TNF) group” included patients taking anti-
TNF (infliximab or adalimumab) in monotherapy or 
combination therapy, and the “Immunosuppression 
group” included those under azathioprine (AZA) either 
in monotherapy or combination with 5-amynosalici-
lates (5-ASA); the remaining patients were under 
monotherapy with 5-ASA or had no therapy. 
Changes in CD treatment in the Staging group and 
Post-op group were only attributable to VCE findings, 
since these patients were in clinical and analytical 
remission. Patients in the Flare group had clinical or 
analytical active disease, but statistical analysis was 
conducted to conclude if VCE findings were associated 
with changes in therapeutic regimen, independent of 
the flare itself. 
Statistical analysis was performed using SPSS 
software version 22 (SPSS Inc., Chicago, IL, United 
States). Continuous variables were analyzed using 
T-student tests or Mann-Whitney test when normal 
distribution was not verified. Categorical variables 
were analyzed using Pearson’s Chi-square, Fisher’s 
exact tests or McNemar test as appropriate. Logistic 
regression was performed in order to assess variables 
independently associated with changes in therapeutic 
regimen. A P value below 0.05 was considered 
statistically significant.
RESULTS
Among the 542 VCEs performed during the analyzed 
period, 135 were performed in patients with CD, after 
positive patency was confirmed by Patency capsule 
(Patency capsule excluded nearly 25% of the patients 
who were supposed to perform VCE). From these 135 
patients, 29 were excluded because they did not have 
established diagnosis of CD at the time of VCE. In 
total, 106 patients were included for the final analysis. 
Most of the procedures were performed in patients 
within the Staging group (n = 73, 69%), with the 
remaining patients in the Flare (n = 23, 22%) and 
Post-op (n = 10, 9%) groups. Baseline characteristics 
are shown in Tables 1 and 2. Fifty-six percent were 
female, with mean age of 40 ± 13 years. Most patients 
(81%) had an inflammatory phenotype; 70% had 
isolated ileal disease. After VCE analysis, upper tract 
involvement was identified in 49 (46%) patients.
The median time between the diagnosis of CD and 
VCE was 5.5 [interquartil range (IQR) 2-10] years. 
Regarding disease activity (Lewis score), 51 (48%) 
had normal or clinical insignificant lesions (25% of 
the total procedures were normal), 14 (13%) had 
mild disease, and 41 (39%) had moderate to severe 
disease. 
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Population characteristics (n  = 106) Value
Male gender 47 (44)
Age - mean 40 ± 13 yr
Median time between diagnosis and VCE 5.5 (IQR 2-10) yr
Montreal classification 
Age at diagnosis
   A1: Below 17 7 (7)
   A2: 17-40 84 (79)
   A3: Above 40 15 (14)
Behavior
   B1: Non-stenosing/non-penetrating 86 (81)
   B2: Stenosing 12 (11)
   B3: Penetrating 8 (8)
Location
   L1: Terminal ileum   74 (70)
   L2: Colonic 10 (9)
   L3: Ileocolonic   22 (21)
   + L4: Upper disease   38 (36)
Treatment before VCE 
Anti-TNF   21 (20)
Immunosuppressors   38 (36)
Aminosalicylates only   40 (38)
No treatment   7 (6)
VCE: Video capsule endoscopy; TNF-α: Tumor necrosis factor α.
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DISCUSSION
VCE is a valuable tool in the assessment of the small 
bowel[13-19], but its importance in the evaluation and 
follow-up of CD patients is not well established[20,21]. 
An indicator to determine the impact of this method 
on CD is modification of the therapeutic approach after 
VCE. Some studies address this issue, but there were 
some limitations. 
A recent study[8] found that the number of patients 
with CD under anti-TNF or immunosuppressants rose 
after VCE. However, most of the patients underwent 
VCE in the first year of the disease; and, consequently, 
48 of 50 patients were only on 5-ASA or steroids 
before VCE (only one was under AZA and one under 
anti-TNF), which makes this difference expectable. 
An advantage of our study is the inclusion of patients 
with long-term disease (median time 5.5 years) and 
patients whose CD is adequately managed, namely 
anti-TNF and immunosuppressants. Our results showed 
that VCE was decisive for therapeutic changes even 
in patients with more than 10 years of CD evolution, 
Overall, VCE results guided changes in the 
treatment of 40% of the patients. At the time of 
VCE, 38% were under 5-ASA, 36% were under 
immunosuppressors, 20% were under Anti-TNF, and 
6% had no treatment. After VCE, no patient remained 
without therapy; and the percentage of patients under 
5-ASA decreased to almost half and those under AZA 
and anti-TNF rose significantly (P < 0.0001, Figure 1). 
Similarly, these results were significant when stratifying 
patients based on time between diagnosis and VCE 
(less than 1 year and more than 1, 5, and 10 years 
of the disease) (data not shown). Overall, only 21% 
of the patients remained free of immunosuppressors 
after VCE compared to 44% before VCE (P < 0.001).
When analyzing Lewis score, only 7% with normal 
or almost normal VCE changed therapy, whereas 67% 
changed therapy when VCE demonstrated moderate to 
severe disease (P < 0.0001, Figure 2). Those patients 
who changed therapy clearly had higher median Lewis 
score values (1446 vs 552, P = 0.006). Patients with 
a Lewis score higher than 1354 had a 90% probability 
of changing their medication [AUROC 0.80 (95%CI: 
0.69-0.88)]. 
We found differences in the median Lewis score 
among the different groups. Patients in the Flare group 
had higher Lewis score values than the Staging (1648 
vs 816, P = 0.040) and Post-Op (1648 vs 327, P = 
0.035) groups. No significant differences were found 
between Staging and Post-op groups.
Regarding the indication for VCE, the percentage 
of patients under AZA was duplicated in the Staging 
group (P < 0.0001) after VCE, while in the Flare group, 
the number of patients doubled under anti-TNF (P = 
0.032). In the Post-op group, there was an increase in 
the number of those taking AZA or anti-TNF, but it was 
not statistically different (P = 0.133, Figure 3).
When performing multivariate analysis, we found 
that the factors age, C-Reactive protein levels, smoking 
habits, or duration of the disease were not linked with 
changes in therapeutic regimen after VCE.
VCE was not retained in any of the patients. 
Furthermore, no clinical symptoms or other adverse 
events were reported in the patients where Patency 
capsule demonstrated negative patency.
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Table 2  Patient characteristics at baseline that could influence 
therapeutic changes after video capsule endoscopy
Variable Univariate analysis Multivariate analysis
Age P = 0.477 -
Male gender P = 0.517 -
Smoking P = 0.771 -
C-reactive protein P = 0.188 -
Disease time duration P = 0.073 -
Age at diagnosis P = 0.097 -
Ileal vs colonic vs ileocolonic 
disease
P = 0.009 P = 0.367
Disease behaviour P = 0.564 -
60
50
40
30
20
10
0
n
Before
After
None                  5-ASA           Immunosup         Anti-TNF
Figure 1  Therapeutic regimens for Crohn's disease before and after 
capsule enteroscopy. TNF: Tumor necrosis factor;  5-ASA: 5-aminosalicylic 
acid.
Figure 2  Changes in therapeutic regimen regarding the Lewis score 
calculated with video capsule endoscopy. 
No changes
Changes
100
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P  < 0.0001
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highlighting the importance of VCE in this pathology. 
Similar results were found in a previous study of 71 
patients with CD that included subjects with long-term 
disease[10]. The treatment modification rate was even 
higher in a study performed in a pediatric population 
with CD[22]. 
VCE promoted changes in therapy in every group, 
although in the Post-op group a statistically significant 
difference was not achieved, probably due to the 
small amount of patients (n = 10). In fact, post-op 
evaluation is emerging as a potential indicator for 
VCE[23,24]. It is considered to have the same sensibility, 
specificity, and negative and positive predictive 
values[2] as colonoscopy. In addition to the latter being 
a more accessible procedure, VCE was previously 
shown to find more endoscopic recurrences than 
colonoscopy[25], with the advantage of allowing for 
proximal small bowel evaluation[26]. 
In the Staging and Flare groups, there was a clear 
and significant modification in therapeutic regimens 
after VCE, with a decrease in the number of patients 
under 5-ASA and an increase in patients under 
AZA (Staging group) and anti-TNF (Flare group). 
Downgrading of therapy was observed in three patients 
(infliximab to AZA), all in the Staging group. Those 
were patients with long-term remission who were 
under combination therapy and, after performing a 
VCE for address the possibility of anti-TNF withdrawal, 
had a normal exam. Previous studies have determined 
the utility of VCE for the assessment of small bowel 
mucosal healing after immunomodulator or biologic 
therapy[27,28], eventually contributing to a downgrade in 
CD therapy.
It should be noted that none of our patients were 
being treated with steroids. This was due to the 
duration of time between the flare and the realization 
of VCE. Patients in the Flare group started steroids as 
indicated, but when they came to undergo VCE, the 
steroid cycle was already completed. This delay in 
VCE could have been a problem in our analysis since 
some patients may escalate therapy upon flare before 
VCE, which could contribute to some attenuation in 
the differences between therapy before or after the 
VCE. Statistical differences were still found despite this 
time lag, making changes in therapy regimens more 
attributable to VCE findings than to clinical or analytical 
flare. 
The importance of the VCE per se in the changes 
in therapeutic regimens was highlighted by the 
regression analysis. As observed, no other factor 
presented at baseline was independently related 
to therapeutic modifications. Age, gender, smoking 
habits, duration of the disease, and inflammatory 
markers at the time of the VCE were not determinant 
for therapeutic decisions, making therapeutic changes 
attributable to the results of VCE. Previous studies had 
already shown a weak correlation between VCE results 
and inflammatory biomarkers, making VCE very useful 
even in the absence of raised C-reactive protein or 
fecal calprotectin[11]. 
Lewis score can be a valuable tool for therapeutic 
management[29]; as expected, higher scores were 
related with more frequent changes in medical therapy, 
since they represent active disease requiring a more 
aggressive treatment. 
All the VCEs were performed after confirming 
small bowel patency using Agile Patency capsules. 
This device proved to be a very useful tool for patients 
with known stenosis[30], but its systematic use, as 
we perform in our institution, is not consensual. 
International guidelines[2] state that the risk of 
capsule retention is high in patients with known CD, 
and, therefore, patency capsule or cross-sectional 
studies must be performed before VCE to exclude 
significant stenosis. In patients with suspected CD, 
the risk appears to be much less significant, and 
its use is controversial. Since patients with CD can 
have inflammatory changes in small bowel mucosa, 
raising the risk of capsule retention, we performed 
Patency capsule in every patient in this setting. In our 
Department, nearly 25% of the patients with CD do 
not perform videocapsule due to negative patency as 
assessed by Patency capsules. Consequently, we did 
not experience any videocapsule retention during VCE.
The main limitations of our study were the small 
number of patients in the Post-Group, which precluded 
significant results (although there was a clear trend 
towards therapeutic modifications after VCE), and its 
retrospective nature. Since this work was not designed 
to compare patients with and without VCE, we did 
not assess the differences in the follow-up between 
them. However, it is well known in the literature that 
a suboptimal treatment of CD could predispose to 
a worse outcome. Therefore, we strongly believe 
that therapy escalation, even in patients with clinical 
remission but with small bowel lesions detected by 
VCE, is of paramount importance for a better long-
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Figure 3  Therapeutic regimens before and after capsule enterosopy 
within the three analyzed groups. TNF: Tumor necrosis factor;  5-ASA: 
5-aminosalicylic acid.
P  < 0.0001 P  = 0.018 P  = 0.038
Santos-Antunes J et al . Capsule enteroscopy and Crohn’s disease therapy
R
es
ul
ts
 - 
Pu
bl
ic
at
io
ns
144
term outcome of CD.
 Overall, we concluded that VCE is a very powerful 
tool for evaluating CD in all groups of patients, 
including those with long-term disease under 
immunosuppressors and anti-TNF. It was decisive 
for treatment guidance, which ultimately can lead to 
an earlier introduction of immunosuppressors and 
anti-TNF therapy, consequently improving overall 
prognosis.
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In the Results section we have included the research articles relevant 
for this thesis. In this Discussion section, the main results of our work 
will be further dissected. 
Virus and IBD
Inflammatory Bowel Disease has been gaining increasing importance 
and interest in the Gastroenterological milieu over the last two decades. 
This is mainly due to 5 reasons: 1. an increase in disease prevalence; 
2. the affection of a young population, leading to a great impairment 
in quality of life and work productivity; 3. better accessibility to small 
bowel disease, enabling to monitor disease activity with non-invasive
methods; 4. the amount of recent knowledge related to disease 
immunopathogenesis; 5. the evolving therapeutic options, with more 
efficacious drugs, able to potentially modify favorably the disease course. 
Despite all these improvements in disease pathogenesis, diagnosis 
and management, a full comprehension of its cause is still lacking. 
The recognition of the importance of microbiome in different digestive 
diseases raised, once more, the interest in a potential role of an infectious
agent in disease etiology/course. The gut virome, the viral component 
of microbiome, outnumbers the gut bacterial population. It has been 
demonstrated its potential to alter host physiology and homeostasis, 
and its change in composition throughout an individual´s life(8). It has 
also been speculated that the interaction of virus and commensal 
microbiome, susceptibility genes and immune system may be 
responsible for patient´s clinical heterogeneity and variability in 
response to different treatments. Several works tried to link viral 
dysbiosis with IBD pathogenesis without consistent results. 
An alternative line of interest is the possible influence of viral reactivation,
during immunosupressive states, in disease course and response to 
therapy. Data from the transplant setting have highlighted the influence of 
reactivation of virus of the Human Herpesviridae family (CMV and EBV) in 
disease course and long term prognosis. In literature there is conflicting
evidence of the implications of viral reactivation in IBD. While some 
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authors suggest that CMV reactivation is more common in UC and 
is associated with disease complications and loss of response to 
immunosupressors, others state that viral load does not impact disease 
outcome(26, 33, 180, 181). On the other hand, the focus on EBV reactivation 
in IBD patients has been centered in the risk of malignancy under 
immunosuppression, especially in young male patients. Little is known 
about its prevalence in IBD patients, its role in disease course and 
response to therapy and the real influence of immunosupressors and 
biologics on viral load and development of lymphoproliferative disorders 
in this context. Another DNA virus of the Herpesviridae family that has 
been implicated in gastrointestinal symptoms in immunosupressed 
patients is HHV-6. In IBD, HHV-6 was found to be more prevalent in 
serum and associated with more severe endoscopic lesions(50). 
One major challenge when evaluating the prevalence and influence 
of these opportunistic infections on disease course is the distinction 
between a superimposed infection and a disease relapse. Recent data 
highlighted the interest of quantifying viral load by PCR in order to 
establish proper diagnosis and management(29, 42, 182).
A previous work from our group(43) has demonstrated that IBD patients, 
irrespective of treatment, have a higher prevalence of EBV in blood 
compared to controls. In that cohort, treatment with infliximab and 
older age were risk factors for EBV prevalence. When that population 
positive for EBV was stratified by the number of EBV copies/ml, no 
differences were found with respect to the type of treatment, and no 
clinical consequences were found.
In our study comparing 95 IBD patients with 50 healthy controls, 
accordingly to previous papers, we found a higher prevalence of 
EBV and CMV in the mucosa of the disease group. Despite the more 
commonly reported association between CMV and UC, we did not find 
any difference in the prevalence of CMV or EBV in the mucosa of CD 
and UC patients. As we hypothesized, we found a higher prevalence of 
both EBV and CMV in areas with active endoscopic disease compared
to areas of normal mucosa (although these results were only 
significant for EBV in both CD and UC). We also tried to determine if 
viral load had any influence in disease severity and prognosis, trying 
to define a cut-off value with therapeutic/management implications. 
(180) Yoshino T et al. Inflammatory Bowel 
Diseases. 2007.
(181) Ganzenmueller T et al. Journal of 
Clinical Virology: the Official Publica-
tion of the Pan American Society for 
Clinical Virology. 2009.
(182) Ciccocioppo R et al. Immunologic 
Research. 2016.
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Comparing median viral loads (copies/105 cells) of CMV, EBV and 
HHV6 in ulcerated and normal mucosa, on both CD and UC, we did not 
find any statistical difference, although we found a higher EBV median
viral load in inflamed mucosa of CD patients. Comparing viral load 
in UC and CD mucosa, we found a higher median EBV viral load in 
inflamed mucosa of CD patients compared with inflamed mucosa of UC 
patients (p=0.010). The same was not true with respect to CMV or HHV6. 
Despite not statistical significant, CMV median viral load was higher 
in ulcerated mucosa of UC patients (p=.429). In this study, we were 
not able to establish a correlation between viral load and endoscopic 
disease activity. In contrast to what our group previously found(43), 
in this cohort we did not find a difference in viral serum prevalence 
between patients and controls nor between different treatment 
regimens. One possible explanation may be the fact that we included
patients with active disease while on the previous work only patients
in remission were analyzed. In addition, the mean age of our 
control group was higher than that published in 2013. In line with 
our findings, there are studies suggesting that only steroids and 
anti-TNF-alpha agents are associated with EBV colitis, and not the use 
of immunossupressors or the duration of therapy(42, 183). 
In summary, we were able to confirm a higher prevalence of EBV, and 
to a lesser extent of CMV, in the mucosa of IBD patients compared 
to healthy controls. According to other reported results(28, 37), we also 
found EBV as the most prevalent agent, with a higher prevalence 
of viral DNA in the mucosa compared to peripheral blood. This may 
suggest a viral potential role in the immune disturbance present on IBD 
patients´ intestinal mucosa, with implication in disease pathogenesis, 
rather than disease severity. Other findings supporting the hypothesis 
of EBV triggering role was the observation of a similar prevalence both 
in inflamed and non-inflamed mucosa. Another supporting factor was 
the absence of correlation between mucosal viral load and severity of 
endoscopic activity. Even in normal mucosa, IBD patients had a higher 
prevalence of EBV compared to healthy controls, although there were 
no significant differences in the median viral DNA levels. 
(183) Ford AC et al. The American Jour-
nal of Gastroenterology. 2013.
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As CMV was inexistent in normal mucosa, and with very low viral 
load in inflammed mucosa, no conclusion could be drawn regarding 
CMV infection. Regarding HHV6, and concordant with other works(49), 
it seems to have no role in IBD pathogenesis, as its prevalence and viral 
load was similar between the 2 groups, suggesting that not all virus of 
the Herpesviridae family are associated with IBD pathogenesis. 
We did not find any major advantage of DNA quantification as we 
could not establish a correlation between endoscopic disease severity 
and viral load. Nevertheless, a note of caution should be made when 
trying to extrapolate these findings to the general IBD population, as 
this cohort includes only patients with endoscopically active disease 
and a high proportion of subjects under immunosuppressors. 
Fecal Markers and Disease Recurrence
Despite the remaining uncertainties concerning disease etiology and 
the role of infectious agents, our knowledge and attitude in disease 
management has evolved enormously in the last decades. As the 
primary therapeutic goal of CD has shifted from clinical remission 
to achieving mucosal healing, it seems more and more important to 
objectively access the response to therapy. As symptoms and serum 
biomarkers have proved not to be good surrogate markers of mucosal 
healing, attention has shifted to endoscopy and fecal markers. In the 
context of postoperative follow-up of CD patients, there is enough 
evidence that endoscopic recurrence, irrespective of the presence of 
clinical recurrence, predicts the clinical course. It has also been shown 
the short-term benefits of postoperative endoscopic evaluation and 
early treatment intensification in recurrent disease. 
All papers published to date concerning post-operative CD, use the 
Rutgeerts Score to classify endoscopic recurrence. However, this score 
is still not validated, lacks inter-observer agreement and gathers in 
the same category patients with lesions limited to the anastomosis 
and patients with new onset ileitis. The Modified Score considers 
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recurrent disease only if lesions develop in the ileum, with strictures and 
ulceration of the anastomosis being considered non-recurrent disease. 
The use of this Modified Score as not been generalized, although to 
our group it conceptually seems more appropriate. In recent years, the 
use of fecal markers in this context has gained a lot of attention, due 
to its noninvasiveness and possibility of being repeated as needed. 
The majority of the initial studies enrolled small number of patients and 
reached conflicting results(165,167-173). A landmark in this subject was the 
study of Wright et al(167) that evidenced the predictive value of serial
monitoring of FC after surgery for identifying patients likely to relapse
and performing early endoscopic evaluation in order to intensify 
therapy if recurrence was diagnosed.    
In our cohort of 99 patients previously submitted to resection, 91% 
were in clinical remission at the time of colonoscopy. Despite that, 34% 
presented endoscopic recurrence with median values of fecal markers
significantly higher than the group of patients with no recurrent 
disease. The calculated best cut-off value for predicting recurrence for 
FC and FL was 100 ug/g and 7.25 ug/g, with NPV of 91% and 90% 
respectively. The AUROC for FC was 0.831 (95% CI, 0.752-0.911; p<0.05) 
and for FL was 0.842 (95% CI, 0.763-0.920; p<0.05). This threshold, as a 
screening test, reassures that the vast majority of patients with lower
values will be in remission and will not be missed for subsequent 
colonoscopy. FL performed equally well in the diagnosis of recurrence, 
but we could not confirm an improvement in diagnostic accuracy by 
combining both markers. Using either FC or FL is sensitive enough 
to diagnose recurrence, and preferring one over the other depends on 
personal experience and local availability. As it would be expected, if 
the Rutgeerts score was used more patients were diagnosed as having 
endoscopic recurrence, and the median values of both FC and FL were 
lower than with the Modified Score, reflecting the group of patients with 
normal FC and FL and only anastomotic disease. Using the Rutgeerts Score 
the performance of both tests would have been extremely jeopardized
with a significant decrease in both accuracy (FC 55% and FL 60%) and 
NPV (FC 33% and FL 37%). 
Our findings, in accordance to previous papers, suggest that both FC 
and FL are sensitive enough to monitor CD recurrence postoperatively, 
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reassuring both clinicians and patients that few endoscopic recurrences
will be missed using these noninvasive tests. We were able to define cut-
off values for both markers, with similar results to previous papers (70). 
An innovative finding was the use of Modified Rutgeerts Score, and the 
reinforcement that the i2 subgroup should be divided in i2a and i2b, 
considering only the latter as endoscopic recurrence. 
In the other study we intended to demonstrate the accuracy of 
FC and FL in diagnosing disease recurrence in the context of 
anastomotic stricture, and the efficacy and safety of EBD in this 
context. We evaluated 48 patients with anastomotic strictures and, in 
this cohort, both FC and FL were able to predict disease recurrence 
guiding the need for EBD. In this group of patients only 17% presented
subocclusive symptoms and no serum biomarker correlated with 
endoscopic or radiographic findings. We demonstrated that patients 
with an asymptomatic anastomotic stricture and a low value of both 
FC and FL, have a high probability of being in remission. On the 
other hand, patients with high levels of fecal markers, have a high 
probability of recurrence, not suspected by clinical or serum markers.
These patients should have the anastomosis dilated in order to 
evaluate the proximal mucosa allowing the optimization of therapy 
accordingly. We diagnosed recurrence in 22/48 patients (16 with 
severe disease) only after EBD. In this cohort, the best calculated 
cut-off values for both FC and FL to predict recurrence were 90.85 ug/g 
and 5.6 ug/g, respectively. This is in accordance with other published 
studies that define in the postoperative setting a cut-off value higher 
than the 50 ug/g used to diagnose IBD.
These two works also used the Modified Rutgeerts Score for the first 
time in comparison to fecal markers. The authors believe that the 
presence of lesions limited to the anastomosis should not define 
recurrent disease as many other conditions may be responsible for that 
finding. We also demonstrated that this modified score has a better 
correlation with fecal markers in recurrence diagnosis, although these 
results need to be validated and reproduced by other groups. 
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Endoscopic Balloon Dilation
Despite being controversial, we believe that strictures should be 
dilated, irrespective of symptoms, in order to evaluate the proximal 
mucosa and treat to target. In our pool of 162 CD patients submitted 
to ileocecal resection/right hemicolectomy, evaluated by colonoscopy
and with a median follow-up period of 4.4 years, a third of patients 
presented an anastomotic stricture. EBD was performed in 26.5%of 
patients, with a technical success rate of 97.7%, no major adverse 
events and a long-term efficacy of 37%. This high success rate is in 
accordance to what is already published(97, 99), and the need to repeat 
dilation did not reduce the procedure efficacy. 
Therapeutic changes were made after dilation in more than a third of 
patients, due to recurrence diagnosis. With this strategy surgery may 
be delayed or even avoided in a large number of patients, by stricture
resolution and by preventing disease progression (therapeutic 
intensification after dilation if needed). Only 2 patients required 
surgery after dilation, due to symptoms worsening. We were not able 
to find any predictive factor of subsequent dilation. Contrary to some 
data in the literature(63, 184), smoking, therapy at the time of dilation, 
endoscopic disease activity or biomarkers were not found to influence 
the need to repeat dilation.
The results of these works, emphasize the need of more sensitive and 
specific markers of disease recurrence, since the majority of patients 
were in clinical remission with normal serum biomarkers. Our results 
reinforce the believe that fecal biomarkers should be incorporated in 
the postoperative management algorithm, both to diagnose recurrence
and to assess response to therapy. In patients with low levels of FC 
(<100 ug/g) and/or FL (<7.25ug/g), in clinical remission, endoscopy 
may be postponed, while in patients with high values of fecal markers,
endoscopy should be performed in order to diagnose disease 
progression and prompt escalate therapy if needed. 
We also demonstrated that EBD is a safe and effective alternative to 
surgery with good short and long-term outcome. Our group has been 
observing that dilating strictures irrespective of symptoms, has an 
impact on patients´ management and disease course, allowing 
evaluation of disease activity and therapeutic adjustments. 
(184) Ding NS et al. Journal of Crohn’s & 
Colitis. 2016.
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Radiology, Fecal Markers, 
VCE and Disease Activity
Despite being considered the gold standard to evaluate disease activity
and response to therapy, in CD ileocolonoscopy alone may be 
insufficient to assess disease location and extension. Cross sectional 
imaging has emerged as the preferred modality in small bowel evaluation, 
both to report disease activity and complications, and to monitor response 
to therapy. As it has been reported a radiological response to anti-TNF 
alpha agents(125) predicting lower rates of hospitalization, surgery and 
steroids use in the long-term, maybe transmural healing will surpass 
mucosal healing as the therapeutic target in CD. 
As ileocolonoscopy is invasive and only evaluates the mucosa, we 
planned to evaluate how well CTE findings and FC correlate with 
endoscopic disease activity. In our prospective cohort of 29 patients, 
we found a positive correlation between endoscopic and radiological 
findings. Some studies have shown a correlation between disease 
activity and mesenteric signs of inflammation(165, 167, 168). With that in mind 
we adapted a CTE scoring system that included mesenteric variables
such as fat densification and proliferation and the comb sign, in 
addition to mural thickening, as signs of disease activity. 
We were able to establish a strong correlation between endoscopic 
activity defined by SES-CD and mesenteric findings. In patients with 
endoscopic remission at one-year, we found a significant improve-
ment in bowel wall hyperenhancement, mesenteric fat densification 
and comb sign with a significative decrease of the median CTE score. 
This was in accordance with previous reports(120, 125). We also demon-
strated a correlation between FC, endoscopic score and CTE signs of 
inflammation. A cut-off value of 100ug/g for FC predicted endoscopic 
remission with a NPV of 81% and an accuracy of 83%. Although there 
are currently alternative diagnostic modalities radiation-free, CTE still 
is the most widely available modality, is cheaper, faster, with the best 
spatial resolution, with no individual limitations and very well tolerated 
by patients. 
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With this work we suggest that both radiological evaluation and 
FC may be used as alternatives to endoscopy in monitoring disease 
response to therapy. Besides mural findings, mesenteric markers of 
inflammation should also be looked for when evaluating disease 
activity. We also believe that similarly to MRE, where several scores 
have been developed, a CTE score of disease activity should be 
developed and validated. In this group, a CTE score ≤ 3 points and a 
FC < 100ug/g accurately predicted endoscopic remission at one year 
follow-up.
Considering other noninvasive method of evaluation of the small 
bowel, VCE is gaining importance and utility as a tool for treatment 
guidance. Knowing that CD is a silent disease, it is reasonable to 
hypothesize that even in patients with long duration compensated 
disease mucosal lesions may be present. Although data available in 
the literature is scarse, there have been some reports of treatment 
modifications in CD patients after VCE(82, 83, 86, 185-187) and evidence 
that mucosal healing assessed by VCE is associated with clinical 
remission in the short and long-term(85, 188). In our experience, the 
performance of VCE in asymptomatic patients with long disease 
duration altered the management in more than 2/3. Unknown upper 
tract involvement was diagnosed in 46% of patients and almost 40% of 
patients presented moderated to severe disease at VCE. In this group, 
therapy was changed in 67% of patients, with a significant increase in 
the use of immunosuppressors and biologicals, based solely on VCE 
findings. As it is well known that a suboptimal treatment of CD may 
predispose to a worse outcome, we strongly believe that evidence of 
mucosal healing should be thoroughly looked for in every affected 
bowel segments, and therapy escalated if lesions are detected, either 
by colonoscopy, VCE or radiological methods. 
(185) Cotter J et al. Journal of Crohn’s & 
Colitis. 2014.
(186) Dussault C et al. Digestive and 
Liver Disease: Official Journal of the 
Italian Society of Gastroenterology 
and the Italian Association for the 
Study of the Liver. 2013.
(187) Kopylov U et al. Inflammatory 
Bowel Diseases. 2015.
(188) Kopylov U et al. Inflammatory 
Bowel Diseases. 2015.
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Referring to the described aims of this Thesis, the following conclu-
sions can be formulated: 
1.  Both EBV and CMV were more prevalent in IBD patients than in 
healthy controls (HC). Both agents were more prevalent in areas 
of mucosa with endoscopic activity but there was no difference 
between CD and UC. Nevertheless, EBV median viral load was 
higher in inflamed mucosa of CD patients, while CMV median viral 
load was higher in ulcerated mucosa of UC patients. With respect 
to HHV6, the prevalence was similar in IBD patients and in HC. We 
also did not find any difference in viral serum prevalence between 
different treatment regimens challenging the idea that the level 
of immunosuppression per se would justify some observations of 
increased viral load in immunocompromised patients. Our findings
suggest a potential role of virus in the immune disturbance 
present on IBD patient´s intestinal mucosa, with implication in 
disease pathogenesis, rather than disease severity. 
2.  We have demonstrated that both FC and FL are sensitive enough 
to monitor CD recurrence postoperatively, with a high negative 
predictive value. We have proposed a cut-off of 100 ug/g for FC 
and 7.25 ug/g for FL for predicting recurrence. We also compared 
the Modified Rutgeerts score and the Rutgeerts Score in predicting 
recurrent disease, and our results suggest that the Modified Rutgeerts
score should be used in clinical practice, allowing to overcome some 
limitations of the Rutgeerts score. We propose serial monitoring of 
fecal markers in the context of postoperative Crohn´s disease, as 
an indicator of which and when, patients should be submitted to 
endoscopic evaluation.
3.  In the context of asymptomatic anastomotic strictures, fecal 
markers performed equally well in predicting recurrence and being 
a noninvasive marker in selecting patients to EBD. In patients with 
high levels of fecal markers, as recurrent disease is highly probable,
EBD should be performed, irrespective of symptoms, in order to 
confirm recurrence proximal to the anastomosis and escalate therapy
if indicated. In this group, the best calculated cut-off value for FC 
was 90 ug/g and 5.6 ug/g for FL.
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4.  In our group of patients submitted to ileocolectomy, almost a third 
presented with anastomotic strictures. The performance of EBD 
was highly successful and safe with a technical success rate of 98%, 
a long-term efficacy of 37% and no major adverse events noted. 
Although repeating dilation was needed in 2/3 of patients, 
re-dilation was as technically successful, supporting the idea that 
this procedure can be done as needed. EDB demonstrated to be 
an effective and safe alternative to surgery, with a good short and 
long-term outcome, postponing and avoiding another surgery. EDB 
also allowed the diagnosis of disease recurrence in patients with no 
signs or biomarkers of active disease.
5.  We found a good correlation between ileocolonoscopy, CTE and 
fecal markers in evaluating disease activity at diagnosis of CD and 
one year after immunosuppressive/biological therapy. In patients 
with endoscopic remission at one year, CTE findings significantly 
improved and the median CTE score significantly decreased. Wall 
hyperenhancement, mesenteric fat densification and comb sign 
significantly correlated with endoscopic disease activity and FC. 
A FC cut-off <100ug/g and a CTE score ≤ 3 points were found to be 
predictors of endoscopic remission. Both noninvasive markers may be 
used to monitor response to therapy.
6.  Although data is scarse, our experience confirms that even in patients 
with long-time quiescent clinical disease, mucosal lesions may exist 
and VCE may be the only method to diagnose it. The recognition of 
active disease impacts patient management with therapy 
modifications.
Regarding the future and following the ideias that came up with this 
work, we believe it is important to rapidly standardize the methodology
for fecal markers determination in order to establish definitive cut-off
values for each clinical context. Non-invasive methods should be 
increasingly used to monitor disease activity, and selecting patients to 
endoscopic evaluation (colonoscopy and VCE). Endoscopy will retain
its irreplaceable value as it allows direct visualization and sample 
collection. The modified Rutgeerts score should be validated in order
to be widely used in clinical practice. The importance of transmural
healing should be further evaluated in order to prevent bowel 
damage. A CTE score should be developed and disseminated in 
clinical practice.
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